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Summary 
In Tanzania, as in most settings of sub-Saharan Africa, malaria is the first reported cause of 
attendance in health facilities. The National Bureau of Statistics estimates that a total of 16 million 
cases and 100,000 deaths (mainly in children) are due to malaria each year. In Dar es Salaam, the 
main city, approximately 3 million attendances are recorded, of which about one third are due to 
fever, mostly considered as presumptive malaria. Recent data show that transmission intensity is 
much lower in urban settings than in rural lowland areas. This is especially true for Dar es Salaam 
where only a small fraction of all fever episodes in children and adults are actually associated with 
Plasmodium parasitaemia.  
Clinical presentation of malaria is largely unspecific. No reliable clinical predictor that allows including 
or excluding the diagnosis of malaria has been identified. In this context, and in the absence of 
diagnostic test, WHO recommended in the past all fever episodes to be treated with antimalarials. 
Such blanket treatment leads first to substantial over-treatment with malaria drugs (in Dar es Salaam 
up to 95% of all treatments are unnecessary) and second to increased risk of missing alternative 
diagnoses with potentially fatal outcome. To address this issue of high public health relevance, we 
undertook a project called IMALDIA (Improving Malaria Diagnosis) aimed at improving the 
management of febrile patients in health facilities in Dar es Salaam, mainly through the 
implementation of Rapid Diagnostic Tests for malaria (mRDT). The project had 3 major components: 
(1) Evaluating the safety of withholding antimalarials in febrile children with a negative mRDT living in 
a moderate and a highly endemic area  
(2) Introducing laboratory diagnosis for malaria in the routine management of fever cases, using 
mRDT. The focus of this operational research was to document how feasible and effective the 
introduction of these tests is in the context of the routine management of fever cases.    
(3) Understanding the aetiologies of fever cases in children by screening a group of 1000 children 
with detailed clinical assessments and a range of laboratory tests in order to better identify the 
diversity of the causes of fever in small children living in an urban and a rural area.  
The overall aim of the IMALDIA project was to improve the diagnostic approach and management of 
fever cases in health facilities in Dar es Salaam, contribute to a more efficient and effective health 
sector, and help Tanzania on its way to reducing infant and child mortality.In a first step, we 
assessed the diagnostic performance of mRDT when used by health workers in routine practice. For 
this purpose, a quality assurance system both at central and peripheral level was set up. This system 
did not detect major problem and showed that the final result of mRDT by health workers was 
reliable.  
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The purpose of the second step was to better estimate the pre-test probability of malaria in 
populations targeted by mRDT (febrile patients of all age groups attending a health facility of any 
type). To this end we undertook a systematic review of the studies giving the proportion of patients 
with associated P. falciparum parasitemia (PFPf) in Sub-Saharan Africa. We found that the median 
PFPf was 35%, and that it had decreased by half when comparing the period before with the period 
after the year 2000 (44% versus 22%). This relatively low pre-test probability nowadays is another 
reason to implement mRDT in Africa. In Dar es Salaam the PFPf was very low (below 10%) hence it 
was even more urgent to start using a reliable malaria test. Microscopy was available in almost all 
public health facilities of the city but its performance was extremely low, with an overall sensitivity of 
71% and a specificity of only 47%.  
On the request of several Tanzanian stake-holders, in particular clinicians working routinely with 
patients, we assessed the safety of withholding antimalarials in children under five years with a 
negative malaria test. We did not observe any complication or death due to a missed diagnosis of 
malaria in our cohort of 1000 children, of which 60% were negative by mRDT. We concluded that the 
strategy of withholding antimalarials in negative children is safe and does not expose the child to an 
increased risk.  
The results of the systematic review coupled with the findings of the safety study led us to question 
the appropriateness of the previous WHO recommendation of treating all fevers with antimalarials in 
children less than five years living in highly endemic areas. WHO has now changed its policy, 
confirming that the IMALDIA findings were very relevant to the changed situation of many African 
countries, including Tanzania.   
The core of this thesis, and the main objective of the IMALDIA project, was to investigate the 
feasibility and value of implementing mRDT in the management of fever episodes in an urban 
malaria setting. Using 2 different designs and 2 independent data sources, we found a three quarter 
reduction in antimalarial consumption following RDT implementation. This massive reduction was 
due to the higher accuracy of routine mRDT compared to routine microscopy (that led to a dramatic 
reduction in the number of positive patients) and to the confidence of health workers in mRDT results 
(the proportion of negative patients treated with antimalarials dropped from 53% to 7%). The impact 
was maintained up to the end of the observation period (18 months). Not surprisingly, mRDT 
implementation increased the prescription of antibiotics by 50% and unfortunately did not have a 
major impact on the quality of the medical consultation.  
We took the opportunity of our near-to-program implementation of mRDT to perform a cost-saving 
analysis in a real situation and in a setting representative of many moderate endemic places in 
Africa. The conclusion was that costs can be saved on drugs, from both the provider and from the 
client’s perspective. For this reason, the overall expenditure for the patient was lower in health 
facilities using mRDT (by 0.31 USD per patient). However, the overall expenditure for the health 
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system was higher (by 1.31 USD per patient) when using mRDT instead of routine microscopy, 
mainly because of the relatively high price of the device. 
The aim of the last study was to explore the other causes of fever (beside malaria), in order to 
generate evidence for a revision of the existing clinical decision-charts for the management of 
patients, in particular the Integrated Management of Childhood Illness (IMCI). Half of the fever 
episodes in children were due to acute respiratory infections (ARI), of which 2/3 were probably of 
viral origin. Only 5% of all ARI were documented pneumonia. Gastroenteritis contributed to 9% of all 
fevers, of which at least 1/3 were due to a virus. In 1/5 of the children, no aetiology of high probability 
could be found but most of them recovered without treatment. Most of the children with acute fever 
thus do not need to receive an antibiotic. Based on these findings, we proposed a limited series of 
modifications to the IMCI chart and concluded that new point-of-care laboratory tests for the main 
infectious diseases are urgently needed.  
In conclusion, the IMALDIA project provided a deep insight into many aspects of the implementation 
of mRDT in near-to-programme conditions in Tanzania. Our findings show that the introduction of 
mRDT is safe, feasible and useful for the routine management of fever cases in all age groups and at 
all levels of the health system. Implementation at large scale will require flexibility on the part of the 
health care provider in order to be able to change his/her behaviour and a strong commitment of all 
persons involved. As malaria diagnosis is only one aspect of the management of patients presenting 
with fever, this will not solve all obstacles for making a proper differential diagnosis and prescribing 
the appropriate treatment for fever episodes. To really improve the quality of care it will be essential 
to develop new improved guidelines for clinicians. These decision charts should be based on the new 
available evidence and could include novel point-of-care tests for the key diseases, once these 
become available. 
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Muhtasari 
Katika Tanzania, kama zilivyo sehemu nyingi kusini mwa jangwa la sahara, malaria ni ugonjwa 
unaoripotiwa zaidi kwa mahudhurio kwenye vituo vya kutoa huduma za afya. Tume ya  takwimu ya 
Taifa, inakadiria kuwa jumla ya wagonjwa milioni kumi na sita na vifo laki moja (wengi wao wakiwa ni 
watoto) vinatokana na ugonjwa wa malaria. Katila jiji la Dar es Salaam,inaripotiwa takribani watu 
milioni tatu huorodheshwa kuhudhuria matibabu na theluthi moja kati yao hutokana na homa na 
hivyo kutibiwa kama malaria isiyothibitishwa. Takwimu za hivi karibuni zinaonyesha kuwa kiwango 
cha maambukizi ya malaria kimepungua zaidi maeneo ya mijini kuliko maeneo tambarare ya vijijini. 
Hali hii inaonekana zaidi katika jiji la Dar es salaam ambako idadi ndogo sana ya matukio ya homa 
kwa watoto na watu wazima inathibitika kuwa ni kutokana na uambukizo wa vimelea wa ugonjwa wa 
malaria. 
Kwa kiasi kikubwa muonekano wa dalili za ugonjwa wa malaria sio mahususi. Hakuna viashiria wala 
dalili zilizokwisha gunduliwa zinazoweza kuthibitisha au kukanusha kuwa mtu ana ugonjwa wa 
malaria. Kwa sababu hii na kutokana na uhaba wa vipimo vya kugundua ugonjwa wa malaria, shirika 
la afya duniani (WHO) limeridhia kutoa dawa za malaria kwa wagonjwa wote wenye homa. Matibabu 
ya jumla kama haya kwanza, husababisha matumizi makubwa ya dawa za kutibu ugonjwa wa 
malaria (katika jiji la Dar es salaam, takribani ailimia 95 ya matibabu ya malaria siyo ya lazima), na 
pili, husababisha uwezekano mkubwa wa kushindwa kugundua magonjwa mengine 
yanayosababisha homa yanyoweza kusababisha vifo. 
Ili kutangaza ujumbe huu, tulianzisha mradi wa kuboresha ubainishaji wa ugonjwa wa malaria 
unaoitwa IMALDIA, unaolenga kuboresha matibabu na huduma kwa wagonjwa wenye homa katika 
vituo vya kutolea huduma za afya jijini Dar es salaam kwa kuanzisha matumizi ya vipimo vya haraka 
vya kubainisha malaria (mRDT)  
Mradi ulikua na sehemu kuu tatu. 
(1) Kutathmini kama kuna usalama kwa kutokutoa dawa za malaria kwa mtoto mwenye homa 
aliyethibitishwa kua hana vimelea vya malaria (mRDT hasi).  
(2) Kuanzisha utaratibu wa kubainisha ugonjwa wa malaria kwa njia ya maabara kwa matibabu ya 
kila siku ya homa kwa kutumia kipmo cha haraka cha malaria (mRDT). Utafiti huu ulilenga kutathmini 
ufanisi na uwezekano wa kutumia vipimo hivi vya haraka kwa matibabu ya homa ya kilasiku.    
(3) Kutambua vyanzo mbalimbali vya homa kwa watoto, na kuawafanyia uchunguzi wa kina wa 
kitabibu watoto wapatao elfu moja na kuwafanyia vipimo mbalimbali vya maabara ili kuweza kubaini 
vyanzo anuai vya homa kwa watoto wadogo mjini na vijijini.  
Lengo kuu la mradi huu wa IMALDIA, ni kuboresha utaratibu wa kubainisha na kutibu wagonjwa 
wenye homa katika vituo vya huduma za afya mkoa wa Dar es salaam na kuchangia kuboresha 
sekta ya afya na kuiunga mkono Tanzania katika juhudi zake za kupunguza vifo vya watoto. 
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Hatua ya kwanza tulitathmini iwapo ufanisi wa kipimo ulizingatiwa na wafanyakazi wa afya wakati wa 
kuwapima wagonjwa. Kwaajili hii, mfumo wa kudhibiti ubora wa kipimo kuanzia ngazi ya juu hadi 
vituoni ulianzishwa. Hakuna mapungufu makubwa yaliyobainika, na ianaonesha kuwa wafanyakazi 
wa afya walitumia vipmo kwa ufanisi.     
Hatua ya pili ilikua kukadiria uwezekano wa majaribio ya malaria kwa walengwa wa kipimo cha 
mRDT (wagonjwa wenye homa wa rika zote wanaohudhuria vituo vya huduma za afya vya ngazi 
zote). Tulipitia tafiti mbalimbali, hatua kwa hatua ili kupata uwiano wa wagonjwa wenye vimelea vya 
malaria aina ya P.falciparum (PFPf) kusini mwa jangwa la Sahara. Tulikuta kua wastani wa PFPf ni 
asilimia 35 nao ulikua umepungua kwa nusu ukilinganisha na kipindi kilichopita na baada ya mwaka 
2000 (aslimia 44 dhidi ya 22). Kiwango hiki kidogo cha uwezekano wa majaribio, ni sababunyingine 
ya kuanzisha matumizi ya kipimo cha mRDT barani Africa kwa sasa. Kutokana na kiwango kidogo 
sana cha PFPf (chini ya asilimia kumi), Dar es salaam, matumizi ya kipimo hiki yalihitajika kwa 
haraka. Pamoja na kua hadubini zilikuwepo katika vituo vyote vya jiji la Dar es salaam, ufanisi wake 
ulikua ni wa kiwango cha chini sana chenye kipima hisi (sensitivity) asilimia 71, na specificity 47%.      
Kwa maombi ya washika dau Tanzania hususan waganga katika vituo mbali mbali vya huduma za 
afya, tulitafiti kuona kama ni  salama kutowapa dawa za malaria watoto wenye  umri chini ya miaka 
mitano ambao wana kipimo hasi cha malaria. Katika utafiti huo, hatukuona madhara yoyote wala vifo 
kutokana na kukosea bainisho la malaria katika utafiti huu wa watoto elfu moja ambao kati yao 
asilimia 60 walikua na mRDT hasi. Tulihitimisha kua ni salama kutokutoa dawa za malaria kwa mtoto 
mwenye majibu hasi ya kipimo cha malaria. Matokeo ya tafiti zilizopita yalilandana na matokeo ya 
tafiti hii tuliyofanya, jambo ambalo lili sababisha tuhoji usahihi wa muongozo wa shirika la afya 
duniani (WHO) unaoamuru kuwapatia dawa za malaria watoto wote wenye umri chini ya miaka 
mitano wenye homa katika maeneo yenye malaria kwa wingi. Kufuatia hoja zetu, shirika la afya 
duniani (WHO) limeridhia kubadilisha sera yake, na hii ina maana matokeo ya utafiti wa IMALDIA 
yalipewa kipaumbele kutumika katika hali ya malaria ya nchi za kiafrika ikiwemo Tanzania.    
Kiini cha tasnifu (thesis) hii na lengo kuu la mradi wa IMALDIA, lilikua ni kuchunguza uwezekano na 
thamani ya kuanzisha matumizi ya kipimo cha haraka cha malaria kwa matibabu ya  homa kwenye 
miji yenye malaria. Kwa kutumia mifumo miwili tofauti na vyanzo viwili vya taarifa vilionyesha kua 
matumizi ya dawa za malaria yalipungua kwa kiasi cha robo tatu ya kiwango cha awali. Hii ilitokana 
na usahihi wa kipimo cha haraka cha malaria (mRDT) dhidi ya hadubini (idadi ya wagonjwa wenye 
majibu chanya ya malaria ilipungua kwa kiasi kikubwa) pia iliwajengea wafanyakazi wa afya kujiamini 
na hivyo kiwango cha wasio na malaria wanaopewa dawa za malaria kilishuka toka asilimia 53 hadi 
asilimia 7. Mafanikio haya yalizingatiwa hadi mwisho wa kipindi cha utafiti cha miezi 18. Kwa bahati 
mbaya matumizi ya mRDT, yamesababisha kuongezeka kwa matumizi ya vijiua sumu (antibiotics) 
kwa asilimia 50 na haikubadilisha ubora wa huduma inayotolewa na wahudumu wa afya.  
Tulitumia nafasi ya kuwa karibu na mradi (near-to-program implementation) kuainisha gharama 
itkayopungua (cost-saving analysis) katika mazingira halisi yanayowakilisha maeneo yenye 
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maambukizi ya wastani ya malaria katika bara la Afrika. Hitimisho lilikua kwamba gharma inaweza 
kupungua kwenye matumizi ya dawa kwa mtazamo wa pande zote mbili, yaani mtoa huduma na 
mgonjwa pia. Gharama kwa mgonjwa zilikua ndogo pia (kwa TsH 383 kwa mgonjwa). Hata hivyo, 
gharama za mfumo wa huduma za afya, zilikua kubwa (kwa TsH 1’607 kwa mgonjwa) mtawalia 
iwapo kipimo cha haraka cha malaria kitatumiwa badala ya hadubini kutokana na gharama kubwa ya 
kipimo cha mRDT. 
Utafiti wetu wa mwisho ulidhamiria kuchunguza sababu nyingine zinazosababisha homa kwa watoto 
(mbali na malaria) ili kutoa ushahidi wa kupitia upya majedwali ya matibabu ya wagonjwa hususan 
mpango wa jumla wa kutibu magonjwa ya watoto (IMCI). Nusu ya matukio ya homa kwa watoto 
yanasababishwa na maambukizi kwenye njia ya hewa (ARI), na theluthi mbili (2/3) kati ya hao 
huenda ni kutokana na virusi. Ni asilimia tano (5%) tu kati ya hao (ARI) ilirekodiwa kuwa ni kutokana 
na  kichomi (pneumonia). Asilimia tisa (9%) katika matukio yote ya homa ilitokana na kuharisha na 
kutapika (gastroenteritis) na kati ya hao, theluthi moja ilisababishwa na virusi mbalimbali. Chanzo 
cha homa kwa sehemu moja ya tano (1/5) ya watoto wote hakikufahamika, ingawa wengi kati ya hao 
walipona bila matibabu. Kwa hiyo, watoto walio wengi wenye homa hawahitaji kiua vijasumu 
(antibiotics). Kutokana na matokeo haya, tulipendekeza marekebisho mabalimbali na kuhitimisha kua 
vipimo vipya vya ki maabara vya kupima maambukizi ya magonjwa makuu, vinahitajika haraka katika 
vituo vya kutoa huduma za afya. 
Kuhitimisha, mradi wa IMALDIA umetoa ufahamu wa kina kwa sura mbalimbali za kutekeleza 
matumizi ya kipimo cha haraka cha malaria RDT. Matokeo yetu yanaonesha kuwa ni muhimu, ni 
salama na inawezekana kutumia RDT kwa matibabu ya homa kwa wagonjwa wa rika zote katika 
ngazi mbali mbali za mfumo wa utoaji wa huduma za afya. Kupanua wigo wa matumizi ya kipimo hiki 
unahitaji kuwa makini ili kuweza kubadilisha tabia na hamasa kwa mtoa huduma ya afya na wote 
wanaohusika. Kuboresha  bainisho la malaria (malaria diagnosis) na matumizi ya kipimo, haitatatua 
mapungufu yote yaliyo katika utaratibu wa kuainisha magonjwa mbalimbali (diferential diagnosis) na 
kutoa tiba sahihi, kwa kuwa ni sehemu tu ya mfumo mzima wa matibabu kwa watu wenye homa. Ni 
muhimu kuandaa miongozo mipya ya matibabu au kuboresha majedwali ya utaratibu wa matibabu ili 
kuweza kuboresha kiwango cha huduma inayotolewa kwa wagonjwa. Majedwali ya matibabu 
yahusishe kikamilifu ushahidi uliopo (evidence based) na ikiwezekana kuhusisha vipimo vipya vya 
magonjwa makuu mara vinapopatikana au kugunduliwa. 
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1.  Background 
1.1 Clinical diagnosis of malaria 
In Tanzania, as in most settings in sub-Saharan Africa, malaria is the first cause of attendance in 
health facilities. Unfortunately, the clinical presentation of malaria is one of the least specific of all the 
major diseases, with a large clinical overlap with other serious conditions, especially with acute 
respiratory infections (ARI) (O'Dempsey et al. 1993; English et al. 1996). For example, respiratory 
distress is a common occurrence in severe malaria (K Marsh et al. 1995). In the absence of any 
laboratory tests (the rule in most health facilities in Sub-Saharan Africa) the dual treatment for 
malaria and pneumonia of febrile children is the standard of care in the frame of the Integrated 
Management of Childhood Illness (IMCI) advocated by WHO and UNICEF. In a study in Uganda, 
over 30% of children presenting with fever at basic health facilities received this dual treatment 
(Källander et al. 2004).   
There have been numerous attempts to develop clinical algorithms to improve the discrimination 
between malaria and ARI but none has proven to be sufficiently reliable to justify withholding one or 
the other treatment on this basis (Chandramohan et al. 2002). With existing algorithms, the risk of 
missing a malaria case on clinical presentation alone is increasing with increasing transmission 
levels, while the risk of over-diagnosis and hence drug wastage is increasing as the transmission 
level decreases. Settings with highly seasonal malaria transmission such as cities in the Sahel belt 
are moving each year from one of these extremes to the other (Olivar et al. 1991).  
1.2 Malaria over/misdiagnosis 
Magnitude of over-diagnosis of malaria in Tanzania 
The strategy of presumptive treatment for malaria was primarily designed for the population (children 
under 5 years) and area (rural Africa) bearing the highest burden of the disease. However, there has 
been a clear tendency to apply this strategy to children older than 5 years and even adults, and also 
in settings with very low transmission of malaria. This strategy was initially introduced because of the 
lack of diagnostic facilities in most settings. Unfortunately, it has been clearly shown that even when 
microscopy is available, results are systematically disregarded by the clinician, for a number of 
reasons (Zurovac et al. 2006).  
The end result is a massive over-diagnosis, resulting in a massive over-treatment of malaria. In 
Tanzania, five studies are available which confirm that the over-diagnosis is extremely high in urban 
settings and low-transmission areas: 95% in Dar es Salaam (Wang et al. 2006a), 96%  in the 
highlands (Reyburn et al. 2006); it is still important in rural areas, even during the rainy season: 41% 
in Rufiji district (Rooth & A Björkman 1992); 43% and 76% in less than five years and older 
children/adults respectively in Kilombero district (Font et al. 2001); 62% in Kibaha district (Nsimba et 
al. 2002). In all these studies, more than 95% of all febrile patients received an antimalarial 
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treatment, which means that the wastage of drugs was almost of the same magnitude as the over-
diagnosis. 
Consequences of over-diagnosis of malaria 
This massive over-diagnosis was bearable as long as cheap and safe drugs such as chloroquine or 
sulfadoxine/pyrimethamine (SP) were efficient against the parasite. A new paradigm is emerging now 
with the introduction of artemisinin-combination therapies (ACT) as first line treatment in more than 
50 African countries, including Tanzania. In this new context, the fact that over-diagnosis is at least 
40% and much higher in urban and low-transmission settings implies that implementing reliable 
diagnosis of malaria has become indispensable. It is indeed impossible to justify engaging 
considerable financial resources for the large-scale introduction of a costly drug knowing that more 
than half of the tablets will be wasted.     
This massive over-diagnosis has a second deleterious consequence: misdiagnosis of febrile patients, 
in whom other causes of fever are not looked for. In two Tanzanian studies dealing with severe 
malaria cases, a higher mortality rate was found in the group of patients without malaria (having 
possibly bacterial infections left untreated) than in the group having documented malaria (Makani et 
al. 2003; Reyburn et al. 2004).  
1.3 Malaria diagnosis using Rapid Diagnostic Tests (mRDT) 
Quality of routine microscopy in Tanzania 
In Tanzania, like in the majority of Sub-Saharan countries, the quality of malaria diagnosis made by 
microscopy, when available, has been generally of poor quality. This is due to poor training and skill 
of personnel, inadequacy of equipment and reagents, absence of supervision and the fact that it is a 
time-consuming technique in a high patient load environment. A recent study performed in the Tanga 
region, aimed at assessing the quality of malaria diagnosis in 35 laboratories, showed that this 
worrying situation has not improved at all (Magesa et al. 2005). In the highlands, the sensitivity and 
specificity of hospital routine microscopy were only 50% and 96% respectively (Reyburn et al. 2006). 
It is thus clear that, even if the human resources were available, implementing microscopic diagnosis 
in health facilities all over Tanzania is unlikely to be a practical solution. 
WHO recommendation regarding malaria diagnosis 
In view of the increasing experience with mRDT, WHO convened a Technical Consultation in 2004 to 
determine whether parasitological diagnosis could provide benefits and cost-savings in areas of 
intense malaria transmission, and to evaluate the operational feasibility of large-scale deployment of 
the currently available tests (WHO 2004). The recommendations were intended to provide guidance 
on the appropriate use of parasitological diagnosis of malaria in areas of stable transmission, with 
specific focus on mRDT use in countries implementing ACTs. 
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The meeting concluded the following: “A prompt and accurate diagnosis of malaria is the key to 
effective disease management.  It guides the management of febrile patients and reduces the 
unnecessary use of anti-malarial drugs. High sensitivity of malaria diagnosis is important in all 
settings, and it is essential for the correct management of the most vulnerable population groups in 
which malaria infection produces an acute illness, which can rapidly progress to death. Microscopy 
and rapid diagnostic tests (mRDT) are the currently recommended methods for parasitological 
confirmation of malaria. In all settings laboratory services providing malaria microscopy should be 
strengthened. Where microscopy is not possible, mRDT should be introduced. Well conducted field 
studies and large-scale operational experiences have shown that mRDT can be effectively used by 
trained health workers at the periphery, including community health workers. To ensure reliable 
results, appropriate systems for quality assurance of microscopy and mRDTs should be implemented 
and maintained.” 
Performance of mRDT 
For more than 20 years in travellers in industrialized countries and almost 10 years in semi-immune 
population in South Africa, mRDT have been used with great success (Figure 1). The performance of 
mRDT devices has been extensively studied. A meta-analysis of studies including 7’396 tests 
performed in non-immune travellers (having generally much lower parasitemia than semi-immune 
patients) showed that their performance to detect Plasmodium falciparum was excellent and very 
consistent: sensitivity ranged from 88 to 99% and specificity from 95 to 100% (Marx et al. 2005). In 
order to be able to exclude malaria in a patient, the key characteristic of performance is the likelihood 
ratio (LR) for a negative result (reflecting mainly sensitivity). In this meta-analysis, it was 0.05 for the 
last generation of HRP2 detecting P. falciparum tests, which is excellent (close to zero).  
 
Figure 1: Content of a kit for mRDT 
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In semi-immune patients, where parasites appear generally before symptoms, giving thus higher 
parasite density at the time of diagnosis, the sensitivity of mRDT is even better. A meta-analysis 
including 48 studies from endemic areas has clearly shown that mRDT are largely good enough for 
clinical management of patients. A comparison between four different malaria diagnosis technologies 
using a statistical method that avoids defining a gold standard demonstrated that mRDT are at least 
as sensitive as microscopy (Ochola et al. 2006).  
The overall sensitivity of mRDT when used in the field has progressively improved along the new 
generations of tests (Marx et al. 2005) and is now often better than that of expert microscopy. Indeed 
between 60% and 92% of the patients with a positive mRDT but a negative microscopy were positive 
by PCR (Dal-Bianco et al. 2007; Bell et al. 2005; Stauffer et al. 2009). As all malaria tests, mRDT 
cannot detect parasite densities below a certain threshold (considered to be 50-100 parasites/µl for 
mRDT). But, for clinical management of patients living in endemic areas, sensitivity is less a problem 
as it is well known that the probability that a fever is due to the current parasites (‘true malaria’) is 
strongly dependant on their density. A very low parasitemia that would be undetected by an mRDT is 
very unlikely to be the cause of the fever. A good case selection for testing (clear history of fever or 
temperature ≥ 38°C) is the way forward since the likelihood that a certain parasite density would be 
reached is much higher. 
The specificity of mRDT used in endemic areas is likely to be lower than in non-endemic areas, 
because of two problems:  
1) mRDT detect persisting antigens for up to 4 weeks after an infection, even if it has been cured. 
This phenomenon will thus tend to increase the prevalence of parasitemia found in community 
surveys (Bell et al. 2005). The practical implication for patients is that mRDT cannot be used for 
follow-up of a treated episode of malaria (Mayxay et al. 2001; Iqbal et al. 2004). However, for the 
differential diagnosis of fever on day 0 the problem due to persisting antigens is not an issue. As 
mentioned before, most of the patients that are mRDT positive but microscopy negative [because the 
density is just under the microscopy threshold of detection but antigens are circulating (Bell et al. 
2005)] are in fact infected and thus in need for treatment. 
2) mRDT, at least those based on the detection of pLDH, detect also gametocytemia (Mueller et al. 
2007), although, pure gametocytemia in the general population is rather rare: it was only 1.3% in a 
cross-sectional survey in the Kilombero/Ulanga Districts in Tanzania (a high endemicity area) in 2008 
(Mulokosi, unpublished data). The real prevalence of gametocytemia based on PCR detection is 
much higher (Shekalaghe et al. 2007), but most of these submicroscopic densities would probably 
not be detected by mRDT. Anyway, the small treatment wastage that a test positive due to 
gametocytemia would imply is nothing compared to the wastage in the present situation.  
An important issue is that the quality of the tests is variable from one brand to the other and this has 
recently been assessed in detail by a multilateral initiative (WHO/FIND/CDC/TDR 2008). For the 
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brands most widely used in the world, more than 95% of the lots tested between 2007 and 2009 by 
the WHO reference laboratories fully passed the quality control procedure (WHO Technical 
Consultation on parasitological confirmation of malaria diagnosis, Geneva, 6-8 Oct 2009).  
1.4 Malaria in Tanzania 
In Tanzania malaria is a major public health problem. Malaria is endemic in almost all parts of the 
country (Figure 2) and is thus a treat for an estimated 32 million people (94% of the population). It is 
estimated that about 16 million cases occur every year, resulting in about 100’000 deaths, of which 
39’000 are among children less than five years (National Bureau of Statistics, Tanzania and Macro 
International Inc. 2007). It is the leading cause of outpatient attendance for children less than five 
years (38%) and for all other patients (32%) (Ministry of Health and Social Welfare 2002). About 65% 
of these episodes are treated in public or faith-based health facilities and 35% are treated outside the 
public health sector in private outlets (National Malaria Control Program 2005). These data are based 
on reported malaria that is essentially not laboratory documented, and thus represent the burden of 
fever episodes rather than that of malaria. Indeed, in Tanzania, about 83% of public health facilities 
do not provide laboratory services. Therefore, only 12-20% of the malaria cases are confirmed 
parasitologically (National Malaria Control Program 2005).  
 
Figure 2: Distribution of malaria endemicity in Tanzania (MARA/ARMA 2002, www.mara.org.za) 
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An estimated 65 million US$ is spent on the prevention and treatment of malaria in Tanzania each 
year, which amounts to 39% of all health expenditures and just under 1.1% of the Gross Domestic 
Product (Jowett & Miller 2005). More recently, a Global Fund for fight AIDS TB and Malaria (GFATM) 
proposal financial analysis indicated amounts varying from 43-154 millions per year, depending on 
the timing of the different interventions implemented 
(http://www.theglobalfund.org/grantdocuments/8TNZM_1766_0_full.pdf).   
Malaria epidemiology in Tanzania 
In 2007/8, 18% of children less than five years were positive for malaria (TACAIDS, ZAC, NBS, 
OCGS & Macro International 2008). Prevalence in rural areas was more than double that in urban 
areas, and there were huge variations across regions (Figure 3).  
 
Figure 3: Malaria prevalence in Children 6-59 months. Source THMIS 2007/8 
 
 
Data from previous surveys and studies indicated that malaria prevalence in Tanzania has roughly 
halved over the past decade (Smithson 2009). There has been a decline of similar timing and 
magnitude in malaria transmission, severe anemia, fever incidence, malaria inpatient admissions and 
the proportion of fever cases positive for malaria. All-cause under-five mortality has declined by 
nearly 40% since 1999. The evidence suggests that malaria-related deaths have declined by a 
similar extent.  
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Malaria control strategy in Tanzania 
A range of complementary malaria control measures have been implemented, commencing in the 
late 1990s. After two decades of growing drug resistance, the first line therapy for clinical malaria 
was changed – first from chloroquine to sulfadoxine/pyrimethamine (SP) in 2002, and later to 
artemether/lumefantrine (ALu) in 2007. The use of SP for prevention of malaria in pregnancy was 
introduced in 2001/2, and continues to-date. Insecticide Treated Net (ITN) social marketing at 
national scale began in 2000 and subsidized ITNs have been provided to pregnant women and 
infants through the “Hati punguzo” voucher scheme since 2004 (Magesa et al. 2005). Free 
distribution of long-lasting ITNs for under-fives took place in the entire country in 2009 and on the 
islands of Zanzibar in 2006. Zanzibar also benefited from indoor residual spraying, as did certain 
areas on the mainland (Muleba Municipality, Kagera Region). Meanwhile, additional interventions at 
pilot stage were deployed in limited localities, including Intermittent Preventive Treatment for infants 
(IPTi; Mtwara and Lindi) and larviciding (Dar es Salaam). The ownership and use of mosquito nets 
has grown steadily, from less than 30% of households in 1999 to over 60% in 2009. Urban net 
ownership has consistently outpaced net ownership in rural. ITN use by children less than 5 years 
and pregnant women has risen from nearly zero in 1999 to more than 35% in 2008. The proportion of 
pregnant women receiving preventive treatment (IPTp, 2+ doses) rose from 22% in 2004/5 to 30% in 
2007/8. 
The reduction in malaria transmission, prevalence and morbidity corresponds closely to the increase 
in use of nets and ITNs. The protection afforded by nets extends beyond individual users to benefit 
the community as a whole. The fact that multiple malaria interventions have been implemented at the 
same time makes it difficult to assign causation to any one particular control measure. 
1.5 Malaria epidemiology in Dar es Salaam 
Currently over a quarter of all Africans live in urban centres and this proportion will increase to half by 
2025 (Keiser et al. 2004). There are an estimated 25-103 million cases of urban malaria each year. If 
truly the large majority of these cases are not actually malaria but have another cause, this 
represents a major public health challenge. Urban malaria has been the subject of a few studies in 
recent years, with a focus on describing existing malaria control practices and the over-diagnosis of 
malaria (Robert et al. 2003; Caldas de Castro et al. 2004; Wang et al. 2005a; Donnelly et al. 2005; 
Othnigué et al. 2006).  
Dar es Salaam has a hot and humid tropical climate with two rainy seasons, a main one during the 
months of March-May, and a short one occurring in November-December. Originally it was an area 
with endemic and perennial malaria. As a result of urbanization and malaria control activities it is now 
an area of low endemicity: the Entomological Inoculation Rate (EIR) was 1.3 in 2009 (Geissbühler et 
al. 2009). A study by Wang et al. could demonstrate that the level of endemicity in Dar es Salaam 
was actually lower than expected (Wang et al. 2006a). Most importantly, this work demonstrated that 
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the malaria-attributable fraction among fevers ranged from 2 to 7%, indicating that between 93% and 
98% of all treatments were unnecessary (Table 1). 
 
Table 1:  Proportion of fevers due to malaria in 4 African cities, by age groups (Wang et al. 
2005a) 
 
          0-1 year 1-5 years 6-15 years >15 years 
Abidjan (Yopougon) 23% 43% 44% 26% 
Cotonou 0 7% 0 1% 
Dar es Salaam 2% 7% 7% 4% 
Ouagadougou 12% 26% 37% 18% 
 
In Dar es Salaam, the reduction in (all-age) malaria prevalence in the community has indeed been 
dramatic – from 24% in 2004 to just 4% in 2008 (Figure 4). It is quite variable from one sector of the 
city to the other, with prevalence in school-children ranging from 0.8% in the centre to 3.7% in the 
rural peripheral areas of the town (Wang et al. 2006a). 
 
Figure 4: All-age malaria prevalence in Dar es Salaam, 2004-8 (Smithson 2009).  
 
 
From 1990 until 2002 the Swiss Tropical and Public Health Institute (Swiss TPH - ex-Swiss Tropical 
Institute) was the executive agency of the Dar es Salaam Urban Health Project (DUHP), which 
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rehabilitated existing infrastructure and improved management practices (Wyss et al. 2000). As a 
result, there is a longstanding and very good relationship between the Swiss Swiss TPH and the City 
Medical Office of Health (CMOH). Malaria control has a long history in Dar es Salaam (Caldas de 
Castro et al. 2004). The Dar es Salaam CMOH together with the Ifakara Health Institute (IHI), the 
Swiss TPH and other institutions have implemented an urban malaria control program in 2002. While 
diagnosis and treatment remain the most important malaria control strategy, the use of preventive 
measures such as insecticide-treated nets is also high, with over 80% of the population of Dar es 
Salaam using regularly a mosquito net. In addition, larval control has been introduced in some areas 
in Dar es Salaam since March 2006 (Chaki et al. 2009). 
1.6 Management of fever episodes in Africa 
As mentioned above, because of the lack of diagnostic tools in Africa, patients presenting to health 
facilities with fever have usually been denied the usual aetiology finding process inherent to any 
medical consultation (Zurovac et al. 2006b). In Tanzania, as in many other countries, the official 
management schedule for children less than five years is the Integrated Management of Childhood 
Illness (IMCI) (Ministry of Health and Social Welfare, Tanzania et al. 2004; Armstrong Schellenberg 
et al. 2004), in which no laboratory test is proposed. To improve this situation, the first step is the 
introduction of malaria diagnosis in the routine management of fever cases. This, however, opens a 
new problem that is a major challenge to clinicians: what should be done when the malaria test is 
negative?  
Strangely, the aetiology of non-malaria fevers has never been studied in a systematic way in sub-
Saharan Africa. As a result, there is no way to guide clinicians with an evidence-based strategy. The 
IMCI decision-chart, although it does at present not include any laboratory test, is an excellent tool 
developed on the basis of the scarce evidence existing in the mid-1990s. Unfortunately, very few 
studies have seriously addressed this question since and we still have an insufficient evidence base. 
Disease-specific studies have been carried out in a few settings, for example for arboviruses on the 
Kenyan Coast (Morrill et al. 1991), Dengue in Somalia (Botros et al. 1989), Mycoplasms and 
Rickettsia sp. in Somalia (Nur et al. 1999). However, no comprehensive study to assess the 
respective contribution of each disease has ever been undertaken in resource-poor, high infectious 
disease burden countries. This hinders any attempt to improve the present IMCI decision chart.  
The reason for the scarce data is that investigating systematically all fevers in inpatients and 
outpatient clinics is a major enterprise that needs rigorous methodology, highly skilled clinicians, and 
laboratory culture facilities. In addition, sophisticated molecular techniques are necessary to 
investigate the fevers with aetiologies still unknown after routine laboratory tests and cultures. This 
lack of knowledge has recently been acknowledged by the international science community and 
several studies are ongoing in different parts of the world. A similar attempt has already been 
conducted to improve knowledge on the aetiology of fevers in returning travellers and migrants. This 
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study has led to the publication of clear guidelines endorsed by the international scientific community 
(D'Acremont et al. 2003) and the construction of a web site (www.fevertravel.ch) aimed at helping 
primary care physicians to deal with such cases (Ambresin et al. 2007).  
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2. Goals and objectives 
 
Goal 
To improve the evidence-based management of fever cases seen in outpatient clinics in malaria 
endemic countries, through the implementation and assessment of accurate malaria diagnosis, and 
through an improved understanding of the main causes of fever in children. 
 
Objectives 
The IMALDIA project had 3 different but closely related objectives:  
1. To evaluate the safety of withholding antimalarials in febrile children with a negative mRDT living 
in a moderate and a highly endemic area 
2. To investigate the feasibility and value of implementing mRDT in the management of fever 
episodes in an urban malaria setting 
3. To describe systematically the aetiologies of fever in children living in an urban and a rural 
environment of Tanzania 
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3. Methodology for the main components of IMALDIA 
The general approach was to conduct operational research to assess the impact of mRDT 
implementation on antimalarial consumption in close to real conditions of large-scale deployment 
For the safety of mRDT in children, we worked in conditions between that of a clinical trial (the 
intervention being to force clinicians not to give antimalarials in children with a negative test) and 
operational research (all other conditions were those encountered in routine practice). For the study 
on aetiologies of fever we moved towards more basic clinical research in fully controlled conditions. 
3.1 Study design 
3.1.1 Safety of mRDT use in children less than five years 
We conducted a prospective two-arm longitudinal study in areas of moderate and high endemicity of 
Tanzania. Children with a history of fever were managed routinely by resident clinicians of two health 
facilities, except that no antimalarials were prescribed when the mRDT was negative. Children were 
followed up at home on day 7 for health outcomes 
Sample size 
300 children aged 6 months to 10 years in Dar es Salaam (moderately endemic setting) and 700 
children aged 2 months to 5 years in Signal (highly endemic setting) 
Primary outcome 
Rate of complications (admissions and deaths) in children mRDT negative at inclusion, with a 
positive mRDT during the follow-up period (mRDT positive children at inclusion were followed up for 
the same outcomes for indirect comparison). 
3.1.2 Feasibility of implementing malaria mRDT for the management of fever 
 
Intervention 
Introduction of mRDT in 9 health facilities in Dar es Salaam. Implementation involved: i) training of 
health care providers and laboratory staff; ii) regular supply of mRDT kits and; iii) regular supervision 
of their performance. Three comparable health facilities (HF) without mRDTs were selected randomly 
as matched controls. 
Method of evaluation 
We used two different data collection tools:  
1) Routine health statistics from health facilities registers of all types collected for 33 months (period 
before and period after mRDT introduction) 
2) Two cross-sectional surveys in all health facilities, one before and one 18 months after mRDT 
introduction, investigating consultation processes (direct observation of clinicians).  
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With both sources of data, we evaluated the impact of mRDT implementation on antimalarial 
prescription using two different analyses:   
1) Comparing data from the period before with the period after mRDT implementation in the 9 
intervention health facilities (before-and-after analysis)  
2) Comparing data from 6 intervention and 3 matched control health facilities 18 months after mRDT 
introduction (cluster-randomized analysis).  
For the before-and-after analysis, changes in practice were likely to be large and could reasonably 
be attributed to the intervention in the frame of a plausibility design (Habicht et al. 1999). To improve 
confidence in our assessment, we added a cluster randomized controlled study.  We matched 3 
primary care control health facilities with 6 primary care intervention health facilities and undertook a 
comparative study at baseline and after the intervention. Unfortunately, suitable controls did not exist 
for the 3 district hospitals, as they were all included in the study. 
Main outcome measures 
1) Using data of health facilities registers: routine statistics (called MTUHA books), laboratory 
registers, ledger books and dispensing books of pharmacies  
• change or difference in the number of antimalarials issued by the pharmacy 
• change or difference in the number of antibiotics issued by the pharmacy  
• change or difference in the number of malaria tests (mRDT and blood slides) performed per 
month 
• change or difference in the number of malaria diagnoses 
2) Based on the observation of clinicians’ consultation (using a standard questionnaire) 
• change or difference in the proportion of patients receiving antimalarials 
• change or difference in the proportion of patients receiving antibiotics  
• change or difference in the proportion of patients tested for malaria (by mRDT or blood slide) 
• change or difference in the proportion of patients tested for other diseases 
Study population and sample size (for the consultation’s observation) 
Patients of any age coming for a first consultation for the present problem, not having a severe 
illness requiring immediate admission or referral. 100 consultations per health facility for each survey 
(total: 2400) 
3.1.3 Aetiologies of fever in children less than five years 
A systematic investigation of the aetiology of fever was carried out in all children presenting at the 
outpatient department of one of the three municipal hospitals in Dar es Salaam (Amana hospital) and 
of the district hospital of Kilombero (St Francis hospital) and fulfilling the inclusion criteria.  
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Study population and sample size 
1000 consecutive children (500 in each site) aged 2 months to 10 years presenting with axillary 
temperature ≥ 38°C were included. 
Procedures 
All study procedures were derived from IMCI. A very detailed medical history, as well as a thorough 
clinical examination was performed on each child.  
- The first step was to identify those illnesses that are reliably diagnosed on clinical ground only. 
- All patients underwent venepuncture to estimate full and differential blood cell count, 
measurement of liver and kidney function tests, mRDT, Giemsa stained thick film for malaria and 
borrelia, Rapid Diagnostic Test for typhoid (tyRDT) and nasal swab. 
- Children with key-symptoms or signs that should lead to specific laboratory investigations (based 
on a pre-defined algorithm) were then identified. 
- A series of pre-defined criteria were used to attribute an aetiology with high (= ‘documented 
diagnosis’), intermediate or low probability. 
- All children without a ‘documented’ diagnosis (on clinical grounds or by the laboratory tests 
performed on the spot) at that stage, were further investigated by blood, urine or stool culture 
during the following days. PCR of respiratory viruses were performed for each child. Further 
molecular techniques and serologies will be done on the children with no clear aetiology. 
3.2 Study area and setting 
Study area in Dar es Salaam 
Dar es Salaam is the economic and political capital city of the United Republic of Tanzania, on the 
East coast of Africa. The current surface area is 1'393 sq. km and the population was estimated to be 
about 2'500'000 in 2002. As many other sub-Saharan African cities, Dar es Salaam has grown 
rapidly over the last decades (growth rate 4.3%).  
Dar es Salaam is governed by a political structure consisting of three levels: region, district and 
division. Table 2 shows the administrative levels in the city.  
 
Table 2: Dar es Salaam political and administrative structure 
District or 
municipal area Divisions Wards Subwards Mtaa Population (2002) 
Ilala  3 22 65 637'573 
Kinondoni  4 27 113 1'088'867 
Temeke  3 24 97 771'500 
Total  10 73 275 2'497'940 
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The three municipals (Kinondoni, Temeke and Ilala) are headed by commissioners. Alongside the 
political structure are the administrative and executive structures. The administrative structure of Dar 
es Salaam has four levels: city, municipality, ward (Kata) and subward (Mtaa). The highest level is 
the Dar es Salaam City Council. Below the City Director are three municipal directors, corresponding 
to the three political districts. The health sector is organized under the City Medical Office of Health 
(CMOH). Each of the three urban District Medical Offices (DMO) is responsible for and manages one 
municipal district hospital, one or two health centres and 13-14 dispensaries. In addition, there are 
non-government health facilities and a thriving private practitioners sector. 
Study area in Kilombero and Ulanga districts 
The Kilombero River separates the two districts of Kilombero and Ulanga districts that are both 
situated in the Morogoro region of the South-East of Tanzania (Figure 5). 
 
Figure 5: Map of Kilombero and Ulanga districts showing Ifakara town 
 
 
 
 
Large parts of the Kilombero Valley are flooded during the rainy season which usually lasts from 
November to May. In 2002, there were 517’000 people living in the 109 villages of the 2 districts. 
Ifakara, the administrative capital of Kilombero, is the major settlement in the valley with a population 
of approximately 46’000. 
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Malaria transmission in the area is intense and perennial with important differences between the rural 
and semi-urban settings. Overall transmission has been however declining over the past 10 years. A 
study conducted between 2001 and 2003 reported an entomological inoculation rate of 349 infective 
bites per person per year (Killeen et al. 2007), but according to recent data it has declined to 81 
(Russell et al, unpublished data). In Ifakara, the transmission rate is about a log order smaller than in 
the surrounding rural areas (Drakeley et al. 2003) 
Study setting 
The intervention of introducing mRDT in routine management of fevers took place in 9 health 
facilities with outpatient departments in Dar es Salaam (figure 6): the 3 municipal hospitals 
(Mwananyamala, Amana and Temeke) and 6 primary care health facilities (Kawe and Tandale in 
Kinondoni municipal, Buguruni and Tabata A in Ilala municipal, Kigamboni and Mbagala kizuiani in 
Temeke municipal). 
 
Figure 6: Health facilities included in the IMALDIA project.  
The pie charts show the malaria positivity rate by mRDT (Kahama-Maro, in preparation) 
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The health facilities were selected in collaboration with the DMO staff according to their size and 
willingness to participate. In addition, three additional primary care health facilities (Sinza in 
Kinondoni municipal, Vingunguti in Ilala municipal, Mbagala rangi tatu in Temeke municipal) were 
selected as control health facilities. 
The study on safety of using mRDT in children less than five years took place in Buguruni health 
centre in Dar es Salaam and Signal dispensary situated North-East of Ifakara (Ulanga district). 
The study on aetiologies of fever took place in the outpatient departments of Amana hospital in Dar 
es Salaam and in St Francis hospital in Ifakara (Kilombero/Ulanga districts).    
3.3 System of quality assurance for mRDT used in IMALDIA 
The reliability of mRDT needs to be monitored when used by health workers (laboratory technicians 
as well as clinicians) in the real conditions of managing a patient. For this purpose, a quality 
assurance system, both at central and peripheral level, was set up for the project.  
Three different brands of mRDT were used during the project [Paracheck (Orchid biomedical system, 
India), ParaHit (Span Diagnostics, India) and ICT malaria test (ICT diagnostics, South Africa)], 
depending on which one was attributed to us by the National Malaria Control Program of Tanzania. 
The quality assurance took place at 3 levels:  
- To make sure that the lots we used were of good quality, a specimen of each new consignment 
of mRDT was sent to a WHO reference laboratory (Muntinlupa City, Philippines and Bagamoyo, 
Tanzania) for lot-testing. All of them passed. 
- In the central pharmacy of Amana hospital, where our consignments were stored, as well as in all 
different storage places of each health facility, we organized every 3 months an check that 
included: 1) check of the minimum and maximum temperatures recorded in the place; 2) blind-
testing of 4 devices with 3 blood samples known to be either negative, or positive with a 
moderate or a high parasite density.  
- Observations of 12 pre-defined steps of the mRDT performance on a real patient for each health 
worker present on the day of the survey were also undertaken every 3 months (Figure 7).  
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Figure 7: Laboratory technician showing the result of mRDT to a patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 Ethics 
Informed consent and treatment of the participants 
Informed consent was obtained from every study participant after explaining the purpose, the risks 
and the benefits of the study.  
For the cross-sectional surveys in the feasibility study of mRDT implementation, as well as the study 
on safety of mRDT in children less than five years (where the patient is managed as usual), consent 
was first asked to the clinician in charge, who asked for oral consent from the patient or caretaker. 
For each patient, the study clinician observing the consultation then signed on the questionnaire to 
testify that informed consent was obtained.  
For the study on aetiologies of fever, written informed consent was obtained. This study was carried 
out by fully-trained and experienced physicians and health workers, strictly following current best 
practices for clinical care in Tanzania. We ensured that an appropriate treatment was offered to each 
child for a disease that was diagnosed within our investigation on fevers. As the Tanzanian National 
Treatment Guidelines had not been updated since 1997, the hospital directors asked us to rather 
prescribe the treatment recommended by the WHO manual for hospital care (WHO 2005a). If for any 
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reason the child could not get that treatment through the usual health care system, the investigators 
provided a treatment that was available in the country and this for the duration of the project. 
Human Immunodeficiency virus in the study on etiologies of fevers 
Originally, we had decided not to test the HIV status of the study children because of the low 
prevalence of HIV in this age group and the ethical and practical issues involved. The currently 
estimated rate of HIV positivity in children aged 1-9 years in Dar es Salaam is below 2% (Dar es 
Salaam City Medical Office of Health, unpublished) and the likelihood that a given fever episode is 
caused by HIV positivity is extremely low in this age group.  For comparison, the measured HIV 
positivity rate in pregnant women was 11% in Dar es Salaam in 2003/4 (National Bureau of Statistics, 
Tanzania and Macro International Inc. 2007).  
On the other hand we used the IMCI clinical criteria to detect a possible case of HIV/AIDS, so that we 
could counsel the caretaker to bring the child to Voluntary Counseling and Testing, available in the 
hospitals we were working in. We did not actively trace the result of the HIV test if it was done and 
left the decision of bringing us back the result at the discretion of the caretaker. Clinical management 
and anti-retroviral therapy for HIV positive adults and children were available free of charge in 
government health facilities of Dar es Salaam and at St Francis hospital in Ifakara. 
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4.1 Abstract 
Background 
Malaria is almost invariably ranked as the leading cause of morbidity and mortality in Africa. There is 
growing evidence of a decline in malaria transmission, morbidity and mortality over the last decades, 
especially so in East Africa. However, there is still doubt whether this decline is reflected in a 
reduction of the proportion of malaria among fevers. The objective of this systematic review was to 
estimate the change in the Proportion of Fevers associated with Plasmodium falciparum 
parasitaemia (PFPf) over the past 20 years in sub-Saharan Africa. 
Methods 
Search strategy 
In December 2009, we searched publications from the National Library of Medicine database using 
the combination of 16 MeSH terms.  
Selection criteria 
Inclusion criteria: studies 1) conducted in sub-Saharan Africa, 2) patients presenting with a syndrome 
of ‘presumptive malaria’, 3) numerators (number of parasitologically confirmed cases) and 
denominators (total number of presumptive malaria cases) available, 4) good quality microscopy.  
Data collection and analysis 
The following variables were extracted: parasite presence/absence, total number of patients, age 
group, year, season, country and setting, clinical inclusion criteria. To assess the dynamic of PFPf 
over time, the median PFPf was compared between studies published in the years ≤2000 and 
>2000. 
Results 
39 studies conducted between 1986 and 2007 in 16 different African countries were included in the 
final analysis. When comparing data up to year 2000 (24 studies) with those afterwards (15 studies), 
there was a clear reduction in the median PFPf from 44% (IQR 31-58%; range 7-81%) to 22% (IQR 
13-33%; range 2-77%). This dramatic decline is likely to reflect a true change since stratified 
analyses including explanatory variables were performed and median PFPfs were always lower after 
2000 compared to before. 
Conclusions 
There was a considerable reduction of the proportion of malaria among fevers over time in Africa. 
This decline provides evidence for the policy change from presumptive anti-malarial treatment of all 
children with fever to laboratory diagnosis and treatment upon result. This should insure appropriate 
care of non-malaria fevers and rationale use of antimalarials.  
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4.2 Background  
Currently, the global target for malaria control is to provide  prompt and effective treatment as well as 
insecticide-treated nets (ITNs) to 80% of the people at risk of malaria by the end of 2010 (Roll Back 
Malaria 2008; Rugemalila et al. 2006). The greatly increased malaria control effort since 2000 has 
been supported by global initiatives such as the Global Fund to fight AIDS, Tuberculosis and Malaria, 
the World Bank Malaria Booster Programme and the US Presidential Malaria Initiative. By the end of 
2008, more than 50 African states had adopted artemisinin-combination therapies (ACTs) and the 
number of ITNs distributed had increased more than 10 times in 14 African states (Roll Back Malaria 
2005). There is evidence now of reduced malaria transmission, morbidity and mortality in locations 
where these strategies have been massively deployed (O'Meara et al. 2008; WHO 2008). There is 
also a documented decline in Africa of Plasmodium falciparum prevalence rates in children aged 2-
10 years from 37% before the year 2000, to 17% after 2000 (Guerra et al. 2008). This decline is 
further evidenced in recent Demographic and Health Surveys (DHS) in malaria endemic countries of 
sub-Saharan Africa: 11 of the 12 national surveys conducted since 2004 showed declines in 
underfive mortality estimates over the previous five years (declines of 5% to 30%, median 23%) (de 
Savigny 2007). 
Theoretically, a reduction of malaria transmission, and hence parasitaemia, should translate into a 
decline of the proportion of fevers due to malaria, but the relationship between these two parameters 
is not straightforward. In part, this is due to the fact that the pattern of other causes of fever found in 
each area or patient population is not uniform and influence therefore the magnitude of the effect. 
Annual episodes of fever among African children have been estimated to be as high as 870 million 
(Robert W Snow et al. 2003). For those patients who reach clinics across the continent, a 
presumptive diagnosis of malaria is done in 30–40% of the cases (Chima et al. 2003a). Malaria thus 
appears to be the number one cause of fever in Sub-Saharan Africa, as well as the leading cause of 
mortality, at least in children (Rowe et al. 2006). However, these data might be largely overestimated 
nowadays due to the lack of specificity of a purely clinical diagnosis. Assigning malaria as a cause of 
fever in the absence of laboratory diagnosis is based on clinical experience but also on an 
understanding of the underlying epidemiology of the disease. Unfortunately, current practice by 
health care providers largely ignores the declining trend of P. falciparum parasite prevalence 
observed in community surveys and the proportion of fevers attributed to malaria does not seem to 
change. This question is of great practical relevance to correctly estimate the burden of disease due 
to malaria and for tracking progress in malaria control.   
The objective of the present project was, therefore, to review the available evidence on the 
proportion of fevers due to malaria over the last 20 years in sub-Saharan Africa, to identify trends 
and to quantify the magnitude of expected changes. This assessment has obvious implications for 
optimizing recommendations concerning the management of fever cases in children under five years 
of age who live in highly endemic areas.  
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4.3 Methods 
Criteria for considering studies for this review  
Type of studies: observational studies or diagnostic studies  
Inclusion criteria were i) study conducted in an area of sub-Saharan Africa where P. falciparum 
is the dominant species, ii) including patients (or a clear subset of patients) presenting at a 
health facility with a syndrome of ‘presumptive malaria’, either considered as such by the health 
worker in charge, or defined on clinical criteria by the investigators, iii) numerator (number of 
parasitologically-confirmed cases) and denominator (total number of presumptive malaria cases) 
available or possible to calculate from text, tables, or obtained after request to the authors, iv) 
good quality microscopy (reference centre or research laboratory), v) no obvious selection bias 
of patients. 
Exclusion criteria were: i) studies using a parasite density threshold for malaria case definition, 
ii) intervention studies and studies aimed at evaluating the incidence of malaria episodes, iii) 
studies including < 100 patients, or those focusing on inpatients only and severe malaria. 
The reasons for excluding these studies are as follows: i) defining a parasite threshold leads to a 
patients population that has lower proportion of malaria than when presence/absence of 
parasitaemia is used to define a case, ii) messages given to subjects in interventions studies 
(’attend as soon as possible in case of any symptom’) lead to a patients population that is likely 
to be biased towards milder cases, and hence potentially lower prevalence of parasitaemia 
(undetectable parasitaemia because of low density), iii) studies with < 100 patients would have 
lacked precision (more than +/- 10% in the prevalence estimate) and be at higher risk of bias 
and confounding because of the limited sampling.  
Type of participants 
Patients of any age 
Type of outcome measures 
Proportion of Fevers associated with Plasmodium falciparum parasitemia (PFPf) 
Search method for identification of studies 
All relevant published studies of human medicine, regardless of language were searched for. In 
the COCHRANE reviews, ‘malaria’ as search term was used. In MEDLINE, a combination of 
several MeSH terms was used in the following way: malaria AND Africa AND (diagnosis OR 
parasitemia OR microscopy) AND (epidemiology OR sensitivity and specificity OR prevalence 
OR seasons OR transmission OR cross-sectional studies OR predictive value of tests) AND 
(aetiology OR fever OR algorithms OR case management). Titles and abstracts to be reviewed 
were listed. On the basis of abstract reading, full papers were selected, reviewed and those that 
matched the selection criteria were retained. Then, abstracts of the related articles of this first 
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series of papers were explored, reviewed and eventually the full paper was read if deemed 
appropriate. All references of the retained papers were also examined. This process was 
performed iteratively until no new suitable study could be found.  
Databases 
Cochrane Infectious Diseases Group Specialized Register (up to 15th December 2009), 
MEDLINE (through 15th December 2009). 
Researchers and organizations 
The following authors were contacted for clarifications on entry criteria of patients or for 
additional information on proportion of malaria among their sample: Pedro Alonso, Patrick 
Kachur, Christoph Hatz, Sophie Yacoub, Babacar Faye, Thomas Mschana and Nadjitolnan 
Othingué.  
Reference lists 
The reference lists of all studies identified by the above methods was checked. 
Methods of the review 
Study selection 
One author (VdA) independently applied the inclusion criteria to all identified studies. All studies 
selected were checked by a second author (BG) for appropriateness. For studies for which there 
were doubts about inclusion, the second author assessed them fully and potential differences 
were discussed until consensus was reached. 
Data extraction 
Besides the proportion of fevers with associated Plasmodium falciparum, eight variables were 
extracted from each paper: year, season [rainy versus dry; when season was not mentioned it was 
searched on the CIA website (www.cia.gov) using dates of beginning and end of recruitment], 
country, setting (urban versus rural), health facility type (hospital versus primary care), age group (<5 
years, 5-15 years, adults), clinical inclusion criteria used and total number of patients.  
Data analysis 
As it was not possible to obtain the original databases of all studies, essentially a descriptive 
analysis on aggregated data was performed. The proportion of fever or presumptive malaria 
cases associated with P. falciparum documented by high quality microscopy, hereinafter 
referred to as proportion of fevers due to malaria (PFPf), was retrieved or calculated from each 
study. To assess the trend of PFPf over time, the median PFPf including all studies (pooled 
analysis) was compared for the period up to the year 2000, and for that from 2001 onwards. 
This threshold was chosen since large-scale interventions started around this time thanks to a 
massive increase in funding for control measures (Waddington 2004). That cut-off is also 
consistent with the analysis by Guerra et al for parasitaemia (Guerra et al. 2008). No formal 
multivariate analysis was possible since individual records for each study were not available. 
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However, to investigate potential confounding factors, a stratified analysis by age group (<5 and 
>5 years), season (rainy and dry), setting (rural and urban), type of health facility (primary care 
and hospital) was performed using data from studies where such information was available. 
These parameters are known to have an effect on malaria fevers and the categories are 
standard to describe the epidemiology of malaria. 
4.4 Results 
Description of studies   
Up to 15th December 2009, 170 titles were extracted from the COCHRANE database, but none was 
relevant for this review. From MEDLINE, 524 titles were identified and extracted, all abstracts were 
reviewed and 41 papers were selected in the first round. Based on the reading of the full article, 20 
met all inclusion criteria and were retained. After iterative cross-referencing of these 20 articles, 19 
additional articles meeting all inclusion criteria were found (see Figure 8). The 39 studies included in 
the final analysis were conducted between 1986 and 2007 and published between 1989 and 2009. 
The total number of patients included was 42,979 (median: 576; range: 149 to 7713). All relevant 
details of the included studies are described in Table 3. 
 
Figure 8:  Flow chart of the MEDLINE articles search 
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Time frame 
24 studies were conducted up to the year 2000 and 15 from 2001 onwards. 
Location 
The included studies were conducted in 16 different African countries. 21 studies took place in East 
Africa, mainly Tanzania (12 studies), 16 studies in West Africa, 1 in Central Africa (Chad)  and 1 in 
the Northern region (Sudan) (Figure 9).  
Age group 
Fifteen studies included children only (age <5 years, n = 8; age <9 years, n = 6; age <12 years, n = 
1). One study included only adults older than 18 years and one study only patients older than 5 
years. The remaining 22 studies included patients of all ages. 
Level of endemicity and transmission season 
Studies on clinical management of malaria have been done mainly in highly endemic areas and a 
period of the year with peak transmission, and this is reflected in the included studies. Patients were 
recruited during the rainy season only, the rainy and the dry seasons and the dry season only in 19, 
16 and 4 studies, respectively.  
Setting and level of health care 
Twenty one studies were conducted in a rural area of Africa (54%), while the remaining took place in 
urban areas. Also, 21 studies were undertaken at primary care level and the rest at hospital level. 
Overall proportion of parasitaemia among fever cases (PFPf) 
The proportion of parasitaemia among fever or presumptive malaria cases (PFPf) varied 
considerably between studies and sub-groups of patients within the same study. Taking each study 
as a unit, the median PFPf was 35% [inter-quartile range - IQR: 20-54%; range 2-81%).  
Variation of PFPf according to key stratification parameters 
Age group-specific PFPf  
Taking into account all studies where data were stratified by age or those that included only one 
defined age group, overall median PFPf was 36% (IQR 21-60%; range 4-77%) for children under five 
years (25 studies) and 26% (IQR 13-33%; range 1-53%) for those above five years (18 studies). In 
the 16 studies providing stratified values of PFPf in both age groups, median PFPf in children under 
five years of age (32%; IQR 18-55%) was not significantly different from that in the group above five 
years (27%; IQR 19-34%). When using only the 10 studies providing details for the older age groups, 
the median PFPf was 27% (IQR 20-50%) for the group under 5 years, 40% (IQR 22-48% for the age 
group of 5-15 years, and 24% (IQR 11-27%) in adults above 15 years.  
Season-specific PFPf  
The overall median PFPf was 37% (IQR 30-60%; range 4-77%) in the rainy season versus 5% (IQR 
4-12%; range 0-28%) in the dry season. Among all factors studied, this was the most dramatic 
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difference observed. This difference remained when restricting the analysis to the 7 studies providing 
stratified value of PFPf for both the rainy and dry seasons: 35% (IQR 25-57%) versus 5% (IQR 4-
9%). 
 
Figure 9: Geographical distribution of sites of included studies (blue pins are for studies ≤ 
year 2000 and red pins > year 2000) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Setting-specific PFPf 
Urban/rural There were 21 studies conducted in rural areas and 18 in urban areas (as defined by 
investigators). The overall median PFPf was 38% (IQR 22-57%; range 4-81%) in rural areas versus 
31% (IQR 19-50%; range 2-64%) in urban settings.   
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Level of health care 21 studies were conducted in primary care facilities and 18 in the outpatient 
department of a hospital. The overall median PFPf was 35% (IQR 22-44%; range 2-81%) in primary 
care settings versus 40% (IQR 16-56%; range 4-70%) in hospitals.  
PFPf up to the year 2000 and afterwards  
When comparing PFPf from studies conducted up to the year 2000 (24 studies) with those done 
afterwards (15 studies), there was a clear reduction in the median PFPf from 44% (IQR 31-58%; 
range 7-81%) to 22% (IQR 13-33%; range 2-77%) (Figure 10). 
 
Figure 10:  Comparison between the Proportions of Fevers associated with Plasmodium 
falciparum parasitemia (PFPf) in years ≤2000 and >2000, stratified by baseline characteristics 
 
 
 
This dramatic decline is likely to reflect a true change since all variables listed above and which were 
shown to have an effect on PFPf were well balanced between the two groups of studies. For studies 
before and after 2000 respectively, 17.5/24 (73%) and 9.5/15 (63%) studies were conducted during 
the rainy season (when a study took place during both the rainy and the dry season, the count was 
0.5 study for each of the season) (p = 0.45); 14/24 (58%) and 7/15 (47%) studies were conducted in 
a rural setting (p = 0.53); and 11/24 (46%) and 10/15 (67%) were conducted at primary care level (p 
= 0.32).  
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In the 11 studies from Tanzania (considered mostly as a highly endemic area), PFPf in children 
under five years during the rainy season decreased from 81% in 1986-88 (Rooth & A Björkman 
1992) to 57% in 1995 (Font et al. 2001), 38% in 1997 (Nsimba et al. 2002) and 21% in 2005 
(Reyburn et al. 2007).  
To further check for potential confounding factors, a stratified analysis was conducted including each 
of the variables listed above. The reduction of PFPf over time was confirmed since median PFPfs 
were almost always lower for the years after 2000 compared to the years ≤2000 (see Figure 10). 
There was one exception in the case of the data collected during the dry season. 
4.5 Discussion 
This systematic review demonstrates a 50% reduction of PFPf for the period after year 2000 when 
compared to that of ≤2000 (22% versus 44%). This decrease by half of the proportion of malaria 
cases among fever episodes is likely to be due to a reduction of malaria transmission. It mirrors the 
reduction observed in parasite prevalence rates collected from community cross-sectional surveys in 
sub-Saharan Africa during the same time periods (17% after year 2000 versus 37% before) (Guerra 
et al. 2008). A decrease in malaria is now observed in many settings across sub-Saharan Africa, 
mainly because of the large scale implementation of effective control measures following a drastic 
increase of funding since the year 2000 (Waddington 2004). Recently, Okiro & Snow demonstrated 
the clear linear relashionship between the risk of infection among febrile children and parasite 
prevalence in the community (Okiro & Snow 2010).  
An inherent difficulty with systematic reviews is that they look at studies which may not be 
comparable. In the present review, the most recent studies report a lower proportion of malaria 
attributable fevers, but some of these later studies have been conducted in areas of lower endemicity 
than those performed previously. This is especially true for some studies in Tanzania, a country 
largely represented in this systematic review. In part, this was due to the fact that some of the recent 
studies were conducted in urban and peri-urban settings, whereas old ones were traditionally done in 
rural places, where transmission of malaria is usually higher. Part of the reduction in the proportion of 
malaria among fevers may thus be ascribed to selection biases. To address this problem, stratified 
analyses for variables known to have an effect on PFPf were performed. These analyses confirmed 
the reduction of PFPf over time when controlling for these different factors. The only exception was 
for dry season and this is easily explainable by the fact that the median PFPf was always rather low, 
irrespective of the period. Whe data are available, such as in Tanzania for example, the substantial 
reduction of PFPf parallels closely the decline of incidence of malaria episodes and overall mortality 
in children under five observed in the same areas over the last fifteen years (Schellenberg et al. 
2004; Masanja et al. 2008; Khatib et al, unpublished data).   
Although the reduction of PFPf was considerable, it is unclear how representative these data are at 
this point in time.  Data are over-represented in sites with research institutions or special situations 
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and it would be a great importance to confirm such trends in other settings, especially in the largest 
malarious countries on the continent, the Democratic Republic of the Congo and Nigeria. Also, within 
a country or region, the reductions are not necessarily uniform. There are still a number of places 
that harbour PFPf over 50%, especially so in areas where healthcare is not readily accessible. 
On the other hand, there is no doubt that malaria control is very successful in many countries (WHO 
2009b) and these trends are expected as a result of greatly improved preventive activities. In any 
case, the immediate practical implication of the changing epidemiology of fever episodes is the much 
increased need for a systematic laboratory diagnosis of every case before initiating treatment for 
malaria (Chapter 6).  
4.6 Conclusions 
This systematic review demonstrates a considerable reduction of PFPf in sub-Saharan Africa 
between the periods before the year 2000 and from 2001 onwards (44% versus 22%). With only 
around a fifth of all fever episodes being associated with malaria parasitaemia, this review provides 
strong evidence to support the new WHO policy of laboratory-based diagnosis and treatment upon 
result (WHO 2010). This should insure appropriate care of non-malaria fevers and rationale use of 
anti-malarials. The relative cost effectiveness and value of introducing diagnosis for febrile children 
will obviously depend on infection prevalence in the community. 
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Table 3: All 39 included studies showing the Proportions of Fevers associated with 
Plasmodium falciparum parasitemia (PFPf) 
 
Reference 
Start 
of the 
study Country 
Urban 
/ rural 
area 
Place of 
recruit-
ment 
Clinical inclusion 
criteria 
Total 
number 
of 
patients 
Overall 
PFPf 
Age 
groups Season PFPf 
Rooth & A 
Björkman 
1992 
1986 Tanzania Rural Primary 
care 
History of fever 596 81% < 9 years Both seasons 81% 
Rougemont 
et al. 1991 1987 Niger Rural 
Primary 
care 
Temp >37.5°C 285 57% < 9 years Rainy season 57% 
< 5 years 61% 
5-18 years 60% Salako et al. 1990 1987 Nigeria Urban Hospital 
History of fever 
or elevated temp 7713 55% 
> 18 years 
Both seasons 
41% 
Ejezie & 
Ezedinachi 
1992 
1988 Nigeria Urban Hospital Presumptive 
malaria  1188 45% < 9 years Both seasons 45% 
< 9 years 28% 
10-14 years 35% Gaye et al. 1989 1988 Senegal Urban  
Primary 
care 
Temp >38°C 353 31% 
> 14 years 
Rainy season 
33% 
Rainy season 62% Olivar et al. 
1991  1989 Niger Urban  
Primary 
care 
Temp >38°C 576 35% < 5 years 
Dry season 5% 
Lubanga et 
al. 1997  1992 Uganda Urban  Hospital History of fever 435 64% < 5 years Rainy season 64% 
Meremikwu 
et al. 1995 1993 Nigeria Urban Hospital Temp >37.5°C 225 63% < 5 years Rainy season 63% 
Redd et al. 
1996  1993 Malawi Rural Hospital 
Presumptive 
malaria 1124 60% < 5 years Rainy season 60% 
Olaleye et al. 
1998 1993 the Gambia Rural 
Primary 
care 
History of fever 
or temp >37.5°C 407 59% < 9 years Rainy season 59% 
Rainy season 17% Weber et al. 
1997  1993 the Gambia Urban Hospital 
Presumptive 
malaria 440 7% < 5 years Dry season 4% 
Rainy season 59% 
All ages 
Dry season 5% 
< 5 years 14% 
Gaye et al. 
1997  1994 Senegal Urban  Hospital History of fever 762 31% 
> 5 years 
Both seasons 
36% 
< 5 years 57% Font et al. 
2001  1995 Tanzania Rural  
Primary 
care 
History of fever  
or temp >37.5°C 641 44% > 5 years 
Rainy season 
24% 
Tarimo et al. 
1998 1996 Tanzania Urban Hospital 
Presumptive 
malaria  400 52% All ages Both seasons 52% 
Cooke et al. 
1999 1996 the Gambia Rural Hospital 
History of fever 
or elevated temp 398 36% All ages Rainy season 36% 
Rainy season 30% Muhe et al. 
1999  1996 Ethiopia Rural  
Primary 
care 
History of fever 
or temp >38°C 2490 22% < 5 years Dry season 6% 
Cortes et al. 
2003  1996 Mauritania Urban Hospital History of fever 416 19% All ages Both seasons 19% 
Rainy season 20% Oster et al. 
2000  1996 Tanzania Rural Hospital 
History of fever  
or temp >37.5°C 168 14% Adults Dry season 0% 
Nsimba et al. 
2002  1997 Tanzania Rural 
Primary 
care 
Presumptive 
malaria 449 38% < 5 years Rainy season 38% 
< 6 years 57% 
7-15 years 44% Akim et al. 2000 1997 Tanzania Rural 
Primary 
care 
History of fever 6580 43% 
> 15 years 
Both seasons 
27% 
< 5 years 32% 
5-15 years 35% Arness et al. 2003 1998 Kenya Rural 
Primary 
care 
Presumptive 
malaria  2796 29% 
> 15 years 
Both seasons 
23% 
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Tarimo et al. 
2001 2000 Tanzania Rural  Hospital 
Malaria based on 
IMCI criteria 395 70% < 5 years Rainy season 70% 
< 5 years 64% Guthmann et 
al. 2002  2000 Uganda Rural Hospital 
Presumptive 
malaria  742 57% > 5 years 
Rainy season 
52% 
< 5 years 55% 
5-15 years 57% Gouagna et al. 2003 2000 Kenya Rural 
Primary 
care 
Presumptive 
malaria  3754 47% 
> 15 years 
Both seasons 
36% 
< 15 years 37% Raharimalala 
et al. 2002 2001 
Madagas- 
car 
Rural Primary 
care 
Presumptive 
malaria  149 35% > 15 years 
Rainy season 
29% 
< 5 years 31% Assoumou et 
al. 2008 2001 Ivory Coast Urban Hospital Temp >37.5°C 902 29% 5-15 years 
Both seasons 
27% 
Rainy season 35% 
All ages 
Dry season     12% 
< 5 years 19% 
5-14 years 50% 
Othnigué et 
al. 2006  2002 
Chad 
 
Urban  Primary 
care 
Presumptive 
malaria 712 30% 
> 15 years 
Both seasons 
27% 
Zurovac et al. 
2006b  2002 Kenya Rural 
Primary 
care 
Sent for malaria 
test by clinician in 
charge 
261 13% > 5 years Rainy season 13% 
< 5 years 11% Malik et al. 
2005  2002 Sudan Urban Hospital History of fever 655 12% 5-16 years 
Dry season 
13% 
< 5 years 36% 
6-15 years 44% Wang et al. 2006c  2002 Ivory coast Urban 
Primary 
care 
History of fever 
or temp >37.5°C 429 35% 
> 15 years 
Rainy season 
26% 
< 5 years 22% 
6-15 years 37% Wang et al. 2005b  2002 Burkina Urban 
Primary 
care 
History of fever 
or temp >37.5°C 560 22% 
> 15 years 
Dry season 
18% 
< 5 years 5% 
6-15 years 7% Wang et al. 2006a  2003 Tanzania  Urban  
Primary 
care 
History of fever 
or temp >37.5°C 717 5% 
> 15 years 
Dry season 
4% 
< 5 years 4% 
6-15 years 0% Wang et al. 2006b  2003 Benin Urban 
Primary 
care 
History of fever 
or temp >37.5°C 379 2% 
> 15 years 
Dry season 
1% 
Yacoub et al. 
2005 2003 Zanzibar Rural 
Primary 
care 
History of fever 
or temp >37.5°C 207 77% < 5 years Rainy season 77% 
Rainy season 62% Ogungbamig
be et al. 2007 2004 Nigeria Urban Hospital Temp >37.5°C 646 53% < 9 years Dry season 28% 
< 5 years 43% Kachur et al. 
2006 2004 Tanzania Rural  
Primary 
care 
History of fever 769 31% 
> 5 years 
Rainy season 
23% 
< 5 years 21% 
5-15 years 17% Reyburn et al. 2007  2005  Tanzania Rural Hospital 
Sent for malaria 
test by clinician in 
charge 
2397 15% 
> 15 years 
Rainy season 
8% 
Reyburn et 
al. 2006  2005 Tanzania Rural Hospital 
Sent for malaria 
test by clinician in 
charge 
214 4% All ages Rainy season 4% 
Mens et al. 
2008 2007 Kenya Rural 
Primary 
care 
History of fever 
or temp >37.5°C 650 17% < 12 years Rainy season 17% 
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5.1 Abstract 
Background 
The availability of a Rapid Diagnostic Test for malaria (mRDT) allows accurate diagnosis at all levels 
of health facilities. The objective of the present study was to evaluate the safety of withholding 
antimalarials in febrile children with a negative test result. 
Methods 
We conducted a prospective 2-arm longitudinal study in areas of Tanzania that are moderately and 
highly endemic for malaria. Children with a history of fever were managed routinely by resident 
clinicians of 2 health facilities, except that no antimalarials were prescribed if the mRDT was 
negative. Children were followed up at home on day 7. The main outcome was the occurrence of 
complications in children with negative mRDT results; children with positive mRDT results were 
followed up for the same outcomes for indirect comparison. 
Results 
One thousand children (median age, 24 months) were recruited. Six hundred three children (60%) 
had a negative mRDT result. Five hundred seventy-three (97%) of these children were cured on day 
7. Forty-nine (8%) of the negative mRDT results spontaneously visited the dispensary before day 7, 
compared with 10 (3%) of the children with positive mRDT results. All children who had negative 
initial results had negative results again when they were tested either at spontaneous attendance or 
on day 7  because they were not cured clinically, except for 3 who gave positive results on days 2, 4 
and 7 respectively but who did not experience any complication. Four children who had negative 
initial results were admitted to the hospital subsequently, all with negative results for malaria tests 
upon admission. Two of them died, of causes other than malaria. 
Conclusions 
Not giving antimalarial drugs in febrile children who had a negative mRDT result was safe, even in an 
area highly endemic for malaria. Our study provides evidence for treatment recommendations based 
on parasitological diagnosis in children <5 years old. 
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5.2 Introduction 
The number of episodes of fever among African children could be as high as 870 million per year 
(Snow et al. 2003). Among children who reach outpatient clinics across the continent, a presumptive 
diagnosis of malaria is given in 30–40% of these cases (Chima et al. 2003b). Malaria appears 
therefore to be the number one cause of fever, as well as the leading cause of mortality, in children in 
Sub-Saharan Africa (Rowe et al. 2006). In 2006, the World Health Organization (WHO) published the 
following treatment recommendation: ‘In areas of high stable malaria transmission, the prior 
probability of fever in a child being caused by malaria is high. Children <5 years of age should 
therefore be treated on the basis of a clinical diagnosis of malaria. There is as yet no evidence to 
show that the benefits of parasitological diagnosis in this highly vulnerable group outweigh the risks 
of not treating false negatives.’ (WHO 2006). Obviously, the prime reason for this recommendation of 
blanket antimalarial treatment is to save lives. It takes into account the lack of sensitivity and lack of 
specificity of the clinical diagnosis of malaria (Chandramohan et al. 2002).  
Although this recommendation was probably sound at the time of its formulation, it should now be 
reviewed because of the steady decline in malaria transmission that is occurring all over Sub-
Saharan Africa. This decrease is due to large-scale control (WHO 2008; Guerra et al. 2008) and the 
availability of reliable, inexpensive and easy-to-use malaria diagnostic tools (Chris Drakeley & 
Reyburn 2009). One consequence of the falling transmission rates is that the blanket approach to 
treatment is not as safe as it was a decade ago, because the malaria-attributable fraction of fevers is 
now significantly lower and therefore the relative likelihood of missing other potentially fatal diseases 
has become higher (Chapter 6). To support a change to this recommendation, WHO looks for 
convincing evidence on the safety of treating children <5 years old who live in areas endemic for 
malaria on the basis of a malaria test result.  
The few studies that have looked at the outcome of treating febrile children who live in areas 
endemic for malaria on the basis of a malaria laboratory test suggest that this strategy might be safe 
(Njama-Meya et al. 2007; Ngasala et al. 2008; Msellem et al. 2009). To our knowledge, our study is 
the first prospective study in an area that is highly endemic for malaria that took place under routine 
implementation conditions with the aim of evaluating the safety of withholding antimalarials in febrile 
children who have a negative result for a rapid diagnostic test for malaria (mRDT). Our primary 
interest was the clinical outcome of the children, namely the rate of complications and deaths, 
irrespective of any other consideration (eg, parasitemia). The mRDT testing by health care workers in 
both of our study settings was found to be reliable in a previous study (Kahama-Maro et al. 2008).  
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5.3 Methods 
Study areas 
This work is part of a larger project on the introduction of mRDT in Tanzania and the evaluation of its 
impact on health outcomes, drug prescriptions, consultation processes, patient and health worker 
satisfaction, and cost saving (IMALDIA: Understanding and improving malaria diagnosis in 
Tanzania). The present study was performed first in an area of moderate endemicity and then in an 
area of high endemicity. This stepwise design was chosen to ensure the safety of the patients. If the 
strategy of withholding antimalarials in febrile children with a negative malaria test were shown to be 
not safe in an area of moderate endemicity, the second part of the study in an area of high 
endemicity area would be canceled.   
Dar es Salaam: Buguruni Health Center of Ilala Municipality in the city center of Dar es Salaam, 
Tanzania was chosen as a place of recruitment because of its characteristics typical of the urban 
setting. This area is moderately endemic for malaria, with parasite rates in the community at ~ 1%-
4% (Wang et al. 2006a) and with only 5%-10% of febrile patients being parasitemic (Chapter 7).  
Signal: Signal is a remote village in the Kilombero Valley (south-central Tanzania). The local health 
facility was chosen because of the ready availability of mRDT, the high percentage of febrile patients 
having parasites (~50%) and the sufficiently high average number of patients attending daily (30), 
compared with the characteristics of the other remote dispensaries in the Kilombero Valley. mRDT 
had been introduced in 7 health facilities in the area 1 year previously, with a 1-day initial training of 
all health care workers, a 2-month follow-up of general performance, and a routine quality assurance 
of the mRDT (including lot testing at a WHO reference laboratory) every 3 months. No further training 
was conducted in the Signal health facility in the frame of the present study. 
Study subjects 
Inclusion criteria were as follows:  
- 1. Children were aged from 6 months to 10 years in Dar es Salaam and from 2 months to <5 
years in Signal. 
- 2. Children attending the health facility for the first time for the present problem. 
- 3. There was a history of fever in the last 48 hours or axillary temperature of >37.5°C at the time 
of consultation. 
- 4. There was an absence of severe illness that required specific treatment or referral 
- 5. The main complaint was neither injury nor trauma. 
Study procedures 
Oral informed consent was obtained from the parent or guardian. Patients were managed at the 
discretion of the clinicians, except that the latter were asked to perform an mRDT (ParaHit-f  
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cassette; Span Diagnostics) and to not prescribe antimalarials if the result was negative. A blood 
slide was also prepared as back-up for retrospective investigation of complicated cases. Patients 
were asked to come back to the same health facility in case of any problem. In Dar es Salaam, 
parents and guardians were informed that they would be visited at home after 7 days (+/- 1 day) to 
assess whether the child was cured. In Signal, we asked them to come back on day 7 for the same 
reason. If they had not returned on the due day before 2:00 PM, they were visited at home on the 
same or on the following day. At each home, the clinician would ask the parent or guardian about the 
status of the child (cured, not improved or condition worsened) and whether they had gone to 
another health facility in the meantime.  
If the child were ill between day 0 and day 7 or not cured on day 7, a new consultation was 
performed by the usual clinician of the health facility, and the patient was tested again with either an 
mRDT (if the test was negative on inclusion) or by microscopy (when the initial mRDT test result had 
been positive). Patient management was again left to the discretion of the clinician, and antimalarials 
were again withheld if the test was negative. The child was then visited at home on day 14 to check 
his or her status. 
Children who had positive mRDT were treated with the recommended first-line antimalarial 
(artemether-lumefantrine [Coartem]) and followed up in the same way as children who had negative 
mRDT results. For obvious reasons, they did not represent a proper control group, because they 
represented a clinically very different group of children. Consequently, no tests of significance were 
performed to compare the 2 groups. 
We calculated that a sample of 500 malaria-negative children was required to estimate an adverse 
event rate of 5% with a precision of ± 2%. This risk was estimated on the basis of the sensitivity of 
routine mRDT (90%) combined with a 50% risk of complication (defined as hospital admission or 
death) due to delayed diagnosis and therefore absence of timely treatment. 
The study protocol and related documents were approved by the Ethikkommission beider Basel 
(EKBB) in Switzerland and by the National Institute for Medical Research Review Board in Tanzania. 
The procedures followed were in accordance with the ethical standards of the responsible committee 
on human experimentation and with the Helsinki Declaration. 
5.4 Results 
Status at inclusion 
In Buguruni health centre (Dar es Salaam), 300 children with a median age of 28 months (range: 3 -
120 months, with 256 [86%] being <5 years old) were included in May-June 2007. One hundred 
forty-three (48%) were female. All had a history of ‘homa’, the Swahili word for fever, although this 
was the main complaint in only 205 (68%) of the cases. The axillary temperature was >37.5°C in 118 
(39%) of the children. At inclusion, 41 (14%) of the 300 children had a positive mRDT result. All 41 
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children with positive results were treated with an antimalarial: 35 (85%) received  artemisinin-
lumefantrine and the rest received oral quinine. Thirteen children with positive results (32%) also 
received an antibiotic. Except for one child, all children with negative results received an antibiotic 
(cotrimoxazole, amoxicillin, and injectable penicillin were mostly used). 
In the Signal dispensary (Kilombero), 700 children with a median age of 24 months (range, 2-59 
months) were included from September 2008 through February 2009. Three hundred forty-one (49%) 
were females. They all had a history of homa, which was the main complaint in 604 (86%) of the 
cases. The axillary temperature was >37.5°C in 404 (58%) of the children. At inclusion, 356 (51%) of 
the 700 children had a positive mRDT result. All children with positive results were treated with an 
antimalarial: 342 (96%) with artemisinin-lumefantrine and the rest received injectable or oral quinine. 
Sixty-four (18%) of the 356 children with positive results also received an antibiotic. Three hundred 
twelve (91%) of the 344 children with negative results received an antibiotic. 
Spontaneous attendance before day 7 
In total, 59 (5.9%) of the 1000 children consulted spontaneously before day 7, the majority of them 
(45 [76%]) visiting the same facility that they visited for the initial consultation. Among the 603 
children who had a negative mRDTresult at inclusion, 49 (8%) (representing 31 [12%] of 259 in Dar 
es Salaam and 18 [5%] of 344 in Signal) attended before day 7 (median, 3 days after inclusion), with 
persisting fever in 37 children (despite antibiotics prescribed at first place in 35 of them). Among the 
397 children who had a positive mRDT result at inclusion, 10 (3%) attended spontaneously before 
day 7 (median, 4 days after inclusion), with persisting fever in 5 children (4 of them had received an 
antibiotic at inclusion in addition to the antimalarial) (Figure 11). 
Outcome on day 7 and 14 
Thirteen (1.3%) of the 1000 children included were lost to follow-up, either because they had moved 
or the address was not sufficiently precise. Among the 591 children who had a negative mRDT 
result, 573 (97%) were cured on day 7. For the remaining 18 children, 15 were examined before or 
on day 7 because of fever, 2 because of diarrhea and one because of a headache. Of these 18 
children, 14 were cured on day 14, 2 died (see below), and 2 were lost to follow-up after day 7 (both 
had negative mRDT results on day 7). Among the 396 children who had a positive mRDT result, 387 
(98%) were cured on day 7 (38 [95%] of 40 in Dar es Salaam and 349 [98%] of 356 in Signal). Eight 
children were still febrile (all had a negative blood slide results) and 1 had asthma. All these children 
were cured on day 14 (1 was lost to follow-up after day 7) (Figure 11). 
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Figure 11: Flow chart of patients in a study of withholding antimalarials in febrile children who 
have a negative result for a rapid diagnostic test in Tanzania. BS, [result of] blood slide for 
malaria; RDTm, [result of] rapid diagnostic test for malaria. 
 
Complications 
Among the 603 children who had a negative mRDT result at inclusion, 4 (1 in Dar es Salaam and 3 in 
Signal) were hospitalized: 1 on day 2 because of severe sepsis with exanthema, 1 on day 4 because 
of severe pneumonia, 1 on day 7 because of gastroenteritis with severe dehydration, and 1 on gay 7 
because of severe anaemia without fever. These 4 children had an mRDT and an expert microscopy 
for malaria performed upon admission at the hospital and all gave negative results. Two children died 
(1 with severe sepsis died on day 6, and 1 with severe pneumonia died on day 8). Among the 397 
children who had a positive mRDT result at inclusion, 1 was hospitalized on day 7, because 
pneumonia had not responded to the first-line intravenous antibiotic treatment (Figure 11). 
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Subsequent mRDT results of the children with negative initial results who consulted before 
day 7 or who were not cured on day 7 
Among the 603 children who had negative mRDT result at inclusion, 55 consulted spontaneously 
before day 7 or were not cured on day 7 when we visited them at home. Of these 55 children, 51 had 
negative mRDT results; one had positive results on day 4 and two on day 7 (all living in Signal, the 
area of high endemicity), and one could not be tested but recovered on day 14 after receiving 
erythromycin prescribed in another health facility. Among the 3 newly positive results, 1 child was 
likely to have had coincidental low-density parasitemia. Indeed, he had positive results on day 4 and 
did not respond to the antimalarial treatment given on that day, but he responded to an antibiotic 
given on day 7. Another child had dysuria at inclusion, received amoxicillin, and recovered, but he 
became feverish again at day 5 with dysuria; he had positive test results at day 7 and was treated 
with intramuscular quinine and cotrimoxazole and was cured on day 14. He had either a coincidental 
or a new infection. The last child had vomiting on day 0 and was treated with cotrimoxazole; then, 
because of persisting fever, he attended another dispensary on day 2 where he was not tested for 
malaria but received oral quinine. He was cured on day 7 but had positive results by mRDT. He 
might have experienced a malaria episode that was not diagnosed on day 0 because of clinical 
symptoms that appeared before patent parasitemia 
5.5 Discussion 
To our knowledge, our study is the first to provide strong evidence that withholding antimalarial 
treatment in children with fever who have a negative mRDT result in a setting highly endemic for 
malaria is safe and does not expose the child to an increased risk of complication or death. Because 
the present study was conducted with programmatic conditions that were reasonably close to routine, 
we believe that the results are applicable more generally.  
Complications or deaths 
In this cohort of 1000 feverish children, 60% had a negative mRDT result at inclusion and were not 
treated with an antimalarial. We did not observe any complication or death due to malaria among 
these children. In total, 4 children (0.7%) were admitted to the hospital and 2 (0.4%) died; malaria 
test results on admission were negative for all 4. Our study provides strong evidence that the 
strategy is safe, irrespective of the level of endemicity of malaria. To our knowledge, the only other 
study with a follow-up of fever episodes in untreated children with negative tests results (tested by 
expert microscopy rather than by mRDT) was the study by Njama-Meya et al in Kampala, Uganda 
(Njama-Meya et al. 2007). That study, designed primarily to assess the efficacy of antimalarial drugs, 
was performed in a highly controlled setting and included children with danger signs. No complication 
or death due to the withholding of antimalarial treatment in children with negative results occurred.  
Although the absence of a proper control group did not allow us to know the usual rate of 
complications in the absence of any reliable malaria test, the lack of admissions and/or deaths due to 
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malaria following mRDT use certainly suggested that this approach is safe. One (0.3%) of the 397 
children in the malaria group and 4 (0.7%) of the 603 children in the nonmalaria group were admitted 
after first consultation. There was no death among the malaria group and 2 deaths in the nonmalaria 
group. We know that these complications in nonmalaria patients were not due to undetected malaria 
parasites, because we had performed ≥3 malaria tests on each of these children and none had 
positive results.  
On the basis of 2 previous studies on severe malaria conducted in Tanzania, we knew that the rate 
of adverse outcomes is higher in nonmalaria patients, compared with the rate in malaria patients, 
because diseases such as pneumonia, typhoid or meningitis have a fatality rate at least as high as 
that of malaria and because severely ill febrile patients are often misdiagnosed as having malaria 
and therefore do not receive appropriate antibiotics (Makani et al. 2003; Reyburn et al. 2004). Such a 
trend was also found in our study which included less severe cases. Therefore, accurate diagnosis is 
essential even at outpatient level to prevent the further occurrence of complications and deaths. This 
is especially true now, because of the regular decrease in malaria transmission in many endemic 
settings of endemicity (WHO 2008; Ceesay et al. 2008; O'Meara et al. 2008), and therefore the 
relative increase of fevers due to other treatable causes in many places in Africa. 
Outcome on day 7 
In our study, the percentage of children not cured on day 7 was very low in both groups (2% in the 
malaria group versus 3% in the nonmalaria group). The 9 malaria patients who were still sick after 1 
week all had a negative result for a follow-up blood slide. Therefore, it is very likely that they were 
suffering from another fever cause, with parasitemia being coincidental. For the nonmalaria cases, 
17 of the 18 children who were not cured on day 7 had received an antibiotic, which suggests that 
they had either a viral disease with prolonged fever or a bacterial disease resistant to the first-line 
antibiotic. In these 2 areas, we know that nonmalaria fevers are composed of 56% acute respiratory 
infections, 10% gastroenteritis, 6% urinary infections, 3% typhoid, 3% other documented infections 
and 22% fever of unknown origin. Furthermore, 68% of acute respiratory infections and 31% of 
gastroenteritis are associated with documented viruses (Chapter 9) that obviously do not respond to 
antibiotics and that therefore tend to persist longer than malaria episodes treated with an effective 
drug. For nonmalaria fevers due to bacteria, the high rate of resistance to first-line antibiotics in 
Tanzania also leads to prolonged episodes (Blomberg et al. 2007). 
Outcome of children with negative initial results and positive subsequent results 
There are several reasons for which a malaria test can yield negative initial results and positive 
subsequent results within a few days: (1) coincidental low-density malaria fluctuating around the 
threshold of detection of a malaria test; (2) symptoms and signs appearing before parasites can be 
detected in the blood by conventional tests, especially in non-immune infants or young children; (3) 
new infections; and (4) failure of the test (negative test result in the presence of normal density 
parasitemia). Coincidental or new infection is the most likely explanation for 2 out of the 3 patients 
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with initial positive results and positive subsequent results. In an area of high endemicity, it is 
expected to have some children presenting with new parasitemia every day. We found in our sample 
of children from Signal an incidence of malaria in the 7 days after a negative test result of 0.45 
episodes per child per year, which is lower than expected. This rate is close to the one reported by 
Njama-Meya et al  (0.42 episodes per child per year) (Njama-Meya et al. 2007) and found by using 
microscopy instead of mRDT. It is also similar to the incidence of malaria episodes in infants (0.43  
episodes per infant per year) found by using passive-case detection in the main town of Kilombero 
District in the year 2000 (Schellenberg et al. 2004). Failure of the mRDT to detect parasitemia of a 
density high enough to be detected by conventional test did not occur in our study, because all 3 
patients who had negative mRDT results at inclusion also had negative results by expert microscopy. 
In Njama-Meya’s study (Njama-Meya et al. 2007), this happened for 2 children diagnosed with expert 
microscopy. False negative results do exist with mRDT but possibly at a lower rate than with expert 
microscopy, as demonstrated by Ochola et al (Ochola et al. 2006) and Bell et al (Bell et al. 2005).  
5.6 Conclusions 
In 2 Tanzanian settings (1 urban and 1 rural), the strategy of mRDT-based diagnosis and treatment 
proved to be safe, with no case missed by a negative initial mRDT result ending in complication or 
death. The sample size of our study allowed us to say with 95% confidence that the probability of 
such an unfavourable event was between 0% and 0.5% (rule of three) (Eypasch et al. 1995). 
Although our study does not provide the definite answer in this matter, it contributes important 
evidence towards a change in policy in malaria diagnosis and treatment, and thus towards a better 
management of fever in countries endemic for malaria.  
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Background to the debate: Current guidelines recommend that all fever episodes in African children 
be treated presumptively with antimalarial drugs. But declining malarial transmission in parts of sub-
Saharan Africa, declining proportions of fevers due to malaria, and the availability of rapid diagnostic 
tests mean it may be time for this policy to change. This debate examines whether enough evidence 
exists to support abandoning presumptive treatment and whether African health systems have the 
capacity to support a shift toward laboratory-confirmed rather than presumptive diagnosis and 
treatment of malaria in children less than five. 
 
In this Viewpoint, Blaise Genton and colleagues argue in favour of abandoning presumptive 
treatment for under-fives. Mike English and colleagues present the opposing Viewpoint in a related 
article: 
English M, Reyburn H, Goodman C, Snow RW (2009) Abandoning presumptive antimalarial 
treatment for febrile children aged less than five years—A case of running before we can walk? PLoS 
Med 6(1): e1000015. doi:10.1371/journal.pmed.1000015 
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Malaria has long been the number one cause of fever and the leading cause of child mortality in sub-
Saharan Africa. As a result, the World Health Organization (WHO) recommends treating any fever 
episode in African children with antimalarial drugs to save lives. However, this approach may not be 
as safe as it was 20 years ago for two major reasons. Firstly, the proportion of fevers due to malaria 
has become significantly lower, even in highly endemic areas, and hence the relative likelihood of 
missing other potentially fatal diseases has become higher. Secondly, we now have new reliable 
rapid diagnostic tests (mRDT) to allow proper diagnosis of malaria at all levels of the health system.  
Evidence of Decreased Malaria Transmission in Sub-Saharan Africa, and 
Declining Proportion of Fevers Due To Malaria  
There is growing evidence documenting a substantial decline in malaria transmission, morbidity, and 
mortality in more than 13 African countries where malaria control interventions have been 
implemented at scale. This reduction is also observed in areas with previously high levels of 
transmission (e.g., WHO, Geneva 2008). Although available data are not always spatially congruent, 
and therefore cannot necessarily be viewed as representing secular changes, the sharp decline in 
sub-Saharan Africa of the Plasmodium falciparum prevalence rate in children aged two to ten 
years—from 37% in the years 1985–1999 to 17% in 2000–2007—clearly documents this trend 
(Guerra et al. 2008). This decrease implies that many of the areas previously defined as “high stable 
malaria transmission” have changed, or will soon change, into “moderate to low transmission” areas.  
The lower the transmission, the lower the probability that a fever episode will be due to malaria. In 
Tanzania, a high endemicity country, only one to four out of ten under-five patients with fever are 
parasitaemic in the rural settings (Kabanywany 2007 and D’Acremont 2008, personal 
communications; (Wang et al. 2006a). With a decline in malaria’s prevalence, the hazard of 
misdiagnosis of many children becomes significant. When giving an antimalarial, the health worker is 
less likely to look for another treatable cause of fever, and this leads to higher morbidity and mortality 
due to delay in giving appropriate treatment, as suggested by studies that showed higher case 
fatality rates among non-malaria fevers compared to malaria fevers (Reyburn et al. 2004). 
Availability of mRDT for Malaria  
The shift from symptom-based diagnosis to parasite-based management of malaria requires that 
clinicians have a reliable, easy-to-use, and inexpensive diagnostic test. It should have good 
sensitivity, require minimal training and equipment, and retain accuracy even after extensive storage 
under tropical conditions. All these characteristics are met by the new generation of mRDT. Two 
meta-analyses have clearly shown that the performance of mRDT is comparable to that of expert 
microscopy (Marx et al. 2005; Ochola et al. 2006). Appropriate action taken on the basis of the test 
result is now the key element for the successful introduction of mRDT. Unfortunately this has not 
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always been achieved in the implementation of mRDT so far, partly because the training was 
insufficient to change the clinician’s perception of malaria risk (Hamer et al. 2007). In addition, the 
ambiguous messages from WHO and national guidelines stating that malaria should be considered 
even in the presence of a negative test have added to the confusion (D'Acremont et al. 2007).  
At present risk levels, the risk of missing a malaria case due to a false-negative test is substantially 
smaller than the risk of the patient dying due to another severe disease because of the focus on 
malaria. The risk of a false-negative test and its potential consequences have recently been 
evaluated thoroughly in Uganda (using microscopy) (Njama-Meya et al. 2007) and in Tanzania (using 
mRDT; Chapter 7), and the safety of not treating malaria-negative children confirmed.  
Other compelling arguments for systematic testing are listed in Box 1 (Lubell et al. 2007; Shillcutt et 
al. 2008).  
 
 
 
 
 
Box 1. Additional Arguments for a Shift from Presumptive Malaria 
Treatment to Laboratory-Confirmed Diagnosis and Treatment 
According To Test Results in Children Under Five with Fever 
 
• Treating all fever patients with antimalarials leads to a huge drug 
wastage, and hence potential for drug shortage 
• Inappropriate use of antimalarials leads to unnecessary adverse drug 
reactions 
• Irrational use of antimalarial drugs leads to increased parasite 
resistance 
• Potential mistrust on the part of the public on the real efficacy of 
artemisinin-based combination therapies (ACTs) due to use for 
inappropriate indications (viral or bacterial disease) 
• Parasitological diagnosis and treatment with ACTs according to test 
results versus presumptive treatment with ACTs is costeffective in all 
current malaria-endemic situations (as long as test result is taken into 
account) 
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Caveat  
A switch from presumptive treatment to laboratory-confirmed diagnosis and treatment is now urgent 
but needs to be carefully planned. Large-scale deployment of mRDT is a great challenge that 
requires theoretical and practical training, regular supervision, and sustained financial mechanisms to 
ensure constant availability. It is crucial that quality assurance is implemented at all steps.  
Also, introduction of reliable diagnosis implies that clinicians need to be trained to manage the 
“negative syndrome” (patients with a negative malaria test). This is challenging after years of 
upholding the notion that fever equals malaria and requires substantial change in the behaviour of 
clinicians and caretakers. This is now a great opportunity to update and re-strengthen the Integrated 
Management of Childhood Illnesses to promote improved case management of African children. 
Conclusion  
The recent trend of malaria decline in Africa calls for a shift from presumptive treatment to laboratory-
confirmed diagnosis and treatment in all areas, regardless of age and level of malaria transmission. 
Such a move is especially relevant with the new momentum towards elimination and is now realistic 
thanks to reliable mRDT. As part of renewed malaria control efforts, it is time to improve clinical 
management and abandon irrational use of drugs, i.e., antimalarial treatment for no malaria and no 
treatment for other potentially fatal causes of fevers. 
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7.1 Abstract 
Background: Presumptive treatment of all febrile patients with antimalarials leads to massive over-
treatment, especially in areas with low malaria endemicity. We aimed to assess the effect of 
implementing malaria rapid diagnostic tests (mRDT) on the prescription of antimalarials and case 
management. 
Methods: After training of health workers, mRDTs were introduced in Dar es Salaam in all 3 district 
hospitals and 6 primary care facilities. Three comparable health facilities (HF) without mRDTs were 
selected randomly as matched controls. We used two different data collection tools: (1) routine 
statistics of antimalarial prescription recorded in ledger books before and after intervention (total 33 
months), and (2) repeated cross-sectional surveys in all HF, investigating consultation processes. 
We evaluated the impact of mRDT implementation on antimalarial prescriptions with three 
independent designs:  (1) comparing drug consumption data before and after mRDT implementation 
(2a) comparing consultations processes before and 18 months after intervention, and (2b) comparing 
contemporaneously consultations processes in 9 intervention and 3 matched control HF (cluster-
randomized analysis).  
Findings: Based on routine statistics, the amount of artemether-lumefantrine blisters used post-
intervention was reduced by 68% (95%CI 57–80) in intervention and 32% (9–54) in control HF. For 
quinine vials, the reduction was 63% (54–72) in intervention and an increase of 2.49 times (1.62–
3.35) in control HF. Repeated cross-sectional surveys before-and-after mRDT implementation 
showed a similar decrease of 77% (from 75% to 20%) in the number of patients receiving 
antimalarial treatment (RR 0.23, 95%CI 0.20–0.26). The cluster-randomised analysis showed a 
considerable difference of antimalarial prescription between intervention HF (22%) and control HF 
(60%) (RR 0.30, 95%CI 0.14–0.70). Adherence to test result was excellent since only 7% of negative 
patients received an antimalarial.  
Interpretation: Programmatic implementation of mRDT in a moderately endemic area reduced 
drastically over-treatment with antimalarials. Properly trained clinicians with adequate support 
complied with the recommendation of not treating patients with negative results.  
7.2 Introduction 
One essential component of the global malaria strategy is prompt diagnosis and treatment (within 24 
hours of onset of illness) with an effective drug (WHO 2006). Because of the scarce availability of 
laboratory facilities and the high mortality of malaria in young children, presumptive treatment in case 
of fever was seen as the only practical solution to improve child survival. This strategy thus became 
part of the Integrated Management of Childhood Illness (IMCI) decision chart. The strategy of 
presumptive treatment was easily and rapidly adopted by health workers to such an extent that it 
started also to be applied: 1) to children older than 5 years and even adults; 2) in low endemicity 
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areas; and 3) in setting where laboratory diagnosis was actually available (Zurovac et al. 2006b). 
This led to a situation in which the principle of proper diagnosis prior to treatment became an 
exception rather than the rule. Whatever the medical history (when taken) and irrespective of the 
clinical examination (if done at all), the same treatment is prescribed: an antimalarial drug, possibly 
supplemented by an antipyretic. When the patient returns with persistent fever a second-line 
antimalarial drug is given, sometimes intravenously. This may go on until either the spontaneous 
recovery of the patient from his/her (often viral) illness or up to a deterioration of the patient’s 
condition due to an unrecognized bacterial infection. The strategy of presumptive treatment of all 
fevers with antimalarials lead clinicians to believe that all fevers are due to malaria, resulting in a 
massive over-diagnosis (Masika et al. 2006; Chapter 7), and more importantly to ignoring non-
malaria causes of fever that have similar, or even higher case fatality rates than malaria (Makani et 
al. 2003; Reyburn et al. 2004).  
The availability of reliable, easy-to-use and affordable rapid diagnostic tests (mRDT) allows now a 
realistic switch from presumptive treatment to laboratory-confirmed diagnosis and treatment upon 
result (Chapter 6). This is especially important considering the trend of malaria decline in Africa, 
which leads to a strong reduction in the proportion of fevers due to malaria. There is now solid 
consensus that diagnosis should be part of fever case management everywhere and WHO is about 
to change its previous recommendation on this (R. Newman, personal communication).  Hence, the 
discussion is now no more on whether laboratory diagnosis for malaria should be deployed (English 
et al. 2009) but on how best to effect it. Zambia was the first Sub-Saharan country to deploy mRDT 
at the national scale in 2004. Since then, several countries have adopted laboratory-confirmed 
diagnosis, even in highly endemic areas. However, the implementation of mRDT at scale poses also 
many challenges. Rigorous procedures to train and supervise clinicians, to strengthen procurement 
systems and to ensure quality assurance need to be established. Strong monitoring and evaluation 
plans need to be put in place. The impact of large-scale implementation of mRDT needs to be 
carefully assessed in different settings and health systems to ensure that it actually reduces over-
diagnosis, wastage of antimalarial drugs and prevents patient suffering.   
In order to evaluate the impact of mRDT implementation on antimalarial use and fever case 
management, we conducted a large study under near-programme conditions in an urban setting of 
Tanzania with low to moderate malaria endemicity. Our primary objective was to measure the 
change in overall antimalarial prescription at different levels of the health system. Secondary 
objectives were to assess the effect of mRDT implementation on the number and type of patients 
tested and/or treated for malaria, the number of non-malaria laboratory tests performed and the 
number of antibiotic prescriptions. To ensure robustness in our findings, we used data from two 
independent sources and evaluated the effects of mRDT implementation with three different designs, 
including a randomized cluster analysis. 
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7.3 Methods 
Study setting and population 
The study took place from January 2006 to September 2008 in Dar es Salaam, the economic capital 
of Tanzania, with an estimated population of over 3’000’000 inhabitants. Dar es Salaam has 3 
municipalities with a public health system organized in 3 levels (district hospital, health centres and 
dispensaries). We included all three district hospitals (Mwananyamala, Amana and Temeke 
hospitals), 4 health centres (HC) among the existing 6, and 5 dispensaries (D) among the existing 10 
in the urban zone of the town. In each municipality we created a trio of similar HC/D (9 in total) on the 
basis of the following criteria: availability of microscopy, accuracy of the general registers (called 
MTUHA books) and laboratory registers, socio-economic status of the catchment population, quality 
of governance of the health facility (HF) and willingness of the staff to participate. We then randomly 
assigned one HC/D in each trio to be the control HF by picking pieces of paper with the names of the 
HF out of a hat.  We thus ended up with 6 intervention HF (2 HC/D per municipality) and 3 control HF 
(one HC/D per municipality), as well as the three hospitals in which the intervention was also 
implemented but for which we could obviously not find controls (Figure 12). 
 
 
Figure 12: Study methodology with 3 different evaluation methods: (1) longitudinal routine 
statistics collection, (2a) repeated cross-sectional surveys on consultations processes with a 
before-and-after comparison and (2b) cluster randomized comparison of consultation 
processes. HF = Health facilities 
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Intervention 
In February 2007, after a sensitization meeting with the persons in charge of the 9 intervention HF, 
the City Medical Officer of Health (who was also one of the investigators) and representatives of the 
Municipal Medical Offices of Health, we organized 5 one-day training sessions attended by a total of 
116 clinicians, 31 laboratory technicians, 31 nurses and 3 pharmacists. The training included one 
hour on the situation of malaria in Tanzania, half an hour on malaria diagnosis in Africa and in Dar es 
Salaam, one hour on the clinical use of each type of malaria tests, one hour practical in which 
participants performed a mRDT on each other, and finally 2 hours of group work on 5 clinical case 
studies. The guidelines for the use of mRDT were the following: 1) only patients complaining of fever 
should be tested; 2) no antimalarials should be prescribed when the result of the mRDT is negative, 
regardless of the age of the patient; 3) for non-malaria problems, IMCI guidelines should be followed 
in children less than five years. Feedback from the health workers on the training was very positive, 
although they would have liked to learn more on how to manage non-malaria fevers.  
We then went to each HF to discuss mRDT implementation using a standard check-list to be filled in 
by the focal person for mRDT. Between mid- and end of March 2007, we brought the first 
consignment of mRDT and did a supervision visit 3 days later in each HF. Thereafter, supervision 
took place 1, 2, 5, 10 and 15 months after mRDT introduction. Specific problems in 4 HF were 
addressed by one or two additional on-site meetings. No incentives were given to any health worker. 
Control HF were given mRDT after 18 months (November 2008), after training their clinical staff. 
Project design 
In order to come to robust conclusions we collected data with two complementary tools, and 
assessment our outcomes with three different designs (Figure 12).   
1) Routine statistics from ledger books 
A longitudinal study based on the continuous monitoring of routine statistics (MTUHA books) was 
conducted for a period of 15 months before (including one long and one short rainy season) and 18 
months after mRDT implementation (including two long and one short rainy season). We collected all 
MTUHA books from the years 2006 to 2008 to get monthly information on the following: number of 
new attendances, number of specific diagnoses, number of laboratory tests, number of malaria tests 
and their results. We also collected for each health facility the number of antimalarials and antibiotics 
dispensed per month from ledger books in the pharmacies. To get the monthly consumption for each 
drug we counted the total number of tablets, vials or blisters (for artemether-lumefantrine - ALu) 
issued by the main store to the different departments of the HF, excluding the drugs issued to 
another HF. To get the monthly number of ALu dispensed to patients, we counted the number of 
patients receiving one of the 4 types of blisters from the books used at the dispensing windows.  
2) Cross-sectional surveys of consultation processes 
We also conducted two cross-sectional surveys, one that took place 2-5 months before and the other 
15-18 months after mRDT implementation in the 9 intervention and 3 control HF (Figure 12). In each 
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HF survey 100 consultations were observed at the Outpatient Department. In order to lessen the 
influence of season, 50 consecutive consultations were observed in each HF in a first week and an 
additional 50 consultations were observed 6 weeks later. The targeted sample size for each of the 
two surveys (before and after) was thus 1200 consultations. The inclusion criteria for attending 
patients were: 1) first consultation for the present problem; 2) absence of severe illness requiring 
immediate admission or referral; 3) main complaint not being an injury or trauma. As clinicians in Dar 
es Salaam tend to consider the diagnosis of malaria even in the absence of fever (Zurovac et al. 
2006b), we did not have fever/history of fever as an inclusion criteria. A standardized questionnaire in 
Swahili language was used by the research clinicians while observing the consultation process.  
A first consent to participate was requested from the observed clinician after explaining him/her the 
aims of the study and the conditions of observation (confidentiality, anonymity and no interference). 
Informed consent was then requested by the observed clinician from each of his/her patients. The 
following were observed: complaints mentioned spontaneously by the patient, questions asked by 
the clinician and the corresponding answers by the patient, signs looked for and laboratory tests 
ordered by the clinician, tests results, diagnoses, drugs and advice given by the clinician. 
This cross-sectional information was analyzed using two designs:  (1) comparing antimalarial 
prescriptions between pre-intervention and 18 months post-intervention surveys in the 9 intervention 
health facilities (thereafter called before-and-after analysis) and (2) comparing antimalarial 
prescriptions between 6 intervention and their 3 matched controls contemporaneously, during the 
post-intervention survey (cluster-randomized analysis) (Figure 12).  
Statistical analyses 
For the routine statistics data, the unit of analysis was the HF rather than the patient, in order to give 
the same weight to each HF. Linear models were fitted to the monthly number of antimalarial or 
antibiotic doses issued and the number of performed diagnostic tests, and results were expressed as 
a percentage of the pre-intervention mean. Random effects allowed accounting for differences 
between health facilities. The results were finally expressed as the ratio of numbers post- over pre-
intervention (PP). From this, the percentage reductions could be calculated as (1-PP) * 100. For drug 
variables, 95% confidence intervals (CI) could not be calculated for the individual HF, because of the 
auto-correlated structure of the data, reflecting month-to-month variations in issuing of drugs. For 
instance, when large drug volumes were issued from the main store on a certain month, there could 
be a compensatory reduction the next month. Data were entered in Microsoft Excel 2002 and 
analysed using the STATA version 10 xtreg command. 
For the cross sectional studies (before-and-after and cluster randomized analyses), the unit of 
analysis was the patient. Since the number of consultations observed in each facility was almost the 
same, the weight given to each HF was almost identical and this allowed a direct comparison with 
the longitudinal study. Comparison of proportions was done by calculating odds ratios using a 
multilevel mixed-effects logistic regression model to account for clustering. Risk ratios (RR) were 
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calculated from the fitted values for each cell of the 2 by 2 tables. P-values (2-sided) were calculated 
using Pearson א2 statistics. Data were entered in Epi Info version 3.5.1 and analyzed in STATA 
version 10.   
The level of agreement between results given by the two different sources of data (the routine 
statistics and the repeated cross-sectional surveys) was measured by the Lin concordance-
correlation coefficient (Lin 1989).   
Role of the funding body 
The sponsor of the study (Swiss National Science Foundation) had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding author had 
full access to all the data in the study and had final responsibility for the decision to submit for 
publication. 
7.4 Results 
1. Routine statistics from ledger books – longitudinal study 
Nearly all required data could be retrieved from the MTUHA books with a few exceptions: among a 
total of 3960 monthly data points to be collected (10 variables measured in 12 HF during 33 months), 
only 36 were missing. For the monthly drug quantification, missing data were replaced by the mean 
of all data of the corresponding pre- or post intervention period. Missing monthly numbers of 
consultations were replaced by the mean of the value from the month before and the month after.  
Impact of mRDT implementation on antimalarial consumption 
The number of ALu blisters issued by the main store of the 9 intervention HF decreased from 20’660 
per month to 7’933 per month after mRDT implementation. It decreased in each of the 9 HF with PP 
ranging from 0.04 to 0.63 (Table 4). When using HF as a unit the overall PP was 0.32 (95% CI 0.20–
0.43) corresponding to an overall decrease of 68%. The impact of mRDT was stronger in 
dispensaries than in health centres or hospitals (PP 0.26 versus 0.35 and 0.34). There was also a 
clear trend when analyzing the data by municipality (PP 0.32, 0.22 and 0.41 for Municipality 1, 2 and 
3 respectively). When only looking at the last 6 months of the study to assess the sustainability of 
mRDT implementation the results were even better (PP 0.25, 95% CI 0.13–0.37). In the 3 control HF, 
the overall PP using the whole period was 0.68 (95% CI 0.46–0.91) (Table 4). 
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Table 4: Routine statistics of ledger books: average monthly number of patients positive by 
mRDT, and ALu blisters & quinine vials issued by the main store, before and after mRDT 
implementation, in intervention and control health facilities. 
ALu blisters £ Quinine vials &  
 
 
 
Health facility 
Patients 
positive by 
mRDT 
Number 
per month 
(SD) 
Before RDT 
initiation* 
Blisters 
 per month 
n 
After RDT 
initiation# 
Blisters 
per month 
n 
Post-intervention 
blisters as a 
proportion of 
pre-intervention 
PP (95% CI)  
Before RDT 
initiation$ 
Vials 
per month 
n 
After RDT 
initiation# 
Vials 
per month 
n 
Post-intervention 
vials as a 
proportion of 
pre-intervention 
PP (95% CI)  
Intervention health facilities       
Hospital 1   495 ç 4560 1326 0.29 3205 1503 0.47 
Hospital 2   323 1500   307 0.20 5049   549 0.11 
Hospital 3   335 3100 1608 0.52 1747 1048 0.60 
Health centre 1   329 3000 1890 0.63   830   272 0.33 
Health centre 2 209 1430   268 0.19   553    86 0.16 
Health centre 3   93 1540   360 0.23   177    92 0.52 
Dispensary 1   43   650     25 0.04    59    26 0.44 
Dispensary 2  101   770   202 0.26   245    85 0.35 
Dispensary 3  210 4110 1947 0.47   303   111 0.37 
Total of 9 HFŦ    0.32   (0.20 - 0.43)   0.37   (0.28 - 0.46) 
Total of 6 matched  intervention HFŦ 0.30   (0.15 - 0.46)   0.36   (0.24 - 0.48) 
Control health facilities       
Control 1 N.A 1900 1952 1.03  280 766 2.73 
Control 2 N.A 3410 1353 0.40  209 151 0.72 
Control 3 N.A 4180  2617 0.63  217 871 4.01 
Total of 3 matched control HFŦ  0.68   (0.46 - 0.91)   2.49   (1.62 - 3.35) 
£ One blister of ALU is needed for one antimalarial course, whatever the age or weight of the patient, & Between 2 
and 6 vials are used per antimalarial course, * observation period of only 3 months because ALu only introduced in 
Tanzania in January 2007, # observation period of 18 months, $ observation period of 15 months, Ŧ allowing for 
random-effect. 
 
Figure 13 shows the monthly consumption of ALu over time, with the contribution of each HF. The 
four weight categories of ALu blisters were included, with one blister counting as one antimalarial 
treatment course. There was a marked decrease in ALu consumption just after mRDT initiation and 
then a further decrease 4 months later. The initial 4 months of the intervention period was used to 
identify and rectify operational problems (use of microscopy instead of mRDT, lack of trust in 
laboratory technicians, conflict of interest with private laboratories, and reshuffle of staff) in the 4 HF 
where little impact was observed during the first 4 months.   
We found a similar reduction of injectable quinine consumption in each of the 9 intervention HF 
(average PP 0.37, 95% CI 0.28–0.46) (Table 4). For quinine there was also a longer period of 
observation before mRDT initiation (15 months) compared to ALu which was only introduced in the 
country in January 2007. In the 3 control HF, there was a marked increase in quinine use over the 
same period (PP 2.49, 95% CI 1.62–3.35). 
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Figure 13: Number of artemether-lumefantrine (ALu) treatments and quinine vials issued 
monthly in each of the 9 intervention health facilities. Pre-intervention follow up times vary 
because ALu was only introduced in January 2007. 
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Table 4 shows that in some HF, the number of issued ALu blisters was much higher than the actual 
number of positive patients (median excess: 168%). These amounts represent the quantities 
‘consumed’ by the HF and not necessarily the numbers of blisters received by patients. When looking 
at data from dispensing books between 6 and 12 months after mRDT implementation this excess 
was confirmed (data not shown). “Mishandling” of drug stocks is likely to be the main reason for the 
over-consumption of antimalarials after mRDT implementation (although at a much lower level than 
before).  
Impact of mRDT implementation on malaria testing 
In the 9 intervention HF, from January 2006 to March 2007 (before mRDT initiation) a total of 20’143 
blood slides were performed on average per month. After mRDT initiation, 27’398 mRDT and 768 
blood slides were performed on average per month (Figure 14). Microscopy was thus almost entirely 
replaced by mRDT as first-line malaria test, except for a few special cases (admitted patients, 
persisting fever in outpatients with malaria, during short periods of mRDT stock out).  
The number of patients attending the 9 intervention HF for a new consultation increased slightly over 
time (61’642 before and 68’065 after mRDT implementation on average per month). The proportion 
of patients tested for malaria increased when mRDT were introduced (PP 1.21) and thereafter the 
proportion of patients tested was stable up to the end of the project (Figure 14).  
 
Figure 14: Number of new consultations, blood slides and mRDTs performed, patients with a 
diagnosis of malaria and positive malaria tests, over time, in the 9 intervention health 
facilities.  
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Impact of mRDT implementation on diagnoses 
The total number of patients with a diagnosis of malaria given by the clinicians was 27’693 per month 
before and 9’920 after mRDT initiation. This represents a 3-fold decrease (PP 0.33, 95% CI 0.28–
0.38) (Figure 14). By contrast, for the diagnoses of acute respiratory infection, pneumonia, diarrhoeal 
diseases and urinary tract infections there was no change or even an increase after mRDT 
implementation (PP 1.02, 1.29, 1.15, 1.46, respectively). The number of “ill defined syndrome” as 
well as of “other diagnoses” increased much more (PP 2.14 and 2.36, respectively). In the 3 control 
HF, there was no change in the number of patients with a diagnosis of malaria (PP 1.03, 95% CI 
0.82–1.24), while acute respiratory infections, pneumonia, diarrhoeal diseases and urinary tract 
infections increased after mRDT implementation (PP 1.59, 1.30, 1.55 and 2.12, respectively). 
Impact of mRDT implementation on malaria positivity rate 
At the time of microscopy, the positivity rate of the routine malaria tests in the 9 HF was very high: 
51% (range 13 - 88%) and it was similar in the 3 types of HF: 41% in hospitals, 49% in health centres 
and 65% in dispensaries. After intervention, the positivity rate of routine mRDT was only 8% (range 6 
– 12%; Figure 14), which is in line with what had been shown in previous studies using expert 
microscopy in Dar es Salaam (Wang et al. 2006a). A baseline assessment performed in the 12 HF 
included in our study had shown that the quality of routine microscopy was poor, with very low 
sensitivity (71%) and specificity (47%) (Kahama-Maro et al. 2008). Conversely, the performance of 
routine mRDT evaluated in one health centre was excellent (97% sensitivity, 97% specificity) and the 
quality assurance results for mRDT testing done all along the study showed excellent results (not 
shown). In control HF that kept on using microscopy, the positivity rate dropped only slightly after the 
intervention in the other HF: from 73% before to 60% after.  
Impact of mRDT implementation on antibiotics consumption 
The total consumption of oral antibiotics did not change after mRDT implementation (PP 1.02, 95% 
CI 0.92–1.13). In control HF, the total consumption of all oral antibiotics increased a bit more (PP 
1.26, 95%CI 1.00–1.52) than in the matched intervention HF (PP 1.14, 95% CI 1.00–1.28).  In 
general, the amounts of antibiotics consumed by HF were very high: about 38% of newly attending 
patients received an oral antibiotic after mRDT implementation versus 40% before.  
Impact of mRDT implementation on laboratory tests other than malaria 
The number of urine analysis and direct stool examination increased slightly after mRDT 
implementation (PP 1.18 and PP 1.23 respectively) in intervention HF. In control HF, both type of 
investigations increased more (PP 1.66 and 1.74 respectively). 
2. Cross-sectional surveys: before-and-after analysis  
The before-and-after analysis was based on the repeated cross-sectional observation of 
consultations before and after intervention in 9 intervention HF (Table 5). The proportion of children 
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were similar in the pre- and the post-intervention surveys (52 versus 53%), while slightly more female 
patients were included in the pre-intervention survey (60 versus 54%, p<0.02).  
Impact of mRDT implementation on antimalarials consumption 
Consultation observations performed before-and-after mRDT implementation revealed a decrease of 
77% (from 75% to 20%) in the total number of patients receiving an antimalarial treatment (Table 5). 
This decrease (RR 0.23, 95% CI 0.20–0.26) was more pronounced in the subgroup of patients not 
complaining of fever (RR 0.16) than in the group complaining of fever (RR 0.25). This reduction was 
mainly due to a drastic change in the adherence of clinicians to test results. At the time of 
microscopy, 53% (95% CI 47–60) of negative patients were treated with antimalarials while this 
proportion was only 7% (95% CI 4–11) with mRDT. 
 
Table 5: Before-and-after analysis based on repeated cross-sectional surveys investigating 
the consultation process: effect of mRDT implementation on the main outcomes 
   Before mRDT 
implementation 
Total patients = 937 
After mRDT 
implementation 
Total patients = 954 
Risk ratio 
(accounting for 
clustering) 
 
p-value 
 
     n*    %    (95% CI)      n*    %    (95% CI) RR   (95% CI)  
Effect of mRDT implementation on antimalarial treatment     
 Patients treated with antimalarials       
  All patients 894 75%    (72-78) 912 20%    (17-22) 0.23   (0.20 - 0.26) < 0.001 
  Patients complaining of fever 755 81%    (79-84) 682 24%    (20-27) 0.25   (0.22 - 0.29) < 0.001 
  Patients not complaining of fever 139 42%    (33-50) 230   7%     ( 4-11) 0.16   (0.10 - 0.27) < 0.001 
Effect of mRDT implementation on adherence to malaria test result   
 Patients treated with antimalarials       
  Patients with a positive malaria test 370 99%   (99-100) 126 99%   (98-100) 1.00   (0.98 - 1.01) 0.8 
  Patients with a negative malaria test 215 53%    (47-60) 628    7%    ( 5-9) 0.09   (0.06 - 0.13) < 0.001 
Effect of mRDT implementation on selection for malaria testing    
 Patients tested for malaria       
  All patients 937 68%    (65-71) 954 83%    (81-85) 1.26   (1.19 - 1.33) < 0.001 
  Patients complaining of fever 782 71%    (68-74) 717 91%    (89-93) 1.31   (1.25 - 1.36) < 0.001 
  Patients not complaining of fever 155 49%    (41-57) 237 58%    (52-65) 1.21   (0.99 - 1.48) 0.06 
Effect of mRDT implementation on antibiotic treatment     
 Patients treated with antibiotics       
  All patients 894 49%    (46-53) 912 72%    (69-75) 1.47   (1.37 - 1.59) < 0.001 
  Patients complaining of fever 755 49%    (45-52) 682 73%    (69-76) 1.50   (1.38 - 1.63) < 0.001 
  Patients not complaining of fever 139 52%    (43-60) 230 71%    (65-77) 1.38   (1.16 - 1.65) < 0.001 
  Patients with a positive malaria test 370 37%    (32-42) 126 35%    (26-43) 0.91   (0.68 - 1.21) 0.5 
  Patients with a negative malaria test 215 54%    (47-61) 628 78%    (75-81) 1.45   (1.28 - 1.65) < 0.001 
Effect of mRDT implementation on other laboratory tests than malaria     
  Patient tested for urinary infection 937   7%    ( 6-9) 954 13%    (11-15) 1.74   (1.31 – 2.31) < 0.001 
 
 Patient tested for typhoid (Widal) 937   2%    ( 1-2) 954   1%    ( 1-2) 0.76   (0.36 – 1.63) 0.5 
 
 
Patient tested for stool parasites 937   6%    ( 5-8) 954   7%    ( 6-9) 1.13   (0.81 – 1.59) 0.5 
* numbers differ from total sample size because of the variables applying to different subpopulations of patients 
(and for drugs because a few patients who did not come back from laboratory to get treatment). 
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Impact of mRDT implementation on malaria testing 
The overall proportion of patients tested for malaria increased by 26%, from 68% to 83%, RR 1.26 
(95% CI 1.19–1.33) after mRDT initiation. This increase was mainly seen in patients complaining of 
fever (from 71% to 91%). In patients without fever, a high proportion was still tested after mRDT 
implementation (49% before versus 58% after, p=0.06). 
Impact of mRDT implementation on antibiotics consumption 
The overall prescription of antibiotics increased after mRDT initiation by 47%, from 49% to 72%, RR 
1.47 (95% CI 1.37–1.59). This increase was slightly more important in patients complaining of fever 
(RR 1.50) than in those not complaining of fever (RR 1.38) and was seen in malaria negative patients 
but not in positive ones. As a result, the vast majority [78% (95% CI 75–81)] of negative patients 
were treated with an antibiotic after the introduction of mRDT. 
Impact of mRDT implementation on laboratory tests other than malaria 
mRDT implementation did not dramatically increase the request for alternative laboratory tests by 
clinicians, which remained generally low.  
Convergence of results between the longitudinal and the before-and-after evaluations 
Although the variability between HF was high, there was a strong intra-health facility convergence of 
the main outcome result (reduction of antimalarial use) between the longitudinal routine data 
assessment and the cross-sectional before-and-after assessment (Lin concordance- correlation 
coefficient: ρc =0.91) (Figure 15). This is a strong confirmation of the robustness of the data. 
3. Cross-sectional surveys:  cluster randomized analysis  
The contemporaneous, post-intervention cluster-randomized comparison of patient consultations was 
carried out in 6 intervention versus 3 control HF (Table 6). Key population characteristics (age, 
gender) and outcome results were similar in intervention and control HF (p>0.05) (results not shown).   
Impact of mRDT implementation on antimalarials consumption 
There was a considerable difference between the two groups in the proportion of patients that were 
prescribed antimalarials: 22% in intervention versus 60% in control HF (from a baseline in both of 
79%) (RR 0.30, 0.14–0.70) (Table 6). The difference was more pronounced in non-febrile than in 
febrile patients since only 9% of non-febrile patients received an antimalarial in intervention HF 
compared to 38% in control HF (RR 0.23, 95% CI 0.10–0.55). The reasons for the low antimalarial 
prescription in intervention HF were multiple: better selection of patients for malaria testing, better 
specificity of mRDT compared to microscopy and better adherence to mRDT result. On the other 
hand, in control HF the lower antimalarial prescriptions in post- versus pre-intervention survey was 
only due to a better trust in malaria test result (negative patients treated with antimalarials decreased 
from 43% to 25%), even if it was still based on microscopy. 
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Figure 15: Association between  the measures for first-line antimalarials consumption 
reductions by two independent assessments: (1) health facility routine statistics based on 
ledger books, and (2) cross-sectional surveys using a before-and-after analysis. 
 
 
Hospital 1, Hospital 3 and Dispensary 3 had difficulties at the start of mRDT implementation that could be solved with one 
additional training/meeting. Therefore, their ALU consumption further dropped after the 5th month of mRDT use. For these 3 HF 
we thus used the data of the last 13 months (instead of the whole period of 18 months). 
 
 
Differences between intervention and control HF regarding antibiotic prescriptions 
The proportion of patients that were prescribed antibiotics was higher in intervention HF than in 
controls:  71% versus 53% respectively (from a baseline of 50 and 51%) (RR=1.34, 95% CI 1.08–
1.70). There was, however, no significant difference by category of patients (with/without fever; with 
positive/negative result), which confirmed that the overall difference in antibiotic prescription was 
almost only due to the higher number of negative patients and not to a behavioural change of 
clinicians. 
Impact of mRDT implementation on laboratory tests other than malaria 
The proportions of patients tested for urine, stool or the Widal test did not increase after mRDT 
implementation in both the intervention and control HF (p >0.05). 
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Table 6: Cluster randomized analysis based on the post-intervention cross-sectional survey 
investigating the consultation process: comparison between 6 intervention and 3 control 
health facilities.  
 
  Intervention 
health facilities 
N=637 
Control 
health facilities 
N=330 
Risk ratio 
(accounting for clustering) 
 
 n* %    (95% CI) n* %    (95% CI) RR   (95% CI) p-value 
Effect of mRDT implementation on antimalarial treatment 
  Patients treated with antimalarials:       
 All patients 618 22%   (19-25) 318 60%   (54-65) 0.30   (0.14 - 0.70) 0.007 
 Patients complaining of fever 473 26%   (22-30) 253 65%   (59-71) 0.31   (0.16 - 0.67) 0.004 
 Patients not complaining of fever 145 9%   (4-14) 65 38%   (26-51) 0.23   (0.10 - 0.55) 0.001 
Effect of mRDT implementation on adherence to malaria test result 
  Patients treated with antimalarials:       
 Patients with a positive malaria test 96 100%   (100-100) 155 100%   (100-100) 1 N.A 
 Patients with a negative malaria test 412 7%   (5-10) 128 25%   (17-33) 0.09   (0.01 - 0.79) 0.03 
Effect of mRDT implementation on selection for malaria testing 
  Patients tested for malaria:       
 All patients 637 82%   (79-85) 330 89%   (86-92) 0.93   (0.86 – 1.04) 0.2 
 Patients complaining of fever 487 90%   (88-93) 263 95%   (93-98) 0.95   (0.91 - 0.99) 0.03 
 Patients not complaining of fever 150 57%   (49-65) 67 64%   (52-76) 0.91   (0.69 – 1.26) 0.5 
Effect of mRDT implementation on antibiotic treatment 
  Patients treated with antibiotics:       
 All patients 618 71%   (67-74) 318 53%   (48-59) 1.34   (1.08 - 1.70) 0.006 
 Patients complaining of fever 473 71%   (67-76) 253 52%   (46-58) 1.44   (1.09 – 1.94) 0.008 
 Patients not complaining of fever 145 68%   (61-76) 65 58%   (46-71) 1.17   (0.94 – 1.49) 0.2 
 Patients with a positive malaria test 96 32%   (23-42) 155 28%   (21-36) 1.14   (0.77 - 1.66) 0.5 
 Patients with a negative malaria test 412 77%   (73-81) 128 74%   (67-82) 1.05   (0.91 – 1.26) 0.5 
Effect of mRDT implementation on other laboratory tests than malaria 
 Patient tested for urinary infection 637 9%   (7-11) 330 11%   (8-15) 0.73   (0.34 – 1.58) 0.4 
 Patient tested for typhoid (Widal) 637 2%   (1-3) 330 8%   (5-11) 0.29   (0.04 – 1.97) 0.2 
 Patient tested for stool parasites 637 7%   (5-9) 330 5%   (3-8) 1.27   (0.50 – 3.29) 0.6 
* numbers differ from total sample size because of the variables applying to different subpopulations of patients 
(and for drugs because a few patients who did not come back from laboratory to get treatment). 
 
7.5 Discussion 
Our pilot implementation of mRDT for malaria in 9 health facilities in Dar es Salaam in near-
programme conditions showed a dramatic reduction in antimalarials consumption. This was 
confirmed in all three methods of evaluation with two independent data sets: the longitudinal analysis 
of routine statistics (PP of 0.32 for ALu and 0.37 for injectable quinine), the before-and-after study 
based on pre- and post-intervention surveys (RR 0.23 for the first line treatment and 0.35 for 
injectable quinine) and the cluster-randomized analysis comparing matched intervention and control 
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health facilities (RR 0.26 for the first line treatment and 0.43 for injectable quinine). The high level of 
convergence of the results gives a strong robustness to the findings. The two main reasons for this 
decrease were illuminated by our observations of patient-provider interactions in the repeated cross 
sectional surveys. Firstly, the higher accuracy of routine mRDT compared to routine microscopy led 
to a dramatic reduction in the number of positive patients. Secondly, as health workers trusted mRDT 
results, the proportion of negative patients treated with antimalarials dropped from 53% to 7%. The 
impact was maintained up to the end of the observation period (18 months) and even increased after 
the initial 4 months thanks to targeted programmatic actions in poor-performing HF. In the control HF 
there was a moderate decrease in ALu consumption (PP 0.68), but a corresponding increase in 
quinine consumption and in the number of patients diagnosed with malaria.  
The repeated cross sectional surveys showed that 1.49 mRDTs were needed to save one malaria 
treatment course. This was, however, at the cost of an additional 0.41 antibiotic treatment courses. If 
clinicians had been fully adherent to both patients selection for mRDT testing and treatment upon 
mRDT result, only 1.22 mRDTs would have been required.  Our post-intervention survey took place 
just after the rainy season, when 18% of patients complaining of fever were positive by mRDT. If the 
malaria prevalence had been 5% (the lowest monthly rate observed in Dar es Salaam), clinicians 
would have needed 1.05 mRDTs per antimalarial treatment saved.  From the longitudinal study, in 
which wastage of drugs between the main store and the dispensing window was important, we found 
that 2.15 mRDTs were necessary to save one ALu blister and half a vial of quinine. These 
observations show clearly how circumstances shape the effectiveness of mRDT implementation. 
An interesting observation was the “contamination” of the control HF with some of the key messages 
passed on during our training activities. This was mainly due to health workers from intervention HF 
being shifted to work in control HF during the study period. Our message that the incidence of 
malaria in Dar es Salaam was much lower than commonly thought was clearly passed on to control 
HF. This helped clinicians to withhold antimalarials when the result of microscopy was negative and 
presumably also the microscopists to refrain from giving so many false positive results. 
Routine statistics were considered meaningful because of the reasonable quality of registers in Dar 
es Salaam. Besides giving a robust confirmation that clinicians’ behaviour changes took place, this 
gave for the first time a unique measure of the amount of antimalarial drug that could be saved 
following mRDT implementation: 12’727 ALu blisters and 6’061 quinine vials per month in 9 HF, 
including the 3 district hospitals. The analysis of these routine statistics also identified another 
important source of drug wastage: the mishandling of drug stocks that were either lost, diverted or 
got expired between the main store and the patients. Initiatives aimed at reducing drug wastage 
should thus not only target clinicians’ prescription behaviour but also drug management more 
generally.  
To our knowledge there are currently 7 studies that looked at the impact of mRDT on antimalarial 
prescription or clinicians’ adherence to mRDT result (Skarbinski et al. 2009; Hamer et al. 2007). One 
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Kenyan study was inconclusive because adherence to test result was already very high prior to any 
intervention (Skarbinski et al. 2009); two studies from Tanzania and Burkina Faso showed no effect 
of mRDT at all (Reyburn et al. 2007; Bisoffi et al. 2009); three studies from Zanzibar, Tanzania 
mainland and Uganda showed a strong impact (RR 0.42 and 0.29 for antimalarial prescription and 
RR 0.29 for over-prescription) (Msellem et al. 2009; Hopkins et al. 2008). A Zambian survey, 
conducted one year after deployment of mRDT at national scale, showed intermediate results (RR 
0.62 for negative patients treated with antimalarials) but was underpowered because of an 
unexpected low number of patients tested for malaria (Hamer et al. 2007). All these studies are very 
heterogeneous in terms of setting, design and type of training and it is therefore difficult to draw 
conclusions on the reasons for failure or success. These studies were all different from ours in 
several ways: they took place in rather controlled conditions (except the Zambian study), used 
consultation observations only, and were conducted shortly after the start of mRDT implementation 
(with or without a baseline survey). The reasons given by the authors of the two studies showing no 
impact was the insufficient training on mRDT given to clinicians in the Tanzanian one and 
artemisinin-combination therapy not being available in the Burkina Faso one (Reyburn et al. 2007; 
Bisoffi et al. 2009). In Zambia, the very first experience of mRDT use in Africa outside South-Africa, 
the main problem was probably the assumption that clinicians would act upon mRDT result without 
problem (Hamer et al. 2007). By contrast, the successful Ugandan study put a strong emphasis on 
training and on giving straightforward messages (Hopkins et al. 2008). The Zanzibar study used a 
weekly cross-over design where nurses received a financial incentive to participate in the study and 
adhere to specific instructions on mRDT (Msellem et al. 2009). It is thus difficult to know if their 
success would be reproducible in a less controlled setting. The Tanzanian mainland study was also 
successful although no direct incentive was given, but a study staff member was physically on-site 
during the entire study period and all facilities were visited regularly by the supervisory staff (Williams 
et al. 2008).   
Based on our observations and on the feed-back given by clinicians, we think that the major 
determinants for the positive results of our programme were the following: (1) the study was 
presented to clinicians as the pilot phase of a planned national deployment of mRDT; (2) as one of 
the main investigator of the study was the City Medical Officer of Health,  health workers considered 
this assessment not just as an isolated research project but rather as the new guidelines for malaria 
management in the city; 3) the training was appreciated by the target audience for the following 
reasons: provision of strong evidence on malaria prevalence, on bad quality of routine microscopy 
and on performance of mRDT (from meta-analyses and data acquired locally), and effort to target 
their own reality with cases studies. The fact that the mutual mistrust between laboratory staff and 
clinicians around malaria test result could be spoken out and that mRDTs were presented as a tool to 
overcome this issue was probably also helpful. Clear take-home messages were given avoiding 
ambiguous messages (D'Acremont et al. 2007). We believe that our experience should be 
reproducible in the context of a well planned programmatic deployment of mRDT in the public health 
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system. Indeed our project is feasible when deployed at scale [short training (one-day), limited 
supervision (once quarterly) and absence of financial incentive]. 
Knowing the difficulty of clinicians to identify other causes of fever than malaria, we expected a 
potentially higher prescription rate of antibiotics. In the cluster-randomized study, we found that the 
overall proportion of patients treated with antibiotics increased by one third in intervention HF, while it 
did not change in control HF. This increase was mainly due to the increased number of negative 
patients, who were more often treated with antibiotics. This clearly highlights the necessity of 
integrating mRDT training in a broader training on management of fevers (IMCI or others).  
Limitations of the study 
In the longitudinal study, the impact of mRDT on antimalarials consumption might have been 
underestimated. Indeed the ALu decrease was less pronounced in the first 4 months post mRDT 
initiation than in the following months. This was related to problems at the start of the implementation 
that could be solved. Also the total number of attendances slightly increased over time, while our 
data for tests and drugs were not corrected by the total number of patients. The pre-intervention 
period was rather short for ALu (3 months), which reduces the strength of the assessment. However, 
the impact measured on the consumption of quinine vials, which was based on a much longer pre-
intervention period (15 months), was quite similar to that of ALu. Also, the high intra-health facility 
convergence between these results and those of the before-and-after repeated cross-sectional study 
speaks for strong robustness of the findings. 
7.6 Conclusions 
When deployed appropriately (official support of the new tool by senior health authorities, high quality 
training, regular routine supervision and monitoring after implementation), mRDTs lead to a 
considerable saving of oral and injectable antimalarial drugs at all levels of the health system, 
including in hospitals. mRDT also prevent patients from misdiagnosis and adverse events of 
unnecessary antimalarial treatments. The potential of antimalarial saving through mRDT use could 
be maximized if other causes of drug wastage were tackled as well, i.e. drug procurement 
mechanisms based on the number of confirmed malaria patients, rigorous and dynamic management 
of stocks, similar diagnostic and treatment strategies in the private sector including pharmacies and 
drug shops. The downside of mRDT implementation is the shift from antimalarial wastage to 
antibiotic wastage due to insufficient knowledge and training on other causes of fever. Deployment of 
mRDT should therefore move hand in hand with strategies aimed at reducing irrational use of 
antibiotics at outpatient level, for example through updated IMCI decision charts promoted by 
innovative approaches for teaching and communication.  
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8.1 Abstract 
Rapid Diagnostic Tests (mRDTs) for malaria may help rationalize anti-malarial use; however, the 
economic effects of these tests may vary. Data on costs were collected from 259 patients in 6 health 
facilities using exit and in-charge interviews plus record reviews during a trial of mRDT roll-out in Dar 
es Salaam, Tanzania. mRDTs lowered patient expenditure on drugs (savings: USD 0.36; p=0.002) 
as well as provider drug costs (savings: USD 0.43; p=0.034) compared to control facilities. However, 
mRDT introduction did not significantly reduce patients’ overall expenditure (USD 1.02 (0.76 – 1.36) 
vs. USD 1.33 (0.99 – 1.77)) and may increase total provider costs (USD 3.63 (3.40 – 3.89) vs. USD 
2.32 (1.99 – 2.69)) when compared to control facilities.  Clinician’s compliance with test results was 
higher with mRDTs than with routine microscopy (95% vs. 82%; p=0.002). mRDTs reduced drug 
costs in this setting but did not offset the cost of the tests, though they also brought non-monetary 
benefits including improved management of patients and increased compliance with test results. 
8.2 Introduction 
Within African public health facilities, malaria is largely diagnosed on clinical grounds alone, and 
fever cases are routinely treated without laboratory confirmation (WHO 2009b). Malaria microscopy, 
when available, is often of poor quality (Mundy et al. 2000; Kahama-Maro et al. 2008). However, with 
the high costs of the new generation artemisinin combination therapy (ACT), as well as concerns 
about the development of drug resistance due to drug overuse, many donors and health system 
managers are searching for ways to improve the rational use of drugs for malaria treatment. 
Additionally, in many endemic areas, intense malaria control activities and rapid urbanization have 
led to falling clinical malaria incidence rates. As a consequence, the malaria-attributable rates in 
fever episodes have been falling, further increasing the need for improved diagnostic strategies 
(Chapter 6).  
The modern generation of HRP2 antigen based rapid diagnostic tests (mRDTs) have been shown in 
trials to have high sensitivity and specificity for the diagnosis of P. falciparum infection among clinical 
patients in Africa (Bell & Peeling 2006; Ochola et al. 2006). Several studies have shown that the 
sensitivity of mRDTs can be higher than expert microscopy and thus far more accurate than routine 
microscopy. (Bell et al. 2005; Dal-Bianco et al. 2007; Stauffer et al. 2009).  
There are potential drawbacks to the use of mRDTs for routine malaria diagnosis, including the 
persistence of the target antigen in the blood stream for up to several weeks after an infection has 
been treated, hence mRDTs cannot be used to measure treatment success (Mayxay et al. 2001; 
Iqbal et al. 2004; Swarthout et al. 2007). Additionally, such tests cannot determine parasite load and 
their specificity may vary with the setting (Bell & Peeling 2006).  
While more accurate laboratory diagnosis may help to rationalize anti-malarial drug use at health 
facilities in Africa, there is also a clear possibility that any cost savings made from the reduction of 
anti-malarial prescriptions may be outweighed by increases in prescription of antibiotics or other 
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drugs to treat test-negative patients (Hume et al. 2008). Additionally, mRDTs add cost to case 
management which is not inversely proportional to the number of patients tested, as is the case for 
microscopy, and which could outweigh cost-savings from reduced anti-malarial consumption (Lubell 
et al. 2007). The effects of diagnostic changes will also depend on the adherence of clinicians to the 
diagnostic result, the frequency with which they request a test, as well as on the prevalence of 
parasitemia among the clinical population (Zurovac et al. 2006a; Lubell et al. 2008a). 
There is a sizable body of literature which has examined the implications of improving malaria 
diagnostic methods, including both empirical and modelling studies. The results of the empirical 
studies have shown that there is a possibility to reduce average cost per patient as well as household 
costs through improved malaria diagnosis - and that such interventions could be implemented in a 
highly cost-effective manner (Jonkman et al. 1995; Zikusooka et al. 2008).  
Modelling studies have helped to confirm and highlight the myriad factors which could influence both 
the cost-effectiveness and the overall cost-saving potential of improved diagnosis. The main factors 
which influence the desirability of one testing strategy over another relate to the proportion of febrile 
cases which are parasite positive, the sensitivity and specificity of the new method and its 
alternatives, the costs of the tests, clinicians’ adherence to test results as well as the cost of the drug 
regimens prescribed to parasite-positive and parasite-negative patients (Shillcutt et al. 2008).  
Since the potential for cost savings appear to be highly situation dependant it is necessary to 
evaluate the economic implications of the decision to shift to mRDTs locally and at specific levels of 
the health care system. While models can be used to explore these implications, there is still a strong 
rationale to assess alternatives and validate models empirically in representative settings (Lubell et 
al. 2008b). This paper describes a study of the economic implications of the implementation of 
diagnosis with mRDTs in a low-endemicity urban African setting in Dar es Salaam, in the United 
Republic of Tanzania. 
8.3 Materials and Methods 
Study area. Dar es Salaam is the economic capital of the United Republic of Tanzania. It is a large 
urban area (population approximately 3 million) with highly heterogeneous land use, including 
commercial districts, industrial districts, residential districts, urban slums, and areas with high levels 
of urban agriculture (Dongus et al. 2009). As a result there is high variability in the number of 
Anopheles sp. breeding sites and hence adult mosquito densities across the city. As of 2009 it is 
considered a low but stable malaria transmission area: EIR ≈ 1.3 (Geissbühler et al. 2009), with low 
parasite prevalence (less than 10% in the general population). All of the health facilities included in 
the costing exercise are located in densely populated low-income areas, though one facility’s 
catchment area (Kawe Dispensary) also includes some peri-urban and higher income areas. 
Twelve public health facilities were selected for inclusion in a trial of mRDT rollout three hospitals and 
9 primary health care facilities The 3 hospitals were assigned to receive the mRDT intervention while 
the 9 primary care facilities were randomly assigned to either receive the mRDT intervention 
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(experimental) or not (control) (Chapter 7). Of these, six primary health care facilities were included 
in the costing exercise. Four primary care facilities were experimental facilities in which mRDTs 
replaced routine microscopy for the diagnosis of malaria. Two primary care health facilities, remained 
as controls with only routine microscopy. These six were selected because this evaluation was 
targeted at the primary care level and these facilities were the most comparable in terms of patient 
population, size and numbers of monthly consultations. Sample size was calculated using EpiInfo 
3.4.1 (StatCalc Module) (U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA) with 
the aim of being able to measure a 25% difference in arithmetic mean patient costs between mRDT 
and control facilities with 95% significance and 80% power. 
Collection of patient and facility costs and resource use. Costing was conducted both from the 
patient and provider perspectives. A large survey examining the effects of mRDT introduction on 
health worker practices and patient response was used as a platform for collecting patient-specific 
and facility costs. This survey was the second in a pre- post cross-sectional survey evaluation of the 
mRDT intervention (that consisted in training of health workers in February 2007, initiation of mRDT 
use at the end of March 2007 and supervision on site 1, 2, 5, 10 and 15 months after mRDT 
introduction) and conducted 15 to 18 months post intervention from July through September of 2008. 
Within the six selected facilities the inclusion criteria were the following: (1) first consultation for the 
present complaint (not a follow-up visit), (2) absence of severe disease, and (3) main complain not 
trauma related. Eligible patients or caretakers of young patients were included if they gave oral 
informed consent to participate. Their consultation was then passively observed by a survey worker 
with clinical training. These patients or caretakers were questioned during an exit interview, which 
included questions relating to their perceptions of the clinical and laboratory consultation, as well as 
episode-related expenditures and any previous treatment seeking and related expenditures. The 
questionnaire also probed travel time and costs, time spent accessing the facility and missed work or 
lost income due both to the attendance at the facility and/or any time taken to care for the patient at 
home. 
All patients or caretakers who participated in the exit interview (and therefore had costing questions) 
were requested to return to the same health facility one week later for a follow-up interview. They 
were also provided with a small incentive to cover transportation costs. At follow up, all patients or 
caretakers were administered a second questionnaire which solicited information on their current 
health status and any treatment seeking activity or expenditure during the intervening week, as well 
as lost income and time taken to care for the patient at home. They were also asked about the 
previous consultation and any associated expenditures, mainly as a check on consistency, as well as 
to potentially garner information about informal payments. If in-person follow-up was not possible we 
attempted a shortened follow-up interview via mobile telephone. All follow-up patients who reported 
at a health facility were tested with an HRP2 based mRDT in order to check for missed infections, as 
well as to identify false negatives or positives in the control facilities given the persistence of the 
HRP2 antigen in treated patients.  Persistence of the antigen was low (<33%) in previously mRDT 
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positive and appropriately treated patients and as such results for the second mRDT were not of use 
for determining numbers of correct diagnoses. For the patients who tested positive by mRDT during 
follow-up it was ascertained whether they had received appropriate first line treatment, and whether 
their condition had improved. If this was not the case we ensured that they were subsequently 
treated for malaria at the health facility.   
In order to assess treatment costs to the provider a health facility survey was conducted in the six 
facilities participating in the cost study to identify per patient resource use at the facility level. In-
charge interviews and a health facility level data survey instrument were used to collect information 
on the number of outpatients and malaria cases seen at the facility over the past three years, as well 
as numbers of blood slides and mRDT tests performed. Additionally, we collected information on 
numbers and grades of staff and estimated effort dedicated to outpatients. We also collected 
additional information used to calculate overhead and patient visit costs, including the facility’s 
spending on electricity, water, other overhead costs, and the numbers of capital items in the facility – 
including microscopes and other clinical equipment. Facility records were also utilized to collect 
information on the use of consumables including laboratory books, Giemsa stain, blood slides, 
lancets, syringes and other consumables. We measured resource use at each of the six facilities 
through a questionnaire administered to the in-charge of health facility, as well as the collection of 
routine data on facility use, numbers of outpatients treated, numbers of malaria test performed, and 
records of consumables used. Additionally, we conducted data collection at the central offices of the 
City Medical Office of Health to estimate the costs of construction of health facilities and other costs 
which we could not obtain directly from the health facilities themselves, including salary ranges for 
various grades of health workers. 
Valuation of resource use. Costs of resource inputs were determined for the provider costs on the 
basis of (1) the Tanzania pharmaceutical and supply price list for 2008, and (2) interviews with the 
appropriate financial managers of the Dar Es Salaam City Medical Office of Health. Information on 
drug prices was obtained from the International Drug Price Indicator Guide database published by 
Management Sciences for Health (MSH) or from a WHO-AFRO database of indicator drug prices 
(Management Sciences for Health 2009; WHO Regional Office for Africa 2003). Patient costs were 
valued according to patients reported expenditures and lost income. 
Costs for the initial implementation of mRDTs, including training and quarterly supervisory visits were 
calculated based on reported expenditure and activities, excluding specific research costs. Costs 
were reported in the local currency (TSH), U.S. Dollars (USD), or Swiss Francs (CHF). All costs were 
converted to USD using official exchange rates for the year in which the cost occurred and adjusted 
into a common year (2008) using the U.S. GDP deflator (U.S. Bureau of Economic Analysis). Capital 
costs were discounted and annualized using a 3% discount rate and assumed lifetimes for 
equipment based on expert opinion and past literature.  All costs attributable to mRDT 
implementation were then divided by the estimated total number of mRDT tests performed in the nine 
experimental (from the full trial) health facilities (328,000 – 435,000) over the entire duration of the 
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project (approximately two years) to calculate an average implementation cost per test. The number 
of tests was estimated in two ways: the first and lower number was the number of mRDTs performed 
according to facility records, and the second and larger number referred to the number of mRDTs 
delivered to the facilities according to project records. This range had little effect on the cost of 
implementation per test (excluding the cost of the test itself). 
For provider costs all costs were related to their allocation to outpatient services (as opposed to 
maternal and child health services) and then related to the number of out-patients seen at the facility 
during the period under which their consumption could be measured (between 2005 and 2008). 
Because some resource usage could not be measured at each facility due to missing records (26% 
of requested records were missing) these costs have been estimated using the mean values per 
patient from the facilities where information could be collected. Prices of drugs have been adjusted to 
account for transport costs and wastage according to the following assumptions. Drugs costs were 
inflated 20% over actual costs to adjust for wastage, then an additional 10% for local transport, and 
finally an additional 10% for international transport where CIF (Cost, insurance and freight) prices 
were not available. 
Statistical analysis. We tested the differences in patient expenditure and provider costs using two 
different statistical tests. We first applied the Kruskal-Wallis test for equality of populations. We used 
this test because, as is typical of expenditure data, the distribution of both patient specific provider 
costs and patients expenditures was highly non-normal, due both to a significant right skew and a 
large zero-mass.  Thus performing significance testing with a non-parametric method was necessary.   
Additionally, we used non-parametric bootstrapping to estimate confidence intervals for each 
expenditure value. This approach was adopted due to the fact that alternative non-parametric 
methods do not compare arithmetic mean costs, transformation of the data to a log scale would 
result in comparison of geometric means, and furthermore, such transformation did not result in a 
normal expenditure distribution. Methodological studies and reviews have suggested this 
methodology to appropriately deal with the need to compare arithmetic means and generate 
confidence intervals on such data (Barber & Thompson 1998; Nixon et al. 2010).     
Total time for patient visits to the health facility was normally distributed and thus amenable to 
standard parametric tests.  Data was entered in EpiInfo 3.4.1 (US CDC), and analyzed in STATA 9.2 
(Stata Corporation, College Station, TX).   
Ethical approval: The protocol and related documents were approved by the National Institute for 
Medical Research Review Board in Tanzania. 
8. Cost-savings from Rapid Diagnostic Tests for malaria in low transmission areas? 
 
  
 
76 
8.4 Results 
General results. 333 patients were recruited during consultation at each of the six selected facilities 
for exit interviews. 259 patients were successfully administered an exit interview. The final rate of 
follow-up (for patients participating in the full costing study) was 84%, and is illustrated in Figure 16. 
No patients or clinicians refused the initial consultation observation. At the 5% significance level, 
patients in mRDT facilities were no more likely to attend the exit interview than those in control 
facilities; after stratifying by the portion of the patient population over age five differences were less 
significant. 
 
Figure 16: Losses to follow-up during the study 
        
 
 
Patients who were lost to follow-up were not significantly different from those who were successfully 
re-interviewed based on several demographic measures (Tables 7a and 7b). No significant 
differences were found for age distribution, patient sex, method of travel to and from the health 
facilities or the occupation of the patients’ head of household (details not shown). Additionally, we 
found no significant differences on the same set of measures between facilities which offered mRDTs 
and those facilities which did not offer mRDTs (Tables 7a and 7b).  Unfortunately, patients who were 
over five years of age were significantly more likely (29% vs. 15%) to leave the health facility before 
completing the exit interview.     
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Table 7a: Comparability of control and experimental populations, and those lost to follow-up 
 N Estimate 95% confidence interval p-value 
Proportion of patients age five years and older 
Control facility 81 51.9 41.0 – 62.7 
mRDT facility 178 47.2 39.9 – 54.5 0.49* 
Lost to follow up 42 59.5 44.7 – 74.4 
Not lost to follow up 217 46.5 39.9 – 53.2 0.12* 
Proportion of patients who were female 
Control facility 81 55.6 44.7 – 66.4 
mRDT facility 178 54.5 47.2 – 61.8 0.87* 
Lost to follow up 42 54.8 39.7 – 69.8 
Not lost to follow up 217 54.8 48.2 -61.5 0.99* 
*p-values are based on Pearson’s χ2 test with d.f.(1)  
 
Table 7b: Comparability of control and experimental populations, and those lost to follow-up 
Patients method of travel to health facility (proportion) 
 Lost to 
follow up 
(N=42) 
Not lost to 
follow up 
(N=214) 
mRDT 
facility  
 
(N=175) 
Control 
facility 
 
(N=81) 
Walking 61.7 60.8 61.7 61.7 
Mini-bus 33.3 35.5 34.9 35.8 
Other 0.0 3.7 3.4 2.5 
p-value 0.529** 1.000** 
**p-values based on Fischer’s Exact Test 
 
Of the 259 patients who were administered exit interviews 178 were interviewed at experimental 
facilities (with mRDTs) and 81 were patients at control facilities (no mRDTs).  Within the mRDT 
facilities, patients were significantly less likely than in control facilities to receive results for a 
laboratory test for malaria (84% vs. 95%; p=0.009 Fischer’s exact), a difference that was also 
significant in patients five years and older (86% in mRDT facilities vs. 98% in control facilities; 
p=0.04) but not for children less than five years (82% in mRDT facilities vs. 92% in control facilities; 
p=0.13).  Patients in mRDT facilities were also significantly less likely to test positive for malaria 
parasites (14% vs. 43%; p<0.001).   While in both control and mRDT facilities large fractions of all 
patients received laboratory diagnosis, clinicians in the mRDT facilities appeared to be more 
parsimonious in their use of tests, at least among adults. 
Adults were significantly more likely than children less than five years to test positive for malaria in 
control facilities, but not in mRDT facilities (55% vs. 28% in control facilities; p=0.016 and 15% vs. 
13% in mRDT facilities; p=0.69). These results clearly confirm the problem with microscopic 
examination, and indeed the low quality of routine microscopy was confirmed in more detailed 
studies in the same facilities (Kahama-Maro et al. 2008).  
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Patients within mRDT facilities were significantly less likely to receive the first line anti-malarial drug 
ALU (artemether-lumefantrine, CoartemTM) compared to patients in control facilities. This was seen 
when the analysis was restricted to patients who left the facility with any drug prescription as well as 
among all patients observed: 12% vs. 52% p<0.001 (with any prescription); 10% vs. 48% p<0.001 
(all patients). This difference remained highly significant regardless of the age of the patient. 
Patients in mRDT facilities were also more likely to receive ALU in correct correspondence with the 
results of their diagnosis. When only patients with a laboratory diagnosis were examined, those in 
mRDT clinics received ALU in correspondence with the laboratory diagnosis 95% of the time vs. 82% 
in control facilities (p=0.002). Since a related study has shown that most positive blood slide results 
in the control facilities are false positives (Kahama J and others, unpublished data), it follows that 
high clinician compliance with microscopy results leads to overuse of anti-malarial drugs. Patients 
under the age of five years appeared no more likely to be correctly prescribed ALU than those over 
five years of age (93% less than five vs. 88% five and older; p=0.17). Differences remained 
statistically insignificant when restricted within either mRDT facilities or within control facilities (details 
not shown).         
Implementation costs of mRDT program (provider). Cost data on implementation was collected 
over a 14 month period. During this 14 month period approximately 435,400 mRDTs were issued to 
implementing facilities and usage data indicated that approximately 330,000 mRDTs for malaria had 
been performed. Due to this high volume of tests, the cost of implementation training and support for 
mRDT roll-out was relatively low when considered per test. The total cost of the mRDT intervention 
over this period (not including the test kits themselves) was estimated to be $16,946 in 2008 USD, or 
$1,883 USD per implementing facility. Thus we estimated that the cost of implementation per mRDT 
test (excluding the test kits themselves) was between 0.04 USD and 0.05 USD. The test kits 
themselves were estimated to cost USD 0.66 each. When calculating the cost per patient in mRDT 
clinics we include the cost of mRDT implementation.      
The bulk of the expenses went to staff salaries for the implementation of the mRDT rollout (72%) and 
for training and quality control at the implementing facilities (22%). The only other substantial line 
item cost was transport, which accounted for 3% of the total cost of implementation. 
Patient perspective – direct costs (expenditure). Patient costs consist of two main parts: direct 
costs due to expenditure on medicines, transport, diagnostics or other health services, and indirect 
costs, such as lost productivity or the opportunity cost due to time spent seeking care. We attempted 
to measure both direct and indirect costs.   
Patient expenditures were directly reported by patients. Table 8 shows arithmetic mean expenditure 
per patient in mRDT or control facilities arising before and during the first consultation, as well as 
after the first consultation for the subset of patients with follow-up. Expenditures have been 
subdivided into several categories, and are reported here in Tanzanian Shillings and USD. 
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Table 8: Patient expenditures. HF=Health Facility. Totals are different than sum of means because of 
varying sample sizes for each group  
Mean cost per patient Type of Expenditure  N 
TSH USD 
Standard 
Deviation (TSH) Significance
+
 
mRDT 178 89 0.07 630 Care pre-HF 
Control 81 46 0.04 298 
0.506 
mRDT 178 464 0.38 1060 Drugs at HF 
Control 81 902 0.74 1407 
0.002 
mRDT 125 79 0.06 117 Out-patient charges 
Control 56 104 0.08 129 
0.347 
mRDT 122 245 0.20 411 Lab fee at HF 
Control 56 252 0.21 431 
0.841 
mRDT 126 198 0.16 1008 Post visit  
Control 56 70 0.06 447 
0.956 
mRDT 178 362 0.30 897 Travel 
Control 81 270 0.22 440 
0.779 
mRDT 122 1247 1.02 2021 Total 
Control 56 1630 1.33 1826 
0.033 
+significance results are based on Kruskal-Wallis tests 
 
Table 8 shows that significant differences in reported expenditure were found between patients at 
mRDT clinics and those at control clinics. Patients’ mean total expenditures were lower in mRDT 
clinics (USD 1.02) compared to control clinics (USD 1.33), and were significantly different using the 
Kruskal-Wallis test for equality of populations. Patients’ mean expenditure on drugs was 0.36 USD 
lower in mRDT clinics than in control clinics. 
Table 9 shows bootstrapped means and bias corrected confidence intervals for each of the 
parameters shown in Table 8. Each estimate is based on 10,000 re-samples of the observed data.  
Arithmetic mean patient expenditures, when reduced into smaller component parts, failed to show 
significant differences in all but the line item expenditure for drugs at the first health facility visit, 
which was highly significantly different in mRDT clinics (using the Kruskal-Walis test: TSH 464 (USD 
0.38) vs 902 (USD 0.74); p=0.002). Bootstrapped confidence intervals showed, however, that the 
difference was only close to significance. 
The similarity of expenditure across the two types of facilities helped to support our assumption that 
the populations of patients in control and mRDT facilities were similar since the cost of transportation 
and actions taken before attending the health facility would not be expected to be significantly 
different between the two groups. Further, it supports the argument that effects on patient 
expenditures were largely limited to those on drug purchases. 
Expenditures on drugs at the health facility accounted for the largest single component of patient 
expenditure, followed by laboratory fees and travel costs. 
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Table 9: Results of non-parametric bootstrap for confidence interval estimation of patient 
expenditures. Totals are different than sum of means because of varying sample sizes for each group  
Mean cost per patient 95% Bias Corrected C.I. Type of Expenditure  
2008 USD TSH 
mRDT 0.07 0.02 – 0.18 Expenditure for care pre-HF  
Control 0.04 0.01 – 0.12 
mRDT 0.38 0.27 – 0.53 Drug expenditure at HF 
Control 0.74 0.52 – 1.03  
mRDT 0.06 0.05 – 0.08 Out-patient charges 
Control 0.08 0.06 – 0.12 
mRDT 0.20 0.15 – 0.27 Lab fee at HF 
Control 0.21 0.13 – 0.32 
mRDT 0.16 0.04 – 0.34 Post visit expenditure 
Control 0.06 0.00 – 0.22 
mRDT 0.30 0.21 – 0.43 Travel expenditure 
Control 0.22 0.15 – 0.31 
mRDT 1.02 0.76 – 1.36 Total expenditure 
Control 1.33 0.99 – 1.77 
 
 
Patient perspective – indirect costs. Additionally, patients incurred indirect costs through lost 
income, reduced productivity, and the opportunity cost of lost time due to attending the facility either 
as patients or as caretakers of patients. One hundred-eight (42%) patients or caretakers reported 
missing work to attend the health facility; of that group, 85% reported lost income as a result. Neither 
result was significantly different at the 10% level between mRDT and control facilities: p=0.16; d.f.(1) 
and p=0.66; d.f.(1). Among those reporting lost income, mean lost income was reported as 7175 
TSH (5.87 USD) a figure which was not significantly different between control and mRDT groups 
(Kruskal-Wallis p=0.16). This figure is significantly larger than patients’ expenditures on all other 
categories. For patients who lose income to attend the facility, the opportunity cost of facility 
attendance is far larger than the direct costs of health care and such large opportunity costs might 
prevent significant numbers of people from accessing care. 
Total time per visit, including transportation time was measured by adding estimates of time at which 
the patients or caretakers left their home or work place to attend the facility to the time they spent at 
the health facility (determined by the time of the start of their exit interview), with an additional time 
factor added for their estimated time to return home. In control clinics mean time per visit was 
estimated to be 4.7 hours, while in mRDT clinics it was estimated at only 4.0 hours (t=2.8703; 
p=0.005). Hence, being a patient in an mRDT clinic in our sample was associated with approximately 
42 minutes shorter total visit time. Though a certain amount of this variation can be attributed to 
slightly shorter travel times to mRDT facilities (mean travel time 35 minutes) compared to control 
facilities (44 minutes; p=0.058) resulting in a mean difference of approximately 9 minutes of travel in 
each direction, or 18 minutes total. Reduced waiting times and total visit times might help to reduce 
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the opportunity costs of facility attendance and thus could improve access to care, though the 
reductions seen here are small (~10%) in relation to total visit time.     
Provider perspective. In this analysis we focus on gross provider economic costs and not net costs, 
which would account for the collection of user fees by health facilities.  Table 10 lists the costs which 
were included in the analysis.   
 
Table 10: Costs included in provider perspective analysis   
Recurrent Costs Capital Costs 
    Clinical staff salaries     Building and furnishings 
    Lab technician salaries     Microscopes 
    Support staff salaries     Other equipment 
    Consumables  
    Drug costs  
    Diagnostics  
    Electricity   
    Water  
    Communication  
 
 
Table 11 shows the results of the provider perspective analysis for the mRDT and control facilities. 
The table shows the results of non-parametric tests for each of three sub-divisions of total provider 
costs. They are analyzed either within control or experimental facilities. “Drug costs” represent the 
cost to the provider of all drugs and prescription provided to a given patient. “Facility cost” is the cost 
of the commodities whose usage is measured at the facility level but not linked to specific patients 
(overhead, staff costs, equipment and general consumables, excluding drug costs), thus there are 
only six observations corresponding to the number of facilities in our study. “Total costs” include drug 
costs, facility costs and other marginal costs including mRDTs and consumables which are patient 
specific rather than general consumables used for all patients.  Significant differences were found for 
all costs except facility cost, though the latter result is compromised by the extremely small sample 
size. 
When patients who attended mRDT clinics were compared to patients who attended control clinics, 
drug costs were significantly lower for patients from mRDT clinics (USD 1.28 vs. USD 1.71; 
p=0.014). However, total provider costs were higher for patients from mRDT clinics USD 3.63 vs. 
USD 2.32; p<0.001 for total cost. 
 
8. Cost-savings from Rapid Diagnostic Tests for malaria in low transmission areas? 
 
  
 
82 
Table 11: Provider costs per patient.  Totals include drug costs, facility level costs and other 
patient specific marginal costs. 
Type of cost  
(per patient) Group N Arithmetic mean 
Standard 
Deviation Significance 
   TSH USD TSH  
Drug cost  mRDT facility 178 1567 1.28 1799 
 Control facility 81 2095 1.71 1938 
0.014+ 
Facility cost mRDT facility 4 1926 1.58 903 
 Control facility 2 720 0.59 424 
0.161* 
mRDT facility 178 4440 3.63 2019 
Total cost 
Control facility 81 2833 2.32 1978 
<0.001+ 
+Kruskal-Wallis based p-values 
*t-test based p-values 
 
 
Again we were confronted with results which were highly non-normally distributed, including in some 
cases a large zero mass and in all cases a significantly right-skewed distribution. Hence we 
estimated confidence intervals using non-parametric re-sampling (bootstrapping) with 10,000 re-
samples for each outcome, excepting facility cost (Table 12). 
 
Table 12: Results of non-parametric bootstrap for confidence interval estimation of provider 
economic costs. Cost values in 2008 USD. 
  All Ages Under Five Over Five 
Type of cost  
(per patient) Group 
Mean 
cost 
95% bias 
corrected 
C.I. 
Mean 
cost 
95% bias 
corrected 
C.I. 
Mean 
cost 
95% bias 
corrected 
C.I. 
Drug cost mRDT facility 1.28 1.07 – 1.50 1.19 0.90 – 1.53 1.38 1.10 – 1.68 
 
Control 
facility 1.71 1.40 – 2.08 1.08 0.74 – 1.57 2.29 1.82 – 2.79 
Total cost  mRDT facility 3.63 3.40 – 3.89  3.59 3.11 – 3.95 3.69 3.36 – 4.03 
 
Control 
facility 2.32 1.99 – 2.69 1.72 1.37 – 2.22 2.87 2.39 – 3.38 
 
 
Bootstrapped confidence intervals generally confirm the results of the Kruskal-Wallis tests. However 
important differences do exist between the two results. The confidence intervals for drug costs 
between mRDT and control facilities show a large overlap when analyzed for all age groups. 
However, when the sample is stratified by over and under five years of age a significant difference 
exists for patients five years of age and older. This may be the result of a combination of high rates of 
ALU prescription in control facilities and the higher cost of this drug for adults in relation to other adult 
drugs. Once facility costs are included, the total cost of treating a patient including all provider costs 
is significantly higher in mRDT facilities than in control facilities.         
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Summary of all results. The results indicate that in the presence of mRDTs, drug cost savings are 
likely to accrue to patients, and may also accrue to the providers, especially for adults. However, 
whether these savings translate into overall cost savings is more in doubt. 
For patients, it appears likely that there is some reduced overall spending when mRDTs are 
available.  However, the savings is small (USD 0.36) and it represents only a small component of the 
total economic costs to patients. 
For providers the drug cost savings is of a similar order (USD 0.43) as a result of mRDT introduction. 
Unfortunately, these savings appear to be too small to offset the entire cost of mRDT introduction 
and use. In fact, it appears that mRDTs may increase the cost of treatment per patient in public 
facilities, despite reducing anti-malarial drug usage and creating drug cost savings for the health 
system. Additionally, the cost savings arise largely from reduced anti-malarial usage among adults 
who are most likely to be charged a user fee for drugs.  Hence, the resulting reduction in user fee 
revenue due to reduced patient drug expenditure will reduce the financial incentives for mRDT 
implementation.  
8.5 Discussion 
This study was conducted under routine conditions in health facilities and sampled patients were 
taken from six different health facilities. As there is likely to be a tendency towards similar prescribing 
practices within facilities, the results should be adjusted for clustering within health facilities (Rowe et 
al. 2002). Unfortunately, because of the small sample size and small number of health facilities 
included in the study, we were unable to formally account for this in most of the statistical analysis. 
Nevertheless we believe that these results are likely to be robust, although the extent to which they 
are generalizable depends on how representative these facilities are of typical Tanzanian facilities or 
more widely of other sub-Saharan African health systems. 
These results are of course sensitive to the relative prices of malaria drugs and antibiotics (ALU: 
USD 0.41 to USD 1.60 depending on dosage; antibiotics USD 0.20 to USD 3.50 depending on drug, 
dosage and formulation) as well as any other drugs used to treat test-positive and test-negative 
patients. It is possible that given changes in drug prices our results could change. One of the most 
expensive drugs commonly in use among this type of patients is artemisinin combination therapy for 
malaria. Much of the drug cost savings seen in this study, both to the patients and to providers, is 
due to reduced anti-malarial usage in mRDT facilities. Hence, a reduction in the price of anti-malarial 
drugs may erase the drug cost savings seen here. Currently a global subsidy scheme for 
antimalarials is at an advanced stage and a virtually free drug at country level might prove to be a 
disincentive to testing for malaria (Gelband & Seiter 2007). Subsidized provision of malaria mRDTs 
should be considered in parallel to help overcome this problem. 
Additionally, we chose to focus on gross provider costs, this could affect our results because it 
excludes health facility receipts for user fees.  However, based on the evidence from the patients 
perspective the primary effect of mRDTs was likely to have been a reduction in user fees due to 
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reduced prescriptions of drugs and no changes in laboratory or general fees.  Thus shifting the 
perspective to net costs at the facility level would have likely made mRDTs appear even more costly 
than microscopy as they reduce the primary source of HF user fee revenue.  
It has been postulated in several studies that mRDTs could produce cost savings to health facilities 
in low transmission settings (Zikusooka et al. 2008; Shillcutt et al. 2008). Here we show based on 
empirical data from six health facilities in Dar Es Salaam that indeed significant drug cost savings 
and reductions in anti-malarial drug usage appear to be achievable in such settings. In addition, there 
was a large reduction in false positive malaria test results due to good specificity of routine mRDT. 
Clinicians’ compliance with test results was also significantly better when mRDTs were in use, and 
this is likely to have contributed to the drug cost savings seen here (Lubell et al. 2008a). Increased 
compliance by providers may be a result of high quality training or their perception of the increased 
accuracy of mRDTs compared to their routine laboratory diagnostic methods. 
However, despite demonstrable drug cost savings we did not see overall cost savings due to the use 
of mRDTs and in fact provider costs appeared to significantly increase in the presence of mRDTs. 
Though some of this increase is likely due to higher fixed costs within the set of facilities selected for 
this study, the drug cost savings that we observed (USD 0.43) were not likely to be large enough to 
offset the cost of the mRDTs themselves when a high percentage (84%) of the patients at the facility 
have the test administered. Further, reduced patient expenditure on drugs leads to falling revenue 
from user fees, which might make the intervention appear economically less attractive at the facility 
level. Other considerations such as reduced effort at the laboratory level may partially compensate 
this loss. 
Our results show that for a significant proportion of all individuals seeking treatment, the indirect 
costs of lost productivity far outweigh the direct costs of transportation and treatment.  When 
averaged over all the patients observed, lost income accounted for approximately two-thirds of all 
costs. Other studies have come to mixed conclusions about the balance of direct and indirect costs 
of uncomplicated malaria morbidity. There is, however, general consensus that the indirect costs of 
morbidity form an important part of the economic burden of malaria (Chima et al. 2003b). Our results 
are consistent with a number of studies, both from Africa and also from other locations, which 
showed that the indirect costs of malaria can outweigh the direct costs of treatment for 
uncomplicated episodes (Ettling & Shepard 1991; Sauerborn et al. 1991; Gatton & Cho-Min-Naing 
2004; Morel et al. 2008). 
Unfortunately, in the context of this study it was not possible to measure differences in health 
outcomes between the groups of patients, nor to assess whether patients were truly malaria infected 
using expert microscopy. Thus, it was not possible to assess the cost-effectiveness of the 
intervention, either per health outcome or per additional correct diagnosis. An in-depth analysis of 
case management practices will determine if mRDTs improved compliance with standard treatment 
guidelines and improved case management (Chapters 7 and 10.1). That information could also be 
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used to calculate a cost per additional correct treatment, as has been done in previous diagnostic 
costing studies (Lubell et al. 2007). 
An additional benefit is that with a more reliable laboratory test it becomes more realistic to monitor 
malaria trends on the basis of routine data. Though it is unclear what monetary value such a benefit 
would have for the health system, substantially improved knowledge of malaria incidence rates could 
lead to efficiencies in other health care domains. Distribution of malaria prevention and treatment 
resources could potentially be more efficiently allocated to high incidence areas. Alternatively, more 
accurate measures of malaria incidence could enhance the responsiveness of health systems to 
malaria epidemics (Abeku et al. 2004). Finally, reduction of unnecessary anti-malarial over-use is 
important to limit the development of resistance to ACTs (Wongsrichanalai et al. 2007).   
Our results show significant savings on drug expenditure to patients and on drug costs to providers in 
the presence of mRDTs. However, the savings are outweighed by other fees and charges and lost 
income for patients - or the cost for mRDTs and higher facility costs for providers. 
Clinicians’ compliance with test results was higher when mRDTs were in use, showing that they 
trusted this new technology. It is also likely that the use of such tests accrues significant other 
benefits, including improved case management, more rational anti-malarial use, and reductions in 
development of resistance to ACTs. While valuation of such benefits is outside of the scope of this 
work they are highly important from a public health perspective.  While mRDTs are likely to bring 
significant benefits to the health system in areas like Dar es Salaam, these benefits may not be fully 
paid for through drug cost savings, but require additional investment. 
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9.1 Abstract 
Background: Several studies have looked at the proportion of either malaria, pneumonia, diarrhoea 
or bacteraemia among fever cases in Africa but none of them has looked at the overall spectrum of 
aetiologies. We aimed at investigating the precise cause of fever episodes in children attending an 
outpatient clinic in urban (Dar es Salaam) and rural settings (Ifakara) in Tanzania. 
Methods: All consenting children aged 2 months - 10 years with an axillary temperature >38C were 
recruited, except for those that required immediate supportive treatment. A detailed medical history 
and clinical examination were done to identify obvious foci of infection. A blood sample was taken to 
perform rapid tests for malaria and typhoid, blood culture as well as serological and molecular 
analyses. All had a throat and nasal swab taken for molecular investigation of respiratory pathogens. 
Urine was taken when no obvious cause of fever was found on clinical examination and a stool 
sample when diarrhoea was present. A chest X-ray was performed when IMCI criteria for clinical 
pneumonia were met. Each diagnosis was assigned a probability level (high, moderate, low) on the 
basis of pre-defined criteria.  
Results: 1010 children were recruited, 510 in DSM and 500 in Ifakara. Preliminary results (prior to 
molecular analysis or serologies on blood) on the causes of fever (of high probability only) were as 
follows: 50% had acute respiratory infection (ARI) [31% URTI, 18% LRTI (4% bronchiolitis, 12% non-
documented pneumonia and 3% pneumonia confirmed by X-ray)], 11% malaria, 9% gastroenteritis 
(3% Rotavirus, 1% Salmonella/ Shigella and 5% unknown), 5% urinary tract infection, 3% typhoid, 
1% skin infection, 1% occult bacteraemia, 1% other infections and 20% still unknown at this stage. 
Only 13% had more than one diagnosis (high probability).  
In severe children, the 3 leading aetiologies were ARI (38%), malaria (36%) and gastroenteritis (8%).  
A virus in the nasopharyngeal swab was isolated in 68% of the children with ARI, 55% with unknown 
disease and 44% with documented disease other than ARI. When Picornaviruses were excluded, 
these rates dropped to 39%, 18% and 13% respectively.  
Conclusion: These results provide for the first time an accurate picture of the respective causes of 
fever in African children. As expected, ARI contribute to the largest burden of disease, most of them 
being URTI. Malaria confirmed to be lower than generally thought. There was a sizeable proportion 
of fevers due to typhoid documented by the rapid test for most of them. Results of molecular 
analyses provided further insight on the contribution of respiratory viruses, a critical issue for 
appropriate management of fever and rational use of antibiotics. 
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9.2 Introduction 
Because of the lack of diagnostic tools in Africa, patients presenting to health facilities with fever 
have often been denied the usual aetiology finding process inherent to any medical consultation 
(Zurovac et al. 2006b). Moreover, based on the fact that malaria was highly prevalent and a deadly 
disease, all fever episodes tended to be considered as malaria and treated as such. With the 
decreasing transmission of malaria in Africa following the implementation of efficient control 
strategies (Chapter 4) and the increasing awareness that non-malaria fevers could be life-threatening 
(Makani et al. 2003; Reyburn et al. 2004), an effort has recently be done to introduce, even in highly 
malaria endemic areas, reliable malaria test in the routine management of fever. Thanks to the 
reliability and ease of use of Rapid diagnostic Tests for malaria, this is now becoming a reality in 
several countries if Africa. But this important step opens a new problem that is a major challenge to 
clinicians: what should be done when the malaria test is negative? The aetiology of non-malaria 
fevers has never been studied in a systematic way. We are thus presently not able to give a precise 
answer to this question and to guide the clinician with an evidence-based strategy. The Integrated 
Management of Childhood Illness (IMCI) decision-chart, although it does not include any test 
because of the risk of their unavailability, is an excellent tool developed on the basis of the scarce 
evidence existing in the mid-1990s. Disease-specific studies have been carried out in a few settings - 
for example for urinary tract infections (Rabasa & Gofama 2009) or acute otitis media (Alabi et al. 
2009) in Nigeria, for arboviruses on the Kenyan Coast (Morrill et al. 1991) or Dengue in Somalia 
(Botros et al. 1989) and for Mycoplasms and Rickettsia spp.  in Somalia (Nur et al. 1999). However, 
no comprehensive and systematic study to assess the respective contribution of each disease has 
ever been undertaken in Sub-Saharan African, and even elsewhere. A list of the proportion of 
patients with some specific diseases is sometimes given in studies not primarily designed for this 
purpose (Njama-Meya et al. 2007; Yacoub et al. 2005; Animut et al. 2009). However the way of 
establishing the diagnosis was not systematic and left at the discretion of the clinician. Also a very 
limited number of investigations were undertaken. Some studies have looked specifically at 
bacteraemia in severe hospitalized patients (Okwara et al. 2004; Ayoola et al. 2005; James A 
Berkley et al. 2005; Bronzan et al. 2007), but no link was done with the aetiology of the fever 
episode. The same drawback is found in one study that has looked at bacteraemia at outpatient 
level, but was aimed as assessing the incidence of invasive bacterial disease in the sick general 
population (Brent et al. 2006). 
Evidence on the aetiology and the prevalence of each non-malaria disease causing fever in children 
is urgently needed to improve management of patients in Africa. Information is essential not only for 
severe cases but also for mild episodes managed at outpatient level. This is necessary to be able to 
update the IMCI decision-chart and hence ensure good health outcome as well as rational use of 
antimalarial and antibiotic drugs at health facility level. Also more and more point-of-care diagnostic 
tools for all kind of diseases are appearing on the market. To know the potential of these tests in 
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African children but also to avoid their irrational use, the first step is to document which diseases are 
existing in a specific setting, what are their respective prevalence as well as their clinical predictors if 
any. This is why we designed a study aimed at assessing the precise aetiology of fever episodes in 
children attending an outpatient health facility in a rural as well as an urban setting in Tanzania. To 
avoid subjective diagnosis by the clinician or by the investigators, we used pre-defined algorithms to 
decide for investigations and pre-defined criteria to establish the final diagnosis. The aim was to 
combine precise clinical information with relevant investigations of high quality and as broad as 
possible (in the frame of infectious diseases producing fever).  
9.3 Methods 
Study setting and population 
The study took place from April to August 2008 at Amana hospital in Dar es Salaam, the economic 
capital of Tanzania, and from end of June to beginning of December 2008 at St-Francis hospital in 
Ifakara, Kilombero district, situated in the centre of Tanzania. Dar es Salaam (DSM) is a moderately 
endemic for malaria, with parasite rates in the community around 1-4% (Wang et al. 2006a) and only 
5-10% of febrile patients being parasitaemic (Chapter 7). Kilombero Valley is considered as a highly 
endemic area with a parasites rate in the community of 10% in 2008 (Mulokozi, unpublished data) 
and about 35% of febrile patients being parasitaemic (Tillya et al. 2009). However in Ifakara town 
where St Francis hospital is situated, only 7% of febrile patients are parasitaemic nowadays (Tillya et 
al. 2009). Patients were recruited at the outpatient department of these two district hospitals. The 
vast majority of them originated from the neighbourhood and attended because it was the nearest 
health facility while a small proportion was referred from the surrounding health centres and 
dispensaries.  
The Expanded Program on Immunization in Tanzania includes BCG, Diphteria-Tetanos-Pertussis, 
Polio, Hepatitis B and Measles and has reached a high coverage (90% in 2007) in the country 
(www.who.int/immunization_monitoring). Outside a few specific research studies, vaccines against 
Hemophilus influenzae b and Pneumococcus were not used up to the time of the study. In Dar es 
Salaam, a measles outbreak response vaccination campaign was organized from 22 to 24 
September 2006, resulting in an estimated coverage of almost 100% for the targeted age group (6 
months through 14 years) (Goodson et al. 2009). A three-day national integrated campaign of 
measles vaccines, vitamin A supplementation, de-worming tablets and long-lasting insecticide 
treated bed nets also took place in August 2008 
(www.unicef.org/infobycountry/tanzania_45503.html). These two interventions probably stopped 
measles transmission in Dar es Salaam and the Kilombero Valley for the period during which the 
study took place. In 2007, a Rift Valley fever outbreak took place in Kilombero district but it had 
subsided at the time of study start (WHO 2007). 
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The standard diagnosis and treatment for children less than five years is the Tanzanian version of 
IMCI (Ministry of Health and Social Welfare, Tanzania et al. 2004). The first-line treatment for malaria 
is arthemeter/lumefantrine (ALu) since January 2007. The first-line antibiotic for pneumonia, acute 
ear infection and dysentery is cotrimoxazole.   
Study subjects 
All consecutive patients aged 2 months to 10 years, categorized as P2 or P3 WHO categories by the 
triage (not requiring immediate live saving procedures) (WHO 2005b), without severe malnutrition 
and with an axillary temperature of ≥ 38°C were further assessed for possible inclusion in the study. 
The caretaker of the child was then asked about the other inclusion criteria, namely: 1) first 
consultation for the present problem; 2) fever lasting for one week or less; 3) main complaint was not 
an injury or trauma and; 4) no antimalarials or antibiotic drug taken in the last week. If all inclusion 
criteria were met, the research clinician asked written informed consent to the caretaker after 
explaining in detail the purpose, risks and benefits of the study.  
Study procedures 
Assessment of the patient 
To record the medical history and child examination findings, the research clinician used a 
questionnaire where all relevant items for a febrile case were listed and had to be checked one by 
one. The main complaint, 23 symptoms with their respective duration, a travel history, sick persons in 
the neighbourhood and chronic conditions were asked for. 49 physical signs were looked at (Figure 
17). The clinician had then to list again all positive items to help her deciding about the working 
diagnosis. A nasal and a throat sample as well as a blood sample of 5 ml (venepuncture) were taken 
for each child. Based on predefined algorithms (see below), the clinician selected the appropriate 
investigation(s) to be done.  
Once the clinician had received the results of all immediately available investigations, she decided 
about the final diagnosis(ses) based on the same predefined algorithms. For clinical findings that 
were not included in the algorithms, she would list an additional diagnosis based on her clinical 
judgment. Thereafter she ticked for the absence or presence of each of 28 acute diseases defined by 
a precise constellation of symptoms and/or signs and/or investigation results. If a diagnosis not 
mentioned in this list was recorded, the items on which it was based had to be described precisely. 
Co-morbidities were also listed. Finally, the IMCI clinical criteria for a suspected HIV infection were 
assessed and if present, the caretaker was advised to bring his child to HIV voluntary testing. The 
clinician mentioned that he/she was free to bring back the result to her afterwards. 
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Figure 17: Physical examination of a patient 
 
 
 
The clinician then decided if the child had to be admitted in the paediatric ward or could be managed 
as outpatient. Based on the standard treatment procedures [following the last WHO 
recommendations for hospital care (WHO 2005a)] given next to the 28 diagnoses listed, she 
prescribed the necessary drugs and advised the mother on how to take them. In the absence of a 
diagnosis or if the diagnosis was not documented by a laboratory investigation or a chest X-ray, the 
caretaker was asked to bring back the child after 7 days for follow-up. His/her phone number was 
recorded to be able to call him/her in case a blood, stool or urine culture would turn positive and a 
further treatment was needed. 
At day 7, as well as when the child was brought back to the hospital in-between, the clinician 
assessed the patient for any new complain or new sign. In case of persisting fever, a full assessment 
similar to the one done at day 0 was performed again. In all cases a blood sample was taken for 
storage. Haemoglobin was measured, not for study purposes but for the direct benefit of the child 
(treatment of chronic anaemia). Finally, based on the new findings, if any, the clinician decided about 
the final diagnosis(ses) for the fever episode and the complementary treatments.     
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Choice of investigations based on pre-defined algorithms 
To avoid performing investigations in children with a very low pre-test probability for a specific 
disease, we developed 7 decision charts starting with a specific symptom or sign and then conditions 
that would justify such or such investigation (see Annex 2). These decision charts, that were not 
mutually exclusive (except for the last one), had the following entry points: 1) neck stiffness or 
bulging fontanel; 2) non-vesicular rash; 3) black spot; 4) cough or difficult breathing; 5) {Pharyngeal 
redness and enlarged tonsils} OR {tonsil exsudate}; 6) diarrhoea with ≥ 3 stools per day; 7) no 
confirmed infection (either clinically or by a laboratory test). 
A full blood cell count, a rapid test for malaria, a thick film for malaria parasites and borrelia bacteria 
examination, a rapid test for typhoid, liver (ALT) and kidney (creatinine) function tests were 
performed in all children. Plasma and serum as well as a nasal and a throat swabs were stored for all 
children. Based on the algorithms, the following investigations could be asked for: a cerebral spinal 
fluid (CSF) direct examination; CSF culture; a skin aspiration for Rickettsia; a rapid test for 
Streptococcus in the throat; a direct stool examination for amoeba; a rapid test for adenovirus and 
rotavirus in the stool; a stool culture; a urine dipstick; a urine culture; a blood culture (available only 
for the DSM site) and a chest X-ray. 
Definitive diagnosis(ses) given by the investigators based on pre-defined criteria 
Using the known diagnostic performance of each clinical condition and laboratory test (from available 
international guidelines or systematic reviews), we established beforehand the criteria necessary to 
diagnose a certain disease (see Annex 3). We also defined the additional criteria necessary to 
decide about the level of probability (low, intermediate or high) for this disease to be the aetiology of 
the acute fever episode. For diagnoses corresponding to different spectrum of the same type of 
disease (for example tracheo-bronchitis and pneumonia being both an acute respiratory infection), 
the criteria were established so that only one of them could be given to a certain child (see Annex 3).  
The designation of ‘severe’ was added to the diagnosis when the child fulfilled the WHO criteria for 
the corresponding group of diseases (for example the criteria for severe/very severe pneumonia 
were applied to all ARI) (WHO 2005a). Whatever the diagnosis, the presence of severe anaemia (as 
defined for malaria: Hb <5 g/dl) would put the child in the severe category, as bacteraemia is the 
strongest predictor (just before malaria) for severe anaemia in African children (Calis et al. 2008). 
Once the diagnoses with their respective levels of probability had been attributed to each patient, a 
ranking of the diagnoses (if more than one) was established using the following strategy: 1) the 
diagnosis with the highest probability was put at first level; 2) if a child had more than one diagnosis 
of the same level of probability, the most documented one (based on the respective levels of 
performance of the clinical, laboratory or radiological test used) was put at first level; 3) if a child had 
no diagnosis of high probability at all, a diagnosis called ‘unknown’ was put at first level and the 
diagnosis of intermediate or low probability at second level. 
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Based on all criteria mentioned above, the final diagnoses were generated by a computer program to 
ensure consistency and eliminate subjectivity. 
Laboratory analyses 
Beside blood cultures performed at the research laboratory of Muhimbili University College of Health 
Science, Tanzania and the PCR on respiratory samples performed at the Laboratory of Virology, 
University Hospital, Geneva, Switzerland, all investigations were done on site [at the routine 
laboratory of Amana hospital in DSM and the research laboratory of IHI in Ifakara].  
Rapid diagnostic tests for malaria [ParaHit-f (Span Diagnostics, India)], for typhoid [TyphiRapid IgM 
(Malasian Bio-Diagnostics research)], for adenovirus and rotavirus [VIKIA Rota-Adeno (BioMérieux, 
France)] and for Streptococcus [QuickVue In-Line Strep A test (Quidel, USA)], as well as the urine 
dipstick [Urilab H10 (Urilab systems Diagnostics, )], were performed following manufacturer’s 
instructions. Thick blood films were stained with 10% Giemsa solution and P. falciparum asexual 
parasites were counted against 200 white blood cells (WBC). The parasite density was calculated 
using the white cell count of the patient. A slide was considered negative if no trophozoites were 
seen after 200 high power fields were examined. Discrepant results between the Rapid Diagnostic 
Test for malaria (mRDT) and the blood slide were reread by a second microscopist whose result was 
considered the final one. Urine and stool cultures were performed using the procedures described in 
the ‘Medical Laboratory Manual for Tropical Countries’ (Figure 18).  
 
Figure 18: Culture at the laboratory of Amana hospital 
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Between 1 and 2 ml of blood were collected in BACTEC PedsPlus culture bottles and incubated in a 
BACTEC 9050 blood culture system for 4 days (Becton Dickinson, BD Biosciences, San Jose, CA, 
USA). We cultured positive samples on blood agar, chocolate agar, and cysteine, lactose, and 
electrolyte deficient agar. We used API biochemical galleries (API, Biomerieux, Durham, NC, USA), 
or serology, or both, to confirm the presence of suspected pathogens. 
Nasal and throat swabs were immediately put in phosphate-buffered saline containing 40 U/mL 
RNase-inhibitor (Roche, Basel, Switzerland). Real-time TaqMan reverse transcription polymerase 
chain reaction (RT-PCR) assays for the detection of influenza A, B and C, respiratory syncytial virus 
(RSV) A and B, parainfluenza virus (PIV) 1, 2, 3 and 4, human rhinovirus (HRV), enterovirus and 
Human metapneumovirus were then performed as described previously (Regamey et al. 2008). 
Radiology 
Chest X-ray were performed on site and read by a paediatric radiologist in Switzerland who classified 
the radiographic findings according to the WHO Pneumococcal Trialist Ad Hoc Committee 
recommendations (WHO Pneumonia Vaccine Trial Investigators Group 2001; Cherian et al. 2005). 
The diagnosis of documented pneumonia was applied to children with a chest X-ray showing a 
‘primary endpoint pneumonia’. The diagnosis of non-documented pneumonia was applied to children 
with other findings on the X-ray or with a negative, unclear or unavailable X-ray. The diagnosis 
‘clinical pneumonia’ is used for children with IMCI criteria for pneumonia, i.e. with documented or 
non-documented pneumonia.  
Statistical analyses 
Simple proportions were used. For analyses over time, as inclusion of patients in Ifakara took place 
only during 3 days in June and 3 days in December, these few patients were grouped under the 
next/previous month. Data were entered in Epi Info version 3.5.1 by the first author and analyzed in 
STATA version 10. 
Role of the funding body 
The sponsor of the study (Swiss National Science Foundation) had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding author had 
full access to all the data in the study and had final responsibility for the decision to submit for 
publication. 
9.4 Results 
Between April and December 2008, 1010 febrile children were recruited (none refused), 510 in DSM 
and 500 in Ifakara. 5 patients (3 in DSM and 2 in Ifakara) were excluded from the study because 
caretakers of 2 children (complaining respectively of fever and cough and fever only) withdraw their 
consent at the moment of blood puncture, blood withdrawal failed in one child having pneumonia and 
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2 children did not have the right age. The 1005 children included had a median age of 18 months (20 
months in DSM and 16 months in Ifakara) (see Table 13 for basic characteristics). 
Table 13: Basic characteristics of patients by study site 
  Dar es Salaam study site  
Total patients = 507 
Ifakara study site 
Total patients = 498 
      n      (%) n      (%) 
Female 237   (46.8) 250   (50.2) 
Age   
 2 -<12 months 150   (29.6) 177   (35.5) 
 12  -<36 months 228   (45.0) 226   (45.4) 
 36 - <60 months   75   (14.8)   85   (17.1) 
 5 years - <8 years   36     (7.1)     8     (1.6) 
 8 years - <11 years   18     (3.6)     2     (0.4) 
Temperature   
 38 - <39°C 382   (75.4) 398   (79.9) 
 39 - <40°C 107   (21.1)    81   (16.3) 
 ≥ 40°C   18     (3.6)   19     (3.8) 
Main complain   
 fever 313   (63.0) 354   (71.5) 
 cough   56   (11.3)   47     (9.5) 
 vomiting   47    (9.5)   28     (5.7) 
 diarrhoea   33    (6.6)   22     (4.4) 
 Abdominal pain   15    (3.0)   19    (3.8) 
 
Aetiology of fever in all patients 
The first diagnosis (as defined in the methodology) found in the 1005 children is shown in Figure 19. 
498 (49.6%) children had an Acute Respiratory Infection (ARI) (31.3% URTI, 4.1% bronchiolitis, 
11.5% non-documented pneumonia and 2.6% pneumonia documented by X-ray), 105 (10.4%) 
malaria, 90 (9.0%) gastroenteritis, 54 (5.4%) urinary tract infections (UTI), 33 (3.3%) typhoid, 26 
(2.6%) other infections and 199 (19.8%) an unknown disease. 
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Figure 19: Diagnosis of high probability at first level in 1005 febrile children 
 
$
 Blood cultures could not be performed in Ifakara; * Pneumonia based on IMCI criteria, chest X-ray was 
normal; # Pneumonia confirmed by chest X-ray; £ URTI: 180 tracheobronchitis, 106 rhinitis, 19 acute otitis 
media and 10 non-streptococcal tonsillitis. & Other diagnoses: 2 meningitis (with clear CSF), 1 mumps, 1 dental 
abscess, 1 chickenpox and 1fifth disease. 
 
Aetiology of fever in severe patients 
Among the 1005 children included (patients in need for life-savings procedures having been 
excluded before inclusion) 78 (7.8%) were admitted to the paediatric ward. Based on WHO criteria 
(WHO 2005a), 104 (10.3%) patients had a severe disease: 39 (37.5%) severe ARI, 37 (35.6%) 
severe malaria, 10 (9.6%) severe sepsis of unknown aetiology, 8 (7.7%) gastroenteritis with severe 
dehydration, 8 (7.7%) severe sepsis with documented infection and 2 meningitis (see Figure 20). 7 
patients were admitted although they did not have a severe disease (by WHO definition): 3 because 
of near to severe anaemia (Hb between 5 and 6 g/dl), 2 because of vomiting in uncomplicated 
malaria and 2 because of bad general condition. 3 children died: one of severe malaria+typhoid, one 
of severe sepsis due to Hemophilus influenzae and one of meningitis in the context of HIV/AIDS. 
The reasons for being classified as severe were (more than 1 reason per child was possible): 29 had 
respiratory distress (with chest indrawing in 27, nasal flaring in 16 and grunting in 5), 20 and 7 had 
jaundice in the context of severe malaria and severe sepsis respectively, 15 had convulsions, 14 had 
severe anaemia (Hb <5 g/dl), 13 were lethargic, 9 had severe dehydration, 4 had pre-choc, 2 had 
meningeal irritation, 2 had hypoglycaemia and 1 had cardiac failure. 
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Figure 20: Diagnosis of high probability at first level in 104 febrile children with severe 
disease 
 
$
 Blood cultures could not be performed in Ifakara; * Pneumonia based on IMCI criteria, chest X-ray was 
normal;      # Pneumonia confirmed by chest X-ray; & Other diagnoses: 2 children with meningitis 
 
 
Diseases by age groups 
Figure 21 shows the distribution of diseases by age groups. Gastroenteritis as well as UTI is 
essentially a disease of infants and small children while typhoid prevalence increases with age. 
Malaria is found much more in older children as expected in moderately endemic areas. ARI is 
frequent in all age groups but tend to decrease slightly with building immunity.  
 
Figure 21:   Proportion of 1005 febrile children with each diagnosis of high probability at first, 
second or third level over age groups 
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Seasonality and geographical distribution of diseases 
Figure 22 shows the proportion of children with the main diseases by month of inclusion for the 2 
different sites. In DSM, malaria peaked in June/July just after the rainy season, while gastroenteritis 
peaked in May. ARI decreased over time and was replaced by UTI and unknown diseases. Typhoid 
did not shown any trend. In Ifakara, compared to DSM, there was more ARI but less typhoid and 
gastroenteritis. In Ifakara, ARI and gastroenteritis show a reverse trend with a peak for ARI and a 
nadir for gastroenteritis in September. Unknown diseases increased strongly towards the end of the 
year, corresponding probably to undiscovered epidemic. Malaria and typhoid did not show any clear 
trend.   
 
Figure 22:  Proportion of 1005 febrile children with each diagnosis of high probability at first, 
second or third level over time by study site 
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Diseases of bacterial origin 
Blood culture was performed in 424 (84%) of the 507 children included on the DSM site. 18 (4.2%) of 
the blood cultures were positive: 5 for a Gram positive cocci (3 Staphylococcus aureus, 1 
Streptococcus pneumonia and 1 Streptococcus spp) and 13 for a Gram negative rod (4 Salmonella 
typhi, 2 for Escherichia coli, 2 for Acinetobacter spp, 1 Salmonella non-typhi, 1 Shigella flexneri, 1 for 
Hemophilus influenzae, 1 for Aeromonas spp, 1 for Pseudomonas aeruginosa). 20 (4.7%) of the 
blood cultures grew for a contaminant. For the 18 children with a significant bacteraemia, 4 had 
typhoid (already diagnosed by the rapid test for 2 of them), 3 had an already diagnosed focal 
infection (2 UTI due to E. coli and one gastroenteritis due to Shigella) being clearly the origin of the 
bacteraemia, 6 had a focal infection unrelated to the bacteraemia and 5 had no focal infection at all. 
Among the latter 11 children, 1 was admitted and died a few hours later of Hemophilus influenzae 
severe sepsis, while the others were managed as outpatient without receiving an antibiotic in 7 
cases. All were cured at day 7 except one who had persistent fever at day 5 and then recovered with 
antibiotics. Bacteraemia was thus occult in 9 children among the 18.  
Urine culture was performed in 144 children and was significantly positive (one bacteria with ≥104 
colonies) in 59 (41%) of them, for the usual gram-negative bacteria in most of the children. Stool 
culture was performed in 54 children and was positive for Salmonella or Shigella (no other bacteria 
was looked for) in 12 (22%) of them (11 for Shigella flexnerii and 1 for Salmonella typhi).   
If we consider that, on top of the documented bacterial diseases [by laboratory as described above or 
clinically (for example purulent skin infections)], all pneumonia documented by X-ray were of 
bacterial origin, it means that 157 (16%) of the 1005 children had a bacterial infection as first, second 
or third diagnosis.  
Diseases of viral aetiology 
Among the 622 children diagnosed with ARI as first, second or third diagnosis, a positive PCR for at 
least one virus was found in 424 (68.2%) of them: 274 (66.5%) of the 412 children with an URTI, 31 
(68.9%) of the 45 children with bronchiolitis, 102 (76.1%) of the 134 children with non-documented 
pneumonia and 17 (54.8%) of the 31 children with documented pneumonia (see Table 14). 
Regarding diarrhoea, rotavirus was found in 28 (27.7%), adenovirus in 1 and both viruses in 2 of the 
101 children with gastroenteritis.  
If, on top of the viral diseases mentioned above, we consider that all URTI, bronchiolitis or non-
documented pneumonia were of viral origin and that the children with an unknown diagnosis (97% 
had recovered at day 7 while only 19% had received an antibiotic) had a viral infection, the overall 
proportion of children with a disease of viral aetiology as first diagnosis would be 71.2% (716/1005).  
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Table 14: Proportion of febrile children with respiratory viruses detected in the nasal and 
throat swabs by diagnostic category 
 
 Total 
number 
of 
children 
At least 
one 
respiratory 
virus* 
At least one 
respiratory 
virus except 
picornavirus* 
Influenza 
A 
Influenza 
B 
RSV human 
meta-
pneumo
virus 
Para-
influenza 
1 and 3 
Picorna 
virus 
Children with an Acute Respiratory Infection #       
 Any type of ARI 622 68% 39% 12% 14%   7%   2%   5% 38% 
 URTI 412 67% 37% 11% 16%   5%   2%   5% 37%  
 Bronchiolitis   45 69% 49% 24%   4% 13%   2%   9% 33% 
 Pneumonia with 
normal X-ray 
134 76% 44% 13% 12% 10%   4%   7% 44% 
 Documented 
pneumonia 
  31 55% 23%   6%   6% 13%   0%   0% 35% 
Children with a fever of unknown aetiology #        
 Unknown 199 55% 18%   4%   9%   4%   1%   2% 38% 
Children with a documented disease and no ARI #       
 Any disease 184 44% 13%   2%   3%   7%   1%   1% 34% 
 Malaria   62 44%   6%   0%   2%   3%   2%   2% 39% 
 Gastroenteritis   59 44% 14%   3%   3%   5%   2%   0% 34% 
 Typhoid   19 47% 26%   0% 16%   5%   0%   5% 21% 
 UTI   40 45% 15%   3%   0% 13%   0%   0% 33% 
 Other disease   13 31% 15%   0%   0% 15%   0%   0% 23% 
* One child can have more than one virus; # Diagnosis at first, second or third level 
 
 
 
Co-diagnoses 
253 (25.2%) children had more than one diagnosis (240 had 2 diagnoses and 13 had 3 diagnoses) of 
any level of probability. 131 and 3 children had respectively 2 and 3 diagnoses of high probability. 
The overlap of the 3 main causes of fever with high level of probability is presented in Figure 23. 
Looking in more detail at co-diagnosis in malaria patients, we found that, among the 105 children 
with any parasite density, 56 (53%) had at least another diagnosis (45 of high, 3 of intermediate and 
8 of low level of probability). The 3 most frequent co-diagnoses of high level of probability with 
malaria were: URTI in 22 children, pneumonia (documented by chest X-ray or not) in 10 children and 
typhoid in 4 children. For the 15 children who had a parasite density <2000 parasites/µl, exactly the 
same proportion (53%) had at least one other diagnosis of any level of probability. Malaria patients 
(with any parasite density) were twice less likely to have a pneumonia (documented or not) and 3 
times less likely to have a documented pneumonia than non-malaria patients. The probability of 
having typhoid was however the same in malaria and non-malaria patients. 
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Figure 23:  Proportion of 1005 febrile children with Acute Respiratory Infections (ARI), malaria 
and gastroenteritis of high probability as first, second or third level 
*Pneumonia as defined in IMCI (documented or not by chest X-ray) 
  
 
 
 
 
9.5 Discussion 
Using a thorough clinical work up, a broad range of laboratory investigations, chest X-ray and precise 
pre-defined criteria for diagnoses and their level of probability, we managed to establish the aetiology 
of fever in 80% of 1005 children attending one rural and one urban outpatient health facility in malaria 
moderately endemic areas in Tanzania. Half of the children had an acute respiratory infection (high 
or low), of which only 5% were confirmed to be pneumonia by chest X-ray. Malaria and 
gastroenteritis represented only 10% and 9% of the fevers, which is much less than generally 
thought for a traditional African setting. Indeed the transmission of malaria is declining in many 
countries (WHO 2009b; Chapter 4) and the sanitary conditions and knowledge have probably 
improved in the last 10 years. The latter also explains the limited number of typhoid fevers that were 
still found more in urban DSM (5.3%) than in rural Ifakara (2.0%). Urinary tract infections 
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documented by culture were few (4%) as expected in a healthy population of children [14% was 
found in hospitalized children in Nigeria (Rabasa & Gofama 2009)]. Many clinicians in Africa perceive 
UTI as a frequent cause of non-malaria fever; this is due to the unavailability of urine culture and the 
very low specificity of the test used instead (microscopy) to document UTI (the same is happening for 
typhoid). Bacteraemia was found in 4.2% of the 424 children with blood culture, which is double than 
what was found (2.0%) in the outpatient Kenyan study (Brent et al. 2006). The proportion of occult 
bacteraemia was 50% in our study and 27% in the Kenyan study. Regarding the 20% of all children 
in whom no diagnosis could be establish, PCR and serologies on the blood samples are ongoing and 
should allow us to know more about the aetiology. As the vast majority of these children recovered 
without antibiotic, they were probably suffering from a viral illness. In 55% of these 199 children, a 
respiratory virus was found in the nasoharyngeal sample and is probably the origin of the fever for 
most of them (except for picornavirus).  
Children with severe disease 
In severe patients, the major change in the distribution of diseases concerns malaria (36% versus 
10% in non-severe patients) and ARI that were shifted towards the more severe forms of the disease 
(pneumonia). The proportion of children with an unknown diagnosis was half compared to the whole 
group. Bacteraemia was documented rarely (3.8%) in severe cases, but was still 2 to 3 times more 
likely than in non-severe cases. A respiratory virus was found at the same rate than in non-severe 
cases (63% and 61% respectively) and was clearly the aetiology of the severe disease in several of 
them (for example, human metapneumovirus, which is known to produce severe ARI, was 
overrepresented in severe cases). Even if the documentation of a bacterial origin in severe cases 
was still low, the management is totally different than in non-severe patients. Antibiotics should 
always be given immediately whatever is the working diagnosis. Indeed diagnostic tools that can 
reliably exclude invasive bacterial infection or confirm with certainty a viral aetiology do not yet exist. 
It is clearly stipulated in IMCI that ‘severe fever’ should receive iv antibiotics immediately but in the 
WHO guidelines for hospital care for children, only one page is devoted to severe sepsis and no 
clear statement on the necessity of treating all febrile children with severe features is given. 
Therefore clinicians are not aware that almost all features that apply to severe malaria are part of the 
definition of severe sepsis due to bacteraemia, and they tend to give quinine and withhold antibiotics, 
even if the malaria test is negative. The consequence is that presently in Africa the mortality is higher 
in non-malaria than in malaria cases (Makani et al. 2003; Reyburn et al. 2004). 
Co-diagnosis 
In these moderately endemic areas for malaria, the overlap between malaria, gastroenteritis (defined 
as ≥ 3 stools/day) and clinical pneumonia (defined by the presence of fast-breathing) was minimal. 
This highlight the fact that the overlap classically described in highly endemic areas might be due to 
the presence of incidental parasitemia in children with pneumonia or diarrhoea rather than a synergic 
co-infection. It is important to keep this in mind when deciding on the strategy of malaria testing for 
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low-endemic areas: it is probably reasonable to withhold malaria testing in a child with pneumonia, 
diarrhoea or skin infection. However, the overlap between URTI and all the other diseases was 
significant, showing that children often harbour an URTI that is probably not the origin of the acute 
fever episode. Therefore malaria testing should probably not be withheld in children with URTI, even 
in low transmission areas. 
Aetiology of acute respiratory infections 
Only 5% of all ARI were confirmed to be pneumonia by chest X-ray. This may mean that 95% of 
these ARI were probably of viral origin and did not need to be treated with antibiotics. Moreover, 
especially in preschool age infants and children, pneumonia are often of viral origin (Brodzinski & 
Ruddy 2009a; Cevey-Macherel et al. 2009), which means that even a higher proportion of all ARI 
were of viral origin. Primary end point pneumonia as defined by WHO has shown to be associated 
with a bacterial aetiology (Enwere et al. 2007) in contrast to ARI with other types of chest X-ray 
abnormalities or with normal X-ray. However the proportion of children with end point pneumonia and 
bacteraemia was still only 12.6%. In our study we found that 69% of the children with URTI, 
bonchiolitis and non-documented pneumonia had a virus in the nasopharyngeal sample and also 
55% of the children with documented pneumonia. It is known that all respiratory viruses, including 
rhinoviruses (Peltola et al. 2008), can produce pneumonia even severe. It is clear that this virus 
might not be the only aetiology of the ARI but rather a co-factor with a bacteria (Cevey-Macherel et 
al. 2009; Nakayama et al. 2007). This is why we are presently testing these samples for 
Pneumococcus and Hemophilus influenzae type b by PCR, knowing the limitation of the result due to 
the impossibility to distinguish commensal from pathogenic bacteria. Whatever the contribution of 
bacteria in low respiratory tract infections, this affected only a very limited number of children and at 
least 95% of these ARI did not need to be treated by antibiotic. Based on the IMCI criteria, 27% of 
these children would have received an antibiotic treatment, which is much more than 5% but much 
less than the current habit of many clinicians to treat almost all ARI with antibiotics (Chapter 7). 
Respiratory viruses isolated in children without ARI 
A respiratory virus was found in 55% of children with a fever of unknown aetiology and 44% of 
children with a documented disease of high probability other than ARI (Table 14). These proportions 
are close to that of children with ARI (68%). When looking at the same data but removing 
picornaviruses, the differences between these 3 categories of children was bigger (39% for ARI, 18% 
for unknown fevers and 13% for other documented diseases). This suggests that part of the 
picornaviruses retrieved were not related to the present fever episode. Indeed small children are 
constantly infected by new strains of respiratory viruses, in particular picornaviruses (rhinoviruses) 
that take a few days to weeks (depending on the type of virus) to clear from the respiratory tract 
(Peltola et al. 2008). Therefore, at the onset of a new fever episode, whatever the cause (ARI, 
unknown or other documented infections), children can still harbour some viruses from a recent 
episode of URTI that is on the road to recovery.  Part of the picornaviruses, and probably most of the 
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other viruses, might still represent the cause of the fever for the children with unknown aetiology [in 
particular for influenza that can present without respiratory symptoms in small children (Calvo Rey et 
al. 2005)] or a co-infection in children with malaria, typhoid or any other disease. 
Typhoid fever 
Among 37 children with documented typhoid, 32 (86%) had a mild presentation. 5 children did not 
receive any antibiotic and cured spontaneously. As we have no way to know which children with mild 
typhoid will get complications later on, it is still desirable to detect them as early as possible. There is 
no good clinical predictor that is sensitive enough to exclude typhoid on clinical grounds (in our study, 
abnormal abdominal palpation had an OR of 8.5 but was still only found in 19% of the cases). 
Therefore a point-of-care laboratory test is highly desirable, especially in Africa where blood culture is 
unavailable and Widal test performed widely despite its very low specificity. A few brands of Rapid 
Diagnostic Tests for typhoid (tyRDT) had shown good sensitivity, although with some variation when 
performed in the field (Naheed et al. 2008). In our study, we used a new generation of tyRDT based 
on the detection of specific IgM that had not yet been tested in real conditions. The sensitivity was 
much higher than blood culture, even early in the course of the disease (the median duration of fever 
mentioned by caretakers was only 2 days). Beside its actual price that is too high, the main problem 
is the necessity to test all febrile children to be able to detect the few existing cases. Age-specific 
prevalence of typhoid might help to better select those should be tested. In any case, mRDT will be 
deployed in many settings where the prevalence of typhoid is possibly close to that of malaria. The 
benefit of using tyRDT in Africa is thus worse being evaluated carefully. 
9.6 Conclusion 
In Dar es Salaam and Kilombero/Ulanga, half of the aetiologies of fever episodes in children were 
ARI, of which 2/3 were probably of viral origin based on clinical and microbiological criteria. Only 5% 
of all ARI were pneumonia (based on WHO criteria for chest X-ray interpretation). Gastroenteritis 
contributed to 9% of all fevers, of which at least 1/3 were due to a virus. In 1/5 of the children, no 
aetiology could be documented with certainty but most of them recovered without treatment. Most of 
the children with acute fever thus do not need to receive an antibiotic. Malaria (defined by any 
parasite density) contributed for only 10% of all episodes meaning that few children are in need for 
antimalarial treatment. It is important for clinicians and other actors of the health system to know 
these different pre-test probabilities to realize that the systematic provision of dual treatment 
(antimalarial and antibiotic) is no long appropriate. It expose the patient to unnecessary adverse 
events and the community to accelerated development of micro-organisms’ resistance to drugs. The 
diversity of febrile causes, of which most cannot be diagnosed on clinical grounds, calls for new 
point-of-care laboratory tests that should be included in an evidence-based clinical decision chart. 
The ultimate goal being to prevent death, there is a need to think of new approaches that would help 
clinicians to detect early in the course of the disease children who are likely to develop complications, 
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whatever is the underlying infection. Beside validated clinical predictors, new biomarkers of 
inflammation predictive of the outcome that could be measured at point-of-care using simple devices 
would thus be invaluable tools. 
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10. Complementary important findings from IMALDIA  
 
Important findings from IMALDIA that are crucial to understand the effects of mRDT implementation 
but not included in the preceding chapters, will be presented below.  
10.1 Impact of mRDT implementation on the consultation process 
Background 
The quality of the consultation performed by clinicians is often poor in Africa (Zurovac et al. 2006b; 
Reyburn et al. 2008). One of the reasons is the absence of reliable malaria diagnosis that drives the 
clinician to consider almost all patients as malaria cases and to omit to look for other causes of fever. 
Implementation of mRDT should trigger clinicians to spend more time on history taking and physical 
examination when the result is negative in order to identify symptoms or signs specific for another 
disease. 
Objective 
To assess the effect of mRDT implementation on the quality of the consultation preformed by 
clinicians in public health facilities.   
Methodology 
Cross-sectional surveys before and 18 months after mRDT implementation in 9 public health facilities 
in Dar es Salaam (see details of methodology in Chapter 7.3). Observation of consultation process 
by independent clinician. 
Results (Table 15) 
The quality of the history taken by clinicians did not improve after mRDT implementation. 40% of 
patients before and 31% after mRDT initiation were not asked about any complaint beside those they 
had mentioned spontaneously. Danger signs (as defined in IMCI) were still not assessed in children 
less than five years. There was improvement on one point only: previous drug intake was more often 
asked for (31% increase).  
Physical examination remained very poor, if non-existent, in most of the patients. It even became 
worse with a 2-fold decrease in the proportion of patients examined for at least one sign (42% before 
versus 21% after). The respiratory rate was still almost never measured (1% of patients before and 
after) and chest auscultation was less often performed (22% before versus 7% after).  
Counselling about the necessity to come back to the health facility in case of ‘persisting fever’ or 
‘getting sicker’ was rare (in 4% and 21% of the patients respectively) at the time of microscopy but 
was done in about half of the patients after mRDT implementation.  
The median duration of consultation remained extremely short after mRDT implementation and even 
decreased slightly (from 6 to 5 minutes, p<0.001). The time spent by patients to wait for the 
laboratory results was however shortened by more than half (92 before versus 39 minutes after 
mRDT initiation). 
10. Complementary important findings from IMALDIA 
 
  
 
108 
Table 15: Effect of mRDT implementation on the consultation process: before-and-after 
analysis. SD = standard deviation 
  Before mRDT 
implementation 
Total patients = 937 
After mRDT 
implementation 
Total patients = 954 
 
 
Risk ratio 
 
 
p-value 
 n %   (95% CI) n    %   (95% CI)   
History taking       
 Patient asked about at least one symptom 937 60%  (57-63) 954 69%  (66-72) 1.14 < 0.001 
 Patient asked about duration of symptoms 937 85%  (83-88) 954 75%  (73-78) 0.88 < 0.001 
 Patient asked about previous drug intake 937 43%  (40-47) 954 57%  (54-60) 1.31 < 0.001 
 Underfive patients asked about danger signs 486 7%   ( 5-10) 501 9%   ( 6-11) 1.16 0.5 
Physical examination       
 Patient examined for at least one sign 937 42%  (39-46) 954 21%  (18-23) 0.49 < 0.001 
 Temperature measured 937 3%  ( 2-4) 954 4%  ( 3-6) 1.68 0.04 
 Respiratory rate measured 937 1%  ( 0-2) 954 1%  ( 0-1) 0.71 0.5 
 Stethoscope put on chest 937 22%  (20-25) 954 7%  ( 5-8) 0.30 < 0.001 
Counselling about when to return to health facility    
 In case of fever / persisting fever 888 4%  ( 3-5) 909 42%  (39-46) 10.78 < 0.001 
 In case of getting sicker 888 21%  (19-24) 909 56%  (53-59) 2.61 < 0.001 
Time spent by the patient at the health facility    
 Median duration of consultation 866 6 min   ( 3-9) 834 5 min  ( 3-7) 1.17 < 0.001 
 Median time spent by the patient at the lab 574 92 min (64-127) 671 39 min  (21-65) 0.42 < 0.001 
 
 
Discussion 
Unfortunately, mRDT implementation did not in itself improve the quality of the medical consultation, 
except for advising patients about when to return to the health facility. During the training, we 
mentioned the importance to take a short and well targeted history and to look for a few key signs 
(such as proposed by IMCI) to guide the request for additional specific laboratory analyses or 
treatment choice. We insisted that a full assessment from head to toe was not necessary and that the 
time to get the few key elements needed was short. The absence of improvement in clinicians 
procedures could mean that they were considering history taking and physical examination only for 
the purpose of trying to guess who had malaria or not, and not for the purpose of doing a differential 
diagnosis. The mistake of considering the usefulness of symptoms and signs mainly for deciding 
about the final diagnosis, which could thus be advantageously replaced by modern technology, is 
widespread in industrialized countries. The fact that symptoms and signs are rather essential to 
assess the pre-test probability of diseases and hence to choose the appropriate investigations (that 
will make this probability jump to a useful level for treatment decision) is not yet clear for many 
clinicians in Africa, but also in Europe and elsewhere. 
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Conclusion 
Training focused on mRDT use is not enough to motivate clinicians to look for other causes of fever 
and thus improve the quality of the consultation. Teaching modules on malaria diagnosis should go 
hand in hand with training on the clinical management of fever cases. The new evidence-based 
approach of medical care, using probabilities and likelihood ratio concepts, needs to be taught to 
clinicians from the start, already at pre-graduate level.  
10.2 Improvement of the IMCI algorithm based on evidence 
Background 
The development by WHO in the mid-1990s of an evidence-based algorithm for the management of 
acute medical conditions in children was an initiative that provided clinicians with a practical tool of 
high quality. Although originally designed for remote dispensaries working without laboratory 
facilities, it remains up to now the best integrated practice guidelines available for the management of 
an acute medical condition in outpatients at any level of the health system. The evidence on 
aetiologies of fevers was scarce in the mid-1990s and not much has been added since, mainly 
because studies are always disease specific and not aimed at assessing the respective contribution 
of each disease in a comprehensive and systematic way. In our study to investigate the causes of 
fever (Fever study), the proportion of each disease in febrile children living in urban Dar es Salaam 
and rural Ifakara was determined (Chapter 9). For each medical condition, it was also possible to 
calculate the performance of the clinical and laboratory predictors. These findings, although specific 
for the setting where the study was conducted, can be a starting point for improving the IMCI 
decision chart. Indeed, the present algorithm is probably very safe: 100% of malaria cases and 
around 80% of bacterial diseases are treated (Factor et al. 2001) but it recommends treatment with 
antimalarials and antibiotics for too many children.  
Objective 
To assess the robustness of the actual IMCI decision chart, evaluate the existing WHO proposals to 
improve these recommendations and articulate suggestions for an update of the IMCI algorithm 
dealing with acute conditions.   
Methodology 
We first compared the list of clinical conditions included in IMCI with the frequency of the aetiologies 
found in the Fever study. For each of the 10 most frequent conditions, we then assessed the 
appropriateness of including them in the IMCI decision chart and the best way to consider them 
based on the likelihood ratios (LR) that we calculated (Deeks & Altman 2004). We only assessed the 
management of acute conditions, ignoring treatment follow-up, chronic conditions and preventive 
measures.   
The need to protect children from complications was weighted against the need to protect 
antimicrobials from micro-organisms’ resistance. The concepts of “threshold for testing” and 
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“threshold for treatment”  according to the probability of diagnosis (Grimes & Schulz 2005) were used 
to help in this decision.   
Results 
When comparing the results of our fever study with the content of IMCI, it appears that the medical 
conditions included in the latter do not match entirely the reality. On the other hand, the basic 
structure and flow of IMCI is still relevant, i.e. first assessing danger signs, then considering different 
predictors for specific conditions in parallel, and then deciding about treatment and action based on a 
combination of the post-test probability and the level of dangerousness of the disease. However, 
some predictors used as entry points and some clinical or laboratory tests need to be updated. The 
aetiologies found in our study were (in descending order of frequency): URTI (31.3%, including 2.5% 
acute otitis media), documented and non-documented pneumonia (14.1%), malaria (10.4%), 
gastroenteritis (8.9%), urinary tract infection (5.4%), bronchiolitis (4.1%), typhoid (3.3%), sepsis due 
to bacteraemia (1.0%) and skin infection (1.0%). The four most frequent conditions are all tackled by 
IMCI, which is good news, but the next five conditions are not addressed at all. Measles is a disease 
that appears in several branches of IMCI, but we did not observe any case in the fever study; thanks 
to the recent vaccination efforts the incidence of measles is now low in many African settings (WHO 
2009a).  
An unexpected observation from the Fever study was that the overlap between the 3 main diseases 
(malaria, pneumonia and gastroenteritis) has considerably decreased compared to the data available 
in the 1990’s (O'Dempsey et al. 1993). This does not question the need for considering aetiologies in 
parallel (without mutual exclusion) as this overlap will never be zero, but it is one more reason to stop 
systematic double treatment for malaria and pneumonia. 
Pertinence of IMCI according to our findings in severely ill children  
With regard to severe disease, the first important finding is that the three leading causes of severe 
disease are still malaria (36%), pneumonia (based on IMCI criteria: 26%) and gastroenteritis (8%). 
For severe malaria, the algorithm for the use of mRDT (see Annex 1) needs to be integrated into the 
IMCI. In any case, severely ill patients should be given antimalarials without testing to avoid delay in 
referral. At hospital level, the patient should be tested by both mRDT and microscopy to increase 
sensitivity, and treated upon result. For severe pneumonia, an antibiotic should obviously be given 
and for severe gastroenteritis, beside re-hydration, an antibiotic should be given as soon as there is 
suspicion of fever, because the child then fulfils the criteria for severe sepsis (Lever & Mackenzie 
2007). For sepsis with bacteraemia without a focus of infection (including typhoid), blood culture is an 
insensitive procedure (Mancini et al. 2010) and as a result it is difficult to know the actual number of 
children affected. Looking at the findings of the Fever study, it is probably between the 6% we found 
in Dar es Salaam (blood culture was not available in Ifakara) and 20% (proportion of children with an 
unknown aetiology or an URTI that cannot in itself explain the severe disease). In addition some of 
the children with a documented viral or parasitological disease (thus a priori not in need of an 
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antibiotic treatment) could have had a concomitant undetected bacteraemia being the real cause of 
the fever. This high pre-test probability combined with the danger of bacteraemia supports the IMCI 
recommendation of treating all severe febrile children with presumptive antibiotics before referring 
them. Because of the lack of diagnostic tools to prove the viral (non-bacterial) origin of a fever, this 
recommendation should also be applied upon admission in the hospital, which is not done in many 
settings in Africa (Reyburn et al. 2008) and not explicit in the WHO guidelines for hospital care (WHO 
2005a). This would clearly save lives with a limited impact on the development of resistance, as 
severe children are few. 
Pertinence of IMCI according to our findings in non-severely ill children (Table 16) 
In non-severely ill children, our findings are quite different since most of the children have a viral 
disease and the aim is to rationalize antibiotic prescription. Indeed, the leading cause of fever was 
ARI (50%), which is associated with a virus in the vast majority of the cases (Chapter 9.4). Most of 
the 20% of children with an unknown aetiology were cured at day 7 without having received an 
antibiotic, which speaks also for a viral aetiology (13% of these children had indeed influenza and 
42% another respiratory virus by PCR). 
Starting with the first IMCI diseases for which antibiotic are prescribed, pneumonia, we found that not 
more than 30% of children with ARI (representing 15% of all children) need antibiotics based on:  i) 
all clinical pneumonia or ii) all ARI without virus documentation. This is probably a conservative 
estimate as only 5% of all ARI were end-point pneumonia as defined by WHO (Cherian et al. 2005). 
X-ray lacks, however, sensitivity due to a delay in the anatomical consolidation process (Coote & 
McKenzie 2000). It is also known that most of pneumonia in pre-school children, at least in 
developed countries, are of viral aetiology (Brodzinski & Ruddy 2009b; Cevey-Macherel et al. 2009). 
The difficulty is to know how to identify children with definite pneumonia. The cut-off point used by 
IMCI is fast breathing because the latter has been shown as the best clinical predictor for pneumonia 
(Palafox et al. 2000). The problem is that this sign is not specific enough. One possibility would be to 
raise the respiratory rate cut-off. Using our data, raising it by 10 breath/minute for each age category 
(very fast breathing: ≥50 for children 2-12 months and ≥60 for children ≥12 months) would have a 
LR(+) of 6.1 and a LR(-) of 0.69. This would imply that we detect only 35% of documented 
pneumonia, which is not enough, except if, similarly to ‘abnormal abdominal palpation’ for typhoid, 
these children correspond precisely to those at risk of dying of pneumonia [the LR(+) of very fast 
breathing for severe ARI was 4.4]. This problem is far from being solved, even in Northern countries 
(Dirlewanger et al. 2002), and research is still needed. The aim would be to identify with a simple test 
children with ARI at risk for a complicated course or those with a bacterial aetiology (co-infection of 
virus and bacteria is often found; Cevey-Macherel et al. 2009) rather those with end-point pneumonia 
on chest X-ray (that are often of viral origin). 
Moving to the next disease for which antibiotics are proposed in IMCI, diarrhoea, we found a virus in 
as many as 31% of children with febrile gastroenteritis using rapid tests that targeted only 2 viruses 
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(rotavirus and adenovirus). Shigella was present in only 11% of them (1% all children). Similar rates 
were found in 3 studies from Dar es Salaam and Ifakara including both febrile and non-febrile 
children (Moyo et al. 2007; Sam et al. 1992; Vargas et al. 2004). These data show that fever is 
clearly not a good criteria to give antibiotics. The WHO recommendation is to treat with antibiotics 
only diarrhoea due to Shigella. This is the reason why IMCI chose ‘blood in stool’ as criterion. In our 
study, ‘blood in stool’ was mentioned by caretakers in only 2 of the 11 children with Shigella and in 
one of the 90 children without Shigella. In practice, this clinical predictor is still the only test available 
and should be kept in the IMCI decision chart as long as no point-of-care laboratory test is 
developed. 
The last condition for which IMCI proposes an antibiotic treatment is ‘ear problem’. In the Fever 
study, we performed an otoscopy in all children and found that the IMCI criteria of ‘ear pain or ear 
discharge for <14 days’ had a LR(+) of 107 and a LR(-) of 0.56 to diagnose acute otitis media. 
However, the real issue here is that numerous studies have shown that the vast majority of 
uncomplicated acute otitis media are self-limiting, and like all other URTI, do not need to be treated 
with antibiotics (American Academy of Pediatrics 2004;Morris & Leach 2009). It would thus be 
appropriate to remove the criteria of ‘ear pain’ and keep only ‘ear discharge for <14 days’ (which can 
reflect an advanced stage of acute otitis media) for treating the child with antibiotics, and reinforce 
the general advice of ‘return to health facility in 2 to 3 days (rather than 5 days as presently advised 
in IMCI) in case of persisting fever’. 
For bacterial diseases not included in the IMCI decision chart, urinary tract infections were found in 
5.4% and typhoid in 3.3% of the sampled children. Occult bacteraemia was found in only 1.8% of the 
children living in Dar es Salaam. The crucial question is: at which threshold of probability should a 
bacterial disease be treated with antibiotics, taking into account the dangerousness of this particular 
disease.  We observed that 6 among the 7 children with untreated occult bacteraemia recovered 
spontaneously. As we treated immediately children with typhoid (based on rapid test result) and 
urinary tract infection (based in dipstick result), we don’t know the proportion that would have been 
cured without treatment. What we can say is that ideally, we would have liked to treat all these 
children with antibiotics in the first place, because they are few (10%). It is clear that this does still not 
ensure that children at risk of complications or death would be targeted. As no good clinical predictor 
can be drawn (from our Fever study and from the studies looking specifically at these three 
diseases), the only way to identify these children is to have an easy and reliable laboratory test. 
These tests should have much better performance than those commonly used in health facilities in 
Africa (Widal for typhoid and microscopy for urinary tract infection), and should rule out a diagnosis at 
a threshold probability of around 10%. For occult bacteraemia, only an invasive and insensitive test 
exists nowadays (blood culture). So we have no mean to detect this rare condition (Brent et al. 
2006).  
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For urinary tract infection, dipsticks should be introduced and replace the direct examination by 
microscopy (when done). Urine dipsticks are cheap and have a much better specificity than routine 
microscopy (64% were reported as positive). Using dipsticks would mean treating with an antibiotic 
15% of all children, which is still too much (6% had really this infection) but much better than the 
present situation. In Northern countries, urinary tract infection is looked for in febrile children aged 
less than 2 years, because symptoms and signs are unspecific in this age group. This is the reason 
why WHO had proposed, in its attempt to integrate urine analysis in IMCI (WHO 2005c), to test only 
children < 2 years. Nevertheless, in our study we found that the typical symptoms/signs of urinary 
tract infection were neither found in the older age group. On the other hand we found that this 
infection was much rarer in children above 2 years (2.7%) than in younger children (8.1%), hence it 
would still be reasonable to restrict urine analysis to children less than 24 months. Using urine 
dipsticks would also have the advantage to treat with antibiotics only 10% rather than 15% of all 
children. 
Typhoid is extremely rare in children younger than 12 months (0.4% in our study). For older children, 
the Widal test could be replaced by the new generation of Rapid Diagnostic Tests for typhoid 
(tyRDT), provided the price comes down. tyRDT are more and more used in Asia although there is 
still doubt on its performance in outpatients (Naheed et al. 2008). However, studies using PCR as 
gold-standard (rather than blood culture) have shown excellent sensitivity and specificity (Prakash et 
al. 2007). The performance of these new tests is anyway better than the Widal test, especially the 
one used routinely in health facilities in Africa. When tyRDT are not available, the clinical predictor 
‘abnormal abdominal palpation’, that had in our study a LR(+) of 7.0 and a LR(-) of 0.83, could be 
used to decide on antibiotic prescription. In other terms, this predictor would help us to identify 20% 
of all children with typhoid at the cost of treating 3% of all children with antibiotics unnecessarily. 20% 
is too low, except if these children correspond precisely to the sub-sample of patients that are at risk 
for bad outcome, which could be the case knowing the pathophysiology of typhoid (gastrointestinal 
tract suffering).   
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Table 16:  Proposed changes to the IMCI decision chart based on our findings. tyRDT = Rapid 
Diagnostic Test for typhoid 
Branch 
(main symptom) Present recommendation Change proposed 
Cough or difficult 
breathing 
Definition of fast breathing:  
2 - <12 months: ( 50 /min 
12 months - 5 years: ( 40 /min 
Definition of fast breathing:  
2 - <12 months: ( 60 /min 
12 months – 5 years: ( 50 /min 
Fever An antimalarial is prescribed in 
all cases (in highly endemic 
areas) 
Perform a malaria test: 
If the result is positive, give an antimalarial 
If the result is negative, do not give an antimalarial 
 Typhoid is not considered If tyRDT is available: 
             If the child is (12 months: Perform a tyRDT: 
If the result is positive, give an antibiotic 
If the result is negative, do not give an antibiotic 
If tyRDT is NOT available: 
             If the child is ( 12 months: Palpate the 
abdomen: 
If abnormal abdominal palpation, give an antibiotic 
If normal abdominal palpation, do not give an antibiotic 
 Urinary tract infection is not 
considered 
If the child is <24 months: Perform a dipstick on clean 
urine: 
If leucocytes or nitrites are present, give an antibiotic 
If leucocytes and nitrites are absent, do not give an 
antibiotic 
Ear problem Reported discharge for <14 
days is not enough to prescribe 
antibiotics; pus must be seen 
draining from the ear 
Reported discharge for <14 days is a criteria sufficient to 
prescribe antibiotics 
 Presence of ear pain is a 
criteria sufficient to prescribe an 
antibiotic 
An antibiotic should be prescribed only when pus is 
seen or discharge reported for <14 days  
 
  
Discussion 
Our analysis done in the light of the findings of the ‘Fever study’ confirmed the appropriateness and 
robustness of the IMCI algorithm that can only be marginally improved using new clinical predictors. 
We are awaiting for new reliable point-of-care laboratory tests, allowing the identification of the micro-
organism causing the illness, preferably for bacterial infections, or even better, the detection of 
biomarkers of inflammation predictive for the severity or the outcome of the illness (in the same way 
that procalcitonine is used in intensive care unit). In the meantime, the few changes we propose 
would save a substantial amount of antimalarials and antibiotics without putting the child at risk for 
adverse outcome. Targeted treatment of children at the first consultation implies, however, that a 
clear advice is given to the caretaker about when to return for follow up. 
The changes we propose are mainly based on the only available study that has looked at aetiologies 
of fevers in a comprehensive way. The Fever study was conducted in a particular setting and findings 
10. Complementary important findings from IMALDIA 
 
  
 
115 
could be quite different in other places, even in the same country. However, it included children living 
in a rural and an urban setting and both places had moderate proportions of fever associated with P. 
falciparum parasitemia (10%), which is the situation that prevails or will prevail in the near future in 
many settings in Africa. More studies aimed at establishing the aetiologies are needed, and the 
recommendations of IMCI should continue to be updated accordingly. The safety of this new versions 
of IMCI need to be assessed carefully, as it was done for the recommendation of withholding 
antimalarials in children when the mRDT is negative (Chapter 5). This is planned in the frame of the 
follow-up project (PeDiAtric). 
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11. General discussion and conclusion 
The aim of this thesis was to assess several aspects pertaining to the feasibility of implementing 
Rapid Diagnostic Tests for malaria (mRDT) in near-to-programme conditions in the Tanzanian public 
health sector. We drew on previous evidence of the high diagnostic performance of mRDT (Marx et 
al. 2005; Ochola et al. 2006) and on the experience of their reliability and feasibility for the clinical 
management of non-immune travellers, a population at special risk of complications if not diagnosed 
in time. Clearly, point-of-care tests could contribute to a dramatic improvement of the management of 
fevers in Africa and to a considerable saving in terms of antimalarial prescriptions.  
The first step of this project was to assess the reliability of mRDT when used by health workers 
(laboratory technicians as well as clinicians) in the real conditions of daily management of patients. 
For this purpose, we set up a quality assurance system both at central and peripheral level. This 
system did not detect major problem and showed that the final result of mRDT testing by health 
workers was reliable.  
The next step was to better estimate the pre-test probability of malaria in populations targeted by 
mRDT (febrile patients of all age groups attending a health facility of any type). For this purpose we 
undertook a systematic review of the studies giving the proportion of patients with associated P. 
falciparum parasitemia (PFPf) in Sub-Saharan Africa (Chapter 4). We found that the median PFPf 
was 35%, and that it had decreased by half when comparing the period before with the period after 
year 2000 (44% versus 22%). This relatively low pre-test probability represents another reason to 
implement mRDT in Africa. In Dar es Salaam, because of the very low PFPf (5% during the dry 
season, Wang et al. 2006a), it was even more urgent to start using a reliable malaria test. 
Microscopy was available in almost all public health facilities in Dar es Salaam, but the quality was 
extremely low, with an overall sensitivity of 71.4% and specificity of 47.3% for the 12 health facilities 
we had selected for IMALDIA (Kahama-Maro et al, in preparation).  
On the request of several Tanzanian stake-holders, in particular clinicians routinely working with 
patients, we added a component to IMALDIA that was not planned initially, i.e. to assess the safety of 
withholding antimalarials in children under five years with a negative malaria test (Chapter 5). We did 
not observe any complication or death due to a missed diagnosis of malaria in our cohort of 1000 
children, of which 60% were negative by mRDT. We concluded that the strategy of withholding 
antimalarials in negative children is safe and does not expose the child to an increased risk of bad 
outcome.  
The results of the systematic review coupled with the findings of the safety study led us to question 
the appropriateness of the WHO recommendation of treating all fevers with antimalarials in children 
less than five years living in highly endemic areas (Chapter 6; English et al. 2009). WHO has now 
changed its policy, which means that the findings of IMALDIA were considered fully relevant to the 
up-coming situation of African countries, including Tanzania.   
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The core of this thesis, and the main objective of the IMALDIA project, was to investigate the 
feasibility and value of implementing malaria Rapid Diagnostic Tests in the management of fever 
episodes in an urban malaria setting (Chapter 7). Using 3 different designs, we found a 75% 
reduction in antimalarial consumption.  This massive reduction was due to the higher accuracy of 
routine mRDT compared to routine microscopy (that led to a dramatic reduction in the number of 
positive patients) and to the confidence of health workers in mRDT results (the proportion of negative 
patients treated with antimalarials dropped from 53% to 7%). The impact was maintained up to the 
end of the observation period of the project (18 months). Unfortunately, mRDT implementation 
increased the prescription of antibiotics by 50% and did not have a major impact on the quality of the 
medical consultation (Chapter 10.1).  
We took the opportunity of our near-to-program implementation of mRDT to perform a cost-saving 
analysis in a real situation and in a setting representative of many moderate endemic places in Africa 
(Chapter 8). The conclusion was that costs can be saved on drugs, from both the provider and from 
the client’s perspective. For this reason, the overall expenditure for the patient was lower in health 
facilities using mRDT (by 0.31 USD per patient). However, the overall expenditure for the health 
system was higher (by 1.31 USD per patient) when using mRDT instead of routine microscopy, 
mainly because of the relatively high price of the device. 
The aim of the last study (Chapter 9) was to explore the other causes of fever (beside malaria), in 
order to generate evidence for a revision of the existing clinical decision-charts for the management 
of patients, in particular the Integrated Management of Childhood Illness (IMCI). Based on these 
findings, we could propose a limited series of modifications but concluded that new point-of-care 
laboratory tests for the main infectious diseases are urgently needed (Chapter 10.2).  
11.1 Feasibility of implementing mRDT in near-to-programme conditions 
During the 18 months of pilot implementation of mRDT in 9 health facilities in Dar es Salaam, we 
achieved a dramatic reduction (of 3/4) of antimalarials consumption. This success was probably due 
to the way the project was deployed in the field, allowing ultimately clinicians and laboratory 
technicians to be convinced about the reliability and usefulness of mRDT. Moreover, the design used 
in the project was fully appropriate to detect an effect of such an intervention relying on a behavioural 
change of clinicians and requiring a health system environment conducive to this change.  
The way IMALDIA project was deployed in the field 
Trust from clinicians in the test result was gained through a series of crucial steps in the development 
and implementation of the project:  
1) The Tanzanian medical authorities were involved in the project from the start (one of the principal 
investigators was the City Medical Officer of Dar es Salaam).  
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2) The principal investigators of IMALDIA and the team working in the field had no doubt on the 
performance of mRDT, once the different steps of the quality assurance system were in place. They 
therefore did not try to compare results given by mRDT with the one given by a blood slide 
examination, which would have only brought confusion in the mind of end-users.  
3) A sensitization meeting was organized at the very start to involve the clinicians in charge of these 
health facilities, a focal person for each facility, members of the MOH and the person in charge of 
laboratories in DSM. 
4) Five one-day training sessions were organized centrally, in which the vast majority of the health 
personnel dealing with the patients in the intervention facilities participated. The training was done by 
the field investigators themselves, with the contribution of the Professor heading the department of 
parasitology at the University hospital of Dar es Salaam and who was also one of the precursors of 
mRDT evaluation (Premji et al. 1994). An evidence-based approach using predictors, pre-test 
probabilities of diseases and likelihood ratios of tests leading to clear clinical decision-charts was 
used. These sessions were highly appreciated by health workers who acknowledged the quality of 
teaching that was tailored for their daily practice (Figure 24). 
5) An organizational strategy for the storage, performance, recording and supervision of mRDT 
adapted to each situation was developed with the focal person and the different persons in charge in 
the facility, just before receiving the first consignment of tests.  
6) Supervision on site took place with decreasing frequency (1, 2, 5, 10 and 15 months after 
initiation) using pre-defined parameters to be recorded for evaluating the adequacy of mRDT use.  
In summary, the key of the success of IMALDIA was the involvement of high level health authorities 
at the start, and of local authorities all along the study, which gave high legitimacy and credibility to 
the project. The other key was to give clinicians a full understanding of the reasons for the change. 
The third key element for the success of IMALDIA was to provide clinicians with training material, in 
particular a clinical decision chart, free from ambiguous messages and inconsistent 
recommendations.  
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Figure 24: Group work during a training session 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appropriateness of the study design to detect an effect of mRDT implementation 
The pre-requisite for a behavioural change when introducing a new diagnostic tool is an in-depth 
change of health care provider’s disease representation, diagnosis conceptions and treatment habits. 
To measure the effect of the introduction of this new intervention, the following designs are 
appropriate, i) a before-and-after study or ii) a cluster randomized study. The minimum level of 
randomization unit should be the health facility. For a larger study, for example in the frame of mRDT 
implementation at national scale, the unit should even be the district or the region (see Chapter 
11.9).  In several previous studies, clinicians were asked to apply the standard strategy (presumptive 
antimalarial treatment) for patient A, the new procedure (mRDT) for patient B and to come back to 
the old strategy for patient C (because of individual randomization). Such a procedure is unlikely to 
achieve significant improvement in clinicians’ behavior. Such procedures and design are unlikely to 
show success because no radical change is actually implemented and confusion is nearly ensured.  
It is interesting to notice that, among the 6 papers published in the area of mRDT implementation 
since the start of IMALDIA, the 3 studies that had a design based on randomization by patient did not 
show any impact of mRDT implementation on antimalarial prescription, while the 3 studies using HF 
as the level of application of the strategy were successful (see Table 17). 
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Having a randomized control group might not even be of prime necessity to measure the operational 
success (not the efficacy or the effectiveness) of a new tool (Victora et al. 2004). This objective may 
be better served by a before-and-after design that avoids the problems of high heterogeneity 
between health facilities and contamination of the control group by the intervention group. In 
IMALDIA we did both a cluster randomized and a before-and-after analysis and clearly the latter 
gave more robust results (closer to the ones found by the longitudinal study based on another source 
of data). 
 
Table 17: Published studies on mRDT implementation, stratified by level of allocation of the 
intervention (individual versus health facility). RCT = Randomized Controlled Trial. 
Reference Country Study design Comparison Outcome measured Result 
Intervention allocated  at the patient level 
Reyburn et al. 
2007 
Tanzania RCT with 8 months follow 
up after training 
Microscopy versus 
mRDT  
Proportion of negative 
patients treated with 
antimalarials 
51% vs 54% 
Bisoffi et al. 
2009 
Burkina 
Faso 
RCT with repeated cross-
sectional surveys after 
training or refresher course 
Presumptive diagnosis 
versus mRDT 
Proportion of patients 
treated with 
antimalarials* 
92% vs 93% 
(rainy season) 
80% vs 84% 
(dry season) 
Ansah et al. 
2010 
Ghana RCT with 17 months 
follow-up after training 
1. Presumptive 
diagnosis versus mRDT 
2. Microscopy versus 
mRDT  
Proportion of patients 
treated with 
antimalarials* 
93% vs 70% 
 
64% vs 62% 
Intervention allocated  at  health facility level 
Hamer et al. 
2007 
Zambia Cross-sectional survey 
performed one year after 
mRDT implementation 
at national scale 
Microscopy versus 
mRDT  
Proportion of negative 
patients treated with 
antimalarials 
58% vs 36% 
Williams et al. 
2008 
Tanzania Surveys at baseline and 2 
months after training 
Before versus after 
mRDT implementation 
‘Overdiagnosis’# 55% vs 16% 
Msellem et al. 
2009 
Zanzibar Cross-over study 
(alternate weeks) 
during 4 months  
Presumptive diagnosis 
versus mRDT 
Proportion of patients 
treated with 
antimalarials* 
85% vs 36% 
D’Acremont 
submitted 
 in 2010 
Tanzania RCT with repeated cross-
sectional surveys at 
baseline and 18 months 
after implementation 
1. Before versus after 
mRDT implementation 
2. Microscopy versus 
mRDT 
Proportion of patients 
treated with 
antimalarials 
75% vs 20% 
 
 
60% vs 22% 
 
D’Acremont 
submitted 
 in 2010 
Tanzania RCT with routine statistics 
collected over 15 months 
before and 18 months after 
implementation 
1. Before versus after 
mRDT implementation 
2. Microscopy versus 
mRDT 
Reduction in 
antimalarials 
consumption 
68% 
 
70% vs 32% 
Hopkins 
in preparation 
Ouganda RCT with repeated cross-
sectional surveys 
1. Before versus after 
mRDT implementation 
2. Presumptive 
diagnosis versus mRDT 
Proportion of patients 
treated with 
antimalarials 
77% vs 22% 
 
65% vs 22% 
* As a change in the proportion of negative patients treated with antimalarials could not be assessed because 
the comparative group had no test, we recalculated the overall proportion of patients treated using numbers 
provided in the paper. 
# Defined as proportion of negative patients among those with a clinical diagnosis of malaria given by clinicians 
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11.2 Applicability of the findings of IMALDIA to the deployment of mRDT at 
scale 
In order to be as close as possible to programmatic conditions, we did not include strategies or 
interventions that were unrealistic in the frame of a deployment of mRDT at scale: 1) the training 
sessions were short, only one day; 2) no financial incentives were given to health workers at any 
level; 3) the frequency and time spent on supervision after mRDT initiation was close to what is 
usually planned (but often not done) by district health teams for this type of activity; 4) for health 
facilities who did not perform well at the start, we limited our additional meetings with the staff to a 
maximum of two sessions per health facility.  
In summary, our project used feasible tools and strategies for implementation of mRDT but applied 
them in an optimal way. It is clear that in a deployment of mRDT at large scale, it is difficult to be 
optimal at all levels and all the time, and the final result will be highly dependent on the setting, in 
particular the strength of the health system.  
With regard to the applicability of our result to other settings, we performed the same type of study, 
although without a control group, in a rural setting in Tanzania (Kilombero/Ulanga districts). The 
adherence of clinicians to the recommendation of not treating negative patients was even higher in 
that remote setting compared to Dar es Salaam (only 1% of negative patients only received an 
antimalarial drug). Interestingly, the impact on the overall consumption of antimalarials was less (a 2-
fold decrease) due to the much higher proportion of fever cases associated with parasitaemia (39% 
instead of 8% in Dar es Salaam). A similar study was conducted in Uganda (although without 
longitudinal data from health statistics) and the preliminary results showed an impact of the same 
magnitude as ours (RR 0.29 for the before-and-after analysis and RR 0.34 for the cluster-randomized 
analysis) (Hopkins et al. 2008). A cross-sectional survey one year after mRDT deployment at scale in 
Zambia clearly showed problems (a decrease from 58% to only 36% in the proportion of negative 
patients treated with antimalarials) (Hamer et al. 2007). This was the very first experience in Africa 
(2005) and the training on mRDT (integrated in the training for the use of ACT as first line treatment) 
was very short. It shows that the proper use of mRDT cannot be taken for granted and that sustained 
efforts are needed to make it work on the middle- and long-term. 
11.3  Undesirable side-effect of mRDT implementation on antibiotic 
prescription 
Because of the lack of guidelines for the management of non-malaria fevers, implementation of 
mRDT runs the risk to increase drastically antibiotic consumption. In IMALDIA, the overall proportion 
of patients treated with antibiotics reached 72% after mRDT implementation. The increase was 
mainly due to the increased number of malaria-negative patients that were more often treated with 
antibiotics than positive patients. During our training, we mentioned that the Integrated Management 
of Childhood Illness (IMCI) algorithm should be used to guide the management of mRDT negative 
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patients, at least for children under five years. Unfortunately, few clinicians had been trained for IMCI 
(which was deployed in rural Tanzania but not much in Dar es Salaam). Our results highlight the 
imperative necessity of integrating mRDT training in a broader training on management of fevers.  
Interestingly, the longitudinal study based on routine statistics did not show any change in the total 
number of antibiotic tablets consumed by health facilities. Before mRDT use, the consumption of 
antibiotics was already very high (compared to what is expected when IMCI is applied), with about 
40% of all patients exiting health facilities receiving an antibiotic. It means that the increase observed 
in the before-and-after study (including only patients with acute medical problems, and not with 
surgical, gynecological, obstetrical or chronic problems) was probably diluted in the overall very large 
consumption of antibiotics by the health facilities. The other hypothesis could be that clinicians 
prescribed more antibiotics that were not available in the health facility but only in private 
pharmacies. The overall consumption of antibiotics in control health facilities also increased between 
2006 and 2008, which shows that other factors than mRDT contributed to this problem. Broader 
strategies aimed at rational use of antibiotics to reduce the spread of resistance, such as those 
deployed presently in industrialized countries (Sabuncu et al. 2009), are thus urgently needed in 
Africa.  
11.4 Impact of mRDT on the selection of patients for malaria testing 
Another important aspect of mRDT implementation is the selection of patients by clinicians for 
malaria testing. Potentially, over-testing would lead to replacing drug wastage by test wastage. In the 
studies published up to date this aspect was not explored, as only patients with history of fever or 
‘clinical malaria’ were included. We deliberately included all patients presenting with a medical 
condition to explore clinicians’ behavior towards malaria test request. A study in Kenya in the 
microscopy era showed that clinicians test many patients without any history of fever and treat them 
most of the time (Zurovac et al. 2006b). Therefore, during the training we emphasized the necessity 
of testing only patients complaining of fever. Unfortunately, we did not manage to have an impact on 
this outcome: about half of non-febrile patients were tested before as well as after mRDT 
implementation. During the feed-back meeting organized after the end of the study, clinicians stated 
that the pressure of patients for testing was high (much higher than for getting an antimalarial) in 
particular when coming for a check-up. Their observation that non-febrile patients are sometimes 
positive (due to incidental parasitemia) did not help clinicians to understand the complexity of malaria 
infection versus disease, and why non-febrile patients should not be tested.  
In the frame of a national scaling up, it is imperative that the National Malaria Control Program first 
decides on the target population for malaria testing based on the malaria transmission situation and 
possibly the number of mRDT available in the country. Clear guidelines needs then to be given to 
clinicians, avoiding criteria such as ‘clinically suspected malaria based on history and examination’. 
In IMALDIA we used ‘history of fever or temperature > 37.5°C’, a criterion that is widely accepted for 
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countries of high transmission. However, in the context of decreasing transmission, a choice need to 
be done between i) restricting malaria testing to a subgroup of patients with a high pre-test probability 
in order to save tests and ii) widening malaria testing with the aim of detecting all infections in order 
to reduce malaria transmission. Whatever decision is taken, simple - and if possible evidence-based 
- criteria need to be chosen and included in the decision chart for clinicians. 
11.5 Improvement of the management of malaria and non-malaria fevers 
One of the biggest challenges for a clinician working in Africa is when a febrile patient does not have 
malaria. The feeling of security about having made a diagnosis, and thus knowing what treatment to 
prescribe, disappears. The alternative diagnoses that clinicians have been taught during their pre-
graduate training all need confirmation by a laboratory test (typhoid fever, urinary tract infection etc.) 
or an X-ray (pneumonia), which are usually unavailable. For a long time malaria has been treated 
presumptively. Initially this recommendation was for children under five years living in highly endemic 
areas but this recommendation was extended to older children and adults, to low endemic areas and 
to setting where laboratory diagnosis was actually available. During the baseline survey of IMALDIA 
(at the time of microscopy), we asked clinicians about the pre-test and post-test probability of malaria 
they estimated in the patient they were assessing: the median pre-test probability was 60% (the real 
one being 8%) and the median post-test probabilities were 85% and 50% when the blood slide was 
positive or negative, respectively. These probabilities were not influenced by the fact that the patient 
had a history of fever or not, or was aged less than five years. Clearly, their mental picture of malaria 
risk was inadequate.  
The real incentive for clinicians to adhere to the malaria test will only come when they will get a tool 
to identify other diseases, based on the existing etiologies of fever. What is needed is a decision 
chart including a few affordable laboratory tests (see Chapter 10.2). The next step would be to find 
an incentive to adhere to this decision chart, as it is well known from experiences in Northern 
countries that the simple provision of practice guidelines is not enough (Cabana et al. 1999). This is 
also one of the obstacles highlighted by the evaluation of the impact of IMCI in the South (Bryce et al. 
2005). In the North, several initiatives have emerged using computer-based guidelines (Shiffman et 
al. 1999), web-based interactive decision charts (Ambresin et al. 2007)  or computerized 
recommendations integrated in the clinician work flow (Damiani et al. 2010). In the South, a 
computerized version of the IMCI teaching module has been developed and recently tested 
(http://www.icatt-training.org) and different guidelines for the use on mobile phones have been 
developed and pilot tested (Mitchell et al. 2009; Marc Mitchell, personal communication). In the 
continuation of the IMALDIA project, a new research project was designed, in collaboration with D-
Tree (http://www.d-tree.org). Its aim is to improve the quality of health care by making standardized 
diagnostic and treatments easily accessible to providers using electronic decision support systems, 
with a special emphasis on the rational use of antibiotics and antimalarials (PeDiAtric project).  
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Another lesson learned from our experience and discussions with health workers is the imperative 
necessity to harmonize existing guidelines for the management of patients and update them 
accordingly. As these different guidelines are usually provided in the frame of vertical initiatives, it is 
crucial that at the top of the health system, stake-holders of the different programs communicate and 
developed standardized guidelines that are well grounded in the field experience by health workers.  
11.6 Translation of research findings into policy and action 
The relationship between the City council of Dar es Salaam and the Swiss Tropical and Public Health 
Institute (Swiss TPH) started in 1990 through the Dar es Salaam Urban health Project (Wyss et al. 
2000), which aimed at strengthening healthcare and public health infrastructure through a 
decentralized system (Mtasiwa et al. 2003). In this context, a community-based mosquito 
surveillance program started in 2002 in the frame of the already existing Urban Malaria Control 
Program (UMCP). This strengthened the relationship between the City Medical Office of Health and 
the National Malaria Control Program - NMCP (Mtasiwa et al. 2004) and brought a favourable 
environment for operational research in the city. Between 2002 and 2003, a rapid urban malaria 
appraisal was carried out by a team from the Swiss TPH in 4 African big cities, including Dar es 
Salaam, where several indicators for the epidemiology of malaria were collected in different areas of 
the city (Wang et al. 2005a). The prevalence of malaria was found to be lower than expected, even in 
the peripheral areas (from 0.8% in the centre to 3.7% in the surrounding rural areas in school 
children). At health facility level, the findings were even more impressive: while the vast majority of 
febrile patients were treated with antimalarials, only 5.2% were in fact positive for malaria. This 
meant that, at the scale of the city, a considerable number of people were treated unnecessarily with 
antimalarials drugs. As a result, the City Medical Officer of Health and researchers from the Swiss 
TPH decided to act on these striking results and designed the IMALDIA project presented in this 
thesis. Recently, a new operational research project called PeDiAtric was set up on the basis of the 
findings of IMALDIA and in the same spirit.  
During the IMALDIA project, we worked intensively at developing further the good relationship and 
confidence between the City council and NMCP. With other stakeholders, we managed to collaborate 
actively in the writing of the ‘National Guidelines for the use of malaria Rapid Diagnostic Tests in 
Tanzania’, which proposed the introduction of universal malaria testing.  
Furthermore, the findings of the systematic review on the proportion of fevers associated with 
Plasmodium falciparum in Africa (Chapter 4), as well as the debate on presumptive malaria treatment 
in febrile children (Chapter 6), were used by WHO to support their decision to change the policy 
towards universal diagnosis of malaria.  Therefore this work had clearly also an international 
dimension. 
11. General discussion and conclusion 
 
  
 
126 
11.7 Implications of mRDT deployment for measuring the burden of malaria 
Assessing the burden of malaria is an essential exercise, not only for the purpose of having accurate 
statistics but mainly because it has direct implications for the selection and planning of interventions 
at national or international level. For example, procurement and even manufacturing of ACTs or 
mRDTs cannot be planned correctly without reliable data on the incidence of malaria. Realistic 
national figures are needed but, with the decentralization of the health system, having good local 
data is also important. Indeed, with the decreasing transmission of malaria in Africa, the geographical 
heterogeneity of the prevalence is increasing (Jorgensen et al. 2010). mRDT have the potential to 
bring a great improvement in the reliability of surveillance data. If the mRDT results are properly 
collected in the health facilities and properly transmitted (for example directly through internet or a 
mobile phone) to the central level, the number of malaria cases managed by the health system can 
be determined precisely. With the progressive deployment of mRDT, the pictures of malaria 
prevalence will change drastically. One consequence is that there is an apparent decrease in malaria 
transmission, which in fact is simply due to the introduction of accurate diagnosis. In the coming 
years, it will be thus essential to know the timing of mRDT introduction in each place to accurately 
interpret the local and national trends of malaria indicators.  
In conclusion, malaria control will never be achieved without proper documentation of all malaria 
cases (Perkins & Bell 2008). With the new worldwide momentum of malaria eradication, resources 
are being allocated to the documentation and elimination of the reservoir of asymptomatic people, 
while patients from high-risk communities attending the dispensary do not even have access to 
proper diagnosis.  
11.8 Further research on the impact of mRDT implementation 
One of the next key steps in the research agenda is to assess use of mRDT in the private sector as 
well as in the frame of the new WHO initiative of integrated management of fever in the community. 
Their potential in such situations can be very large but it requires careful evaluation. 
In addition, it would be desirable to find an appropriate methodology to assess the health impact of 
mRDT use at district or regional level. mRDT might have a direct impact on the case fatality rate in 
admitted patients (Makani et al. 2003; Reyburn et al. 2004), and by extension in outpatients, if the 
quality of the management of non-malaria patients is really improved through better diagnostic 
procedures and treatment. However, measuring the benefit of mRDT on mortality will probably not be 
easy at population level, firstly because this happens in the context of numerous other malaria 
interventions aimed at decreasing overall mortality. Secondly, the use of mRDT for case 
management might anyway not have much of a direct health impact in settings where the previous 
habit was to treat presumptively all febrile patients. 
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In this context, we are probably left with being able to only measure process indicators, such as the 
proportion of admitted patients with a diagnosis of malaria or the proportion of deaths attributed to 
malaria, parameters that should both decrease drastically with proper documented diagnosis. 
Similarly, the proportion of patients diagnosed with malaria at primary level should decrease almost 
everywhere. Ideally the proportion of febrile patients treated with antimalarials would be a good 
indicator but this information is rarely available from the routine statistics. The amounts of first-line 
antimalarial drugs ordered by health facilities to the district should also be reduced. 
In conclusion, mRDT is a tool aimed at improving the ability of clinician to make the right diagnosis 
and hence give the appropriate treatment. In a context where the tendency was to treat everybody 
with an antimalarial and an antibiotic, the short- or middle-term target cannot be better than non-
inferiority, at least in terms of mortality. On the other hand, assessing improvement in process 
indicators after mRDT implementation, such as the reduction in antimalarials consumption, is a 
realistic goal. On the long-term, mRDT should lead to health benefits due to the better clinical 
management and the slowing down of parasite resistance to antimalarials.  
11.9 Conclusion      
The IMALDIA project provided a deep insight into many aspects of the implementation of mRDT in 
near-to-programme conditions in Tanzania. Our findings show that the introduction of mRDT is safe, 
feasible and useful for the routine management of fever cases in all age groups and at all levels of 
the health system. It is clearly feasible at large scale, provided the deployment is:  i) carefully 
planned, ii) starts by a quality training that provides clear guidelines, iii) accompanied by regular 
supervision on site, iv) a few process indicators are monitored, and iv) includes a quality assurance 
system. The implementation requires flexibility on the part of the health care provider and a strong 
commitment of all persons involved. We demonstrated that acceptability of the test by patients and 
caretakers was good. Patients were rather satisfied to be tested and trusted the result.  
As malaria diagnosis is only one aspect of the whole management of patients presenting with fever, 
improving its quality and utilization will not solve all obstacles for making a proper differential 
diagnosis and prescribing the appropriate treatment. To really improve the quality of care of these 
patients, it is essential to first develop new guidelines or improve the existing algorithms for clinicians. 
These decision charts designed for both children and adults should be based on the new evidence 
available and could include novel point-of-care tests for the key diseases, once these become 
available. Ideally, biological markers of severity should also be included. These new tools should 
then be made available to clinicians using new information and communication technologies to 
improve adherence to the guidelines. Targeting malaria diagnosis was the first step; it is now time to 
move to the improvement of the quality of the management of childhood and adulthood illnesses 
using an integrated approach.  
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12. Recommendations 
12.1 Type of mRDT that should be used for deployment at scale in Tanzania 
 
- Only brands performing well in the WHO/FIND product test should be used, taking into 
account the price of the device and the production capacity of the manufacturer 
- Different brands of tests should be used to familiarize users with different technologies, to 
maintain competition between manufacturers and to avoid sudden stock outs due to limited 
production of one manufacturer 
 
12.2 Target audience, content and planning of the training for mRDT use by health workers 
 
- All laboratory personnel and clinicians should be trained for mRDT appropriate use; if 
possible, also nurses and pharmacists. 
- Data on the prevalence of malaria in the region where health workers are located should be 
provided during the training in order to give them a realistic notion of risk.  
- Guidelines on the use of mRDT in a form of a decision chart should be given and explained to 
clinicians during the training. It should include only one predictor (fever) or a combination of 
predictors (in very low endemic areas) for the selection of patients for testing and a clear 
statement on the action to take upon result of the test. Any ambiguous message, non 
evidence-based affirmation and contradictive statement should be avoided during the training. 
- Practical case studies corresponding to the clinical situations most often seen by clinicians 
should be proposed and worked out by the clinicians themselves.  
- If possible, a training module on the diagnosis and management of non-malaria fevers (for 
example IMCI) should be added to the session on malaria diagnosis. If this is not possible, a 
few hours should at least be spent on the differential diagnosis of fever episodes, the 
approximate prevalence of the most frequent diseases found in the region and the reliability 
of the laboratory tests used routinely in the place.    
12.3 Quality assurance for mRDT in the field 
 
- Each new consignment entering the country or the project should be lot-tested in a WHO 
reference laboratory 
- Accurate performance of the device using prepared Plasmodium positive (with a known 
density) and negative blood samples should be assessed on a regular base in all storage 
places. As soon as the positive control wells (developed presently by WHO/FIND) will be 
available, the latter should replace these prepared blood samples.  
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- The ability of all health workers performing mRDT should be assessed on a regular basis, by 
observing them closely while performing a test on a patient. 
- Quality control of the end product is not sufficient; all steps of quality assurance mentioned 
above should be performed.  
- Using sub-optimal reference microscopy for quality control should be avoided by all means. 
When high quality microscopy is not available, no comparison of test results should be made.    
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Annex 1: Algorithm for the use of mRDT used in IMALDIA 
project 
 
 
 
 
 
 
 
Severe malaria 
Give iv quinine 
Severe illness (NOT malaria) 
•  STOP antimalarials 
•  Give an appropriate iv antibiotic 
•  Investigate for other causes of fever 
•  Repeat RDT and BS after 12-24 hrs 
Admission 
Give an antimalarial and an antibiotic 
DANGER SIGNS ? 
History of fever 
or 
Temperature >37.5°C 
or 
Pallor ? 
Perform mRDT 
Uncomplicated 
malaria 
Give an antimalarial 
Febrile illness 
(NOT malaria) 
•  Do NOT give 
antimalarials 
•  Investigate for 
 
Malaria not suspected 
Do NOT perform mRDT 
NO 
YES 
Suspected Malaria 
NO YES 
Perform mRDT 
and Blood slide 
 
BS and mRDT both 
negatives  
mRDT and/or BS 
positive(s) 
positive negative  
Algorithm for the use of Rapid Diagnostic Tests for malaria (RDT) 
PRIMARY LEVEL SECONDARY LEVEL 
Refer the patient 
immediately  
PRIMARY AND SECONDARY LEVEL 
Follow up 
the patient 
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YES 
Fast breathing * 
OR 
Chest indrawing 
OR 
Abnormal chest 
auscultation 
* Respiratory rate  > 50/min (< 1 year)  
                              > 40/min ( > 1 year) 
 
Chest X-ray 
ABNORMAL 
NORMAL or  
UNCLEAR 
URTI
PNEUMONIA
MENINGITIS 
Vit. A 
Chloramphenicol Skin 
aspiration  
Possible 
AFRICAN TICK 
BITE FEVER 
Amoxicillin 
Perform lumbar puncture 
(if no contraindication)  
Admit the child 
for iv antibiotic 
Neck stiffness OR bulging fontanel 
CSF direct examination  
 CSF culture  
Non-vesicular rash 
Suggestive 
of Measles 
Not suggestive 
of Measles 
Black spot 
Possible 
AFRICAN TICK 
BITE FEVER 
Chloramphenicol Skin 
aspiration  
Follow-up 
Day 7 and Day 21 
Cough OR difficult breathing 
Follow-up 
Day 7 and Day 21 
Possible 
PNEUMONIA Amoxicillin 
NO GOTO ‘No confirmed infection’ 
 (ask for urine dipstick, typhoid test and blood culture) 
STOP 
STOP 
STOP 
Annex 2: Algorithm for the research clinician undertaking the 
‘Fever study’ 
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Urine dipstick 
LEUCOCYTES + 
or NITRITES + 
POSITIVE 
NEGATIVE Rapid test Rota/adeno 
TYPHOID 
Rapid test for 
Streptococcus 
Streptococcal 
TONSILLITISPOSITIVE 
NEGATIVE 
Possible bacterial 
TONSILLITIS 
UTI 
Amoxicillin 
Diarrhea ( > 3 stools /day) 
Amoebic 
GASTRO-ENTERITIS 
Viral 
GASTRO-ENTERITIS
Possible bacterial 
GASTRO-ENTERITIS
Metronidazole 
POSITIVE 
NEGATIVE Cipro- floxacine 
Follow-up 
Day 7 
No confirmed infection (either clinically or by a laboratory test)  
No LEUCOCYTES 
and no NITRITES 
Cotrimoxazole 
Urine 
culture 
POSITIVE 
NEGATIVE 
Follow-up 
Day 7 
{Pharyngeal redness and enlarged tonsils} OR {tonsil exsudate} 
Ciprofloxacine 
Rapid Test 
for Typhoid 
Follow-up 
Day 7 
Blood 
culture 
Investigations 
for diarrhea 
Stool 
examination 
for amoeba 
 
Blood 
culture 
TYPHOID POSITIVE 
NEGATIVE 
Follow-up 
Day 7 
Ciprofloxacine 
Rapid Test 
for Typhoid 
2) 
1) 
3) 
1) 
2) 
3) 
No antibiotic 
Amoxicillin 
STOP 
STOP 
STOP 
STOP 
STOP 
STOP 
STOP 
YES > 2 criteria : 
 - exsudate 
 - adenopathy 
 - NO cough  NO Viral TONSILLITIS No antibiotic STOP 
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Annex 3: Criteria for the computer based diagnosis and its level 
of probability for the ‘Fever study’ 
 
Illness 
Minimum Criteria to 
consider the diagnosis 
Criteria for a 
diagnosis of low 
probability 
Criteria for a 
diagnosis of 
intermediate 
probability 
Criteria for a diagnosis 
of high probability Exceptions 
Malaria 
malaria all children   RDTmalaria positive OR 
blood slide positive 
 
Upper Respiratory Tract Infections 
rhinitis runny nose for < 7 days 
and no other ARI 
  runny nose without 
cough 
 
Streptococcal 
tonsillitis 
(pharyngeal redness 
AND enlarged tonsils) 
OR (tonsil exsudate) 
  RDT strepto A positive  
Non-streptococcal 
tonsillitis 
(pharyngeal redness 
AND enlarged tonsils) 
OR (tonsil exsudate) 
  RDT strepto A negative  
Pharyngitis no other ARI outside 
rhinitis 
  red pharynx  
Acute otitis media all children   ear discharge <14 days 
OR bulging tympanum 
OR very red tympanum 
 
Mastoiditis all children   swelling behind ear  
Sinusitis runny nose  painful sinus 
percussion 
  
Tracheobronchitis cough AND no fast 
breathing AND normal 
chest auscultation 
documented typhoid 
without runny nose 
malaria without 
runny nose OR 
documented 
typhoid with runny 
nose 
no malaria without runny 
nose AND no 
documented typhoid  
If tonsillitis or acute 
otitis media or 
mastoiditis  
 no additional 
diagnosis 
Bronchiolitis 
Bronchiolitis cough   X-ray= “Bronchitis”  
Bronchiolitis OR 
tracheobronchitis 
with asthma 
cough AND (ronchi at 
chest auscultation  OR 
wheezing) 
  X-ray normal  
Pneumonia 
Non-documented 
pneumonia 
cough AND (fast 
breathing OR abnormal 
chest auscultation) 
  X-ray normal, non 
interpretable or non 
available 
Ronchi at chest 
ausc  OR wheezing 
OR chest Xray=”B” 
 bronchiolitis 
Documented 
pneumonia 
cough AND (fast 
breathing OR abnormal 
chest auscultation) 
  X-ray=”Primary end-
point pneumonia” 
 
Gastroenteritis 
Amoebic gastro-
enteritis 
diarrhea 
(≥ 3 stools/day) 
  stool direct examination 
positive for amoeba 
 
Bacterial gastro-
enteritis 
diarrhea 
(≥ 3 stools/day) 
  stool culture positive for 
salmonella or shigella 
 
Viral gastro-
enteritis 
diarrhea 
(≥ 3 stools/day) 
  RDT rota-adeno positive  
Unknown gastro-
enteritis 
diarrhea 
(≥ 3 stools/day) 
  stool direct examination 
negative for amoeba 
AND stool culture 
negative for salmonella 
or shigella AND RDT 
rota-adeno negative 
 
Urinary tract infection 
Urinary tract 
infection 
leucocytes or nitrites in 
urine by dipstick 
Urine culture 
negative (OR E.coli 
<104) 
No urine culture 
available OR Urine 
culture with mixed 
growth 
urine culture positive 
(E.coli >104, other than 
mixed growth) 
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Typhoid 
Typhoid all children abnormal abdominal 
palpation AND RDT 
typhoid negative 
AND no Salmonella 
typhi in blood or 
stool AND no urinary 
tract infection AND 
no malaria AND no 
gastroenteritis 
 RDT typhoid positive OR 
Salmonella typhi in 
blood or stool 
 
Other 
Sepsis blood culture positive for 
a non-contaminant 
bacteria 
  no other diagnosis OR 
other diagnosis unlikely 
to be due to the bacteria 
 
Meningitis all children   neck stiffness OR 
bulging fontanel 
 
Measles generalized rash  typical rash OR 
Koplick spots 
serology/PCR positive  
Mumps all children   enlarged parotid(s)  
Chickenpox all children   typical vesicular eruption  
Fifth disease 
(Parvovirus B19) 
generalized rash  slapped cheek 
erythema 
PCR positive  
Rickettsiose black spot OR purpuric 
generalized rash 
 black spot PCR on skin positive  
Relapsing fever all children   Giemsa thick blood film 
positive 
 
Skin infection all children   furonculosis OR 
pustules OR cellulitis OR 
skin abscess 
 
Osteomyelitis all children   elicited pain of a limb 
OR refusal to move/use 
a limb OR redness, pain 
and swelling of a limb 
 
Dental abscess all children   pain and swelling around 
tooth 
 
Unknown 
Unknown all children   No diagnosis of high 
probability 
 
RDT= Rapid Diagnostic Test; PCR= Polymerase Chain Reaction 
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